0	35673599	Comparison of characteristics and laboratory tests of COVID-19 hematological patients from France and Brazil during the pre-vaccination period: identification of prognostic profiles for survival COVID-19 disease presentation is heterogeneous, from asymptomatic up to severe life-threatening forms.	('COVID-19', 'Disease', (195, 203))	('COVID-19', 'Disease', (54, 62))	('COVID-19', 'Disease', 'MESH:C000657245', (195, 203))	('patients', 'Species', '9606', (77, 85))	('COVID-19', 'Disease', 'MESH:C000657245', (54, 62))
2	35673599	We aimed to identify profiles of hematology patients hospitalized with COVID-19 that would be associated with survival and to assess the differences between cohorts A binational cohort of 263 patients with COVID-19 and hematological disease was studied in Paris, France and Sao Paulo, Brazil.	('COVID-19', 'Disease', (71, 79))	('sur', 'Gene', (110, 113))	('COVID-19', 'Disease', (206, 214))	('hematological disease', 'Disease', (219, 240))	('COVID-19', 'Disease', 'MESH:C000657245', (206, 214))	('patients', 'Species', '9606', (192, 200))	('hematological disease', 'Disease', 'MESH:D006402', (219, 240))	('sur', 'Gene', '6833', (110, 113))	('patients', 'Species', '9606', (44, 52))	('COVID-19', 'Disease', 'MESH:C000657245', (71, 79))
3	35673599	Patient profiles were based on age, comorbidities, biological measurements, COVID-19 symptoms and hematological disease characteristics.	('hematological disease', 'Disease', (98, 119))	('sur', 'Gene', (65, 68))	('COVID-19', 'Disease', (76, 84))	('sur', 'Gene', '6833', (65, 68))	('COVID-19', 'Disease', 'MESH:C000657245', (76, 84))	('hematological disease', 'Disease', 'MESH:D006402', (98, 119))	('Patient', 'Species', '9606', (0, 7))
4	35673599	A semi-supervised learning method with a survival endpoint was first used, following which, a classifier was identified to allow the classification of patients using only baseline information Two profiles of patients were identified, one being young patients with few comorbidities and low C-reactive protein (CRP), D-dimers, lactate dehydrogenase (LDH) and creatinine levels, and the other, older patients, with several comorbidities and high levels of the 4 biology markers.	('low', 'NegReg', (286, 289))	('C-reactive protein', 'Gene', (290, 308))	('creatinine', 'MPA', (358, 368))	('CRP', 'Gene', (310, 313))	('sur', 'Gene', (41, 44))	('D-dimers', 'MPA', (316, 324))	('patients', 'Species', '9606', (398, 406))	('C-reactive protein', 'Gene', '1401', (290, 308))	('patients', 'Species', '9606', (208, 216))	('creatinine', 'Chemical', 'MESH:D003404', (358, 368))	('patients', 'Species', '9606', (250, 258))	('sur', 'Gene', '6833', (41, 44))	('CRP', 'Gene', '1401', (310, 313))	('patients', 'Species', '9606', (151, 159))
5	35673599	The profiles were strongly associated with survival (p < 0.0001), even after adjusting for age (p = 0.0002).	('associated', 'Reg', (27, 37))	('sur', 'Gene', (43, 46))	('sur', 'Gene', '6833', (43, 46))
7	35673599	The Brazilian analysis emphasized the importance of age, while the French focused on the comorbidities This analysis showed the importance of CRP, LHD and creatinine in the COVID-19 presentation and prognosis, whatever the geographic origin of the patients.	('creatinine', 'MPA', (155, 165))	('COVID-19', 'Disease', (173, 181))	('CRP', 'Gene', (142, 145))	('importance', 'Reg', (128, 138))	('LHD', 'Disease', (147, 150))	('patients', 'Species', '9606', (248, 256))	('COVID-19', 'Disease', 'MESH:C000657245', (173, 181))	('creatinine', 'Chemical', 'MESH:D003404', (155, 165))	('CRP', 'Gene', '1401', (142, 145))	('LHD', 'Disease', 'None', (147, 150))
8	35673599	Since the coronavirus disease 19 (COVID-19) outbreak began in the province of Wuhan in China, the virus has spread throughout the world in an unprecedented way.	('coronavirus disease 19', 'Disease', (10, 32))	('COVID-19', 'Disease', (34, 42))	('coronavirus disease 19', 'Disease', 'MESH:C000657245', (10, 32))	('COVID-19', 'Disease', 'MESH:C000657245', (34, 42))
10	35673599	Patients with hematological disorders, especially malignancies, may be more vulnerable to SARS-CoV-2 infection because of the underlying disease and its treatment.	('vulnerable', 'Reg', (76, 86))	('SARS-CoV-2 infection', 'Disease', (90, 110))	('hematological disorders', 'Disease', (14, 37))	('malignancies', 'Disease', (50, 62))	('malignancies', 'Disease', 'MESH:D009369', (50, 62))	('Patients', 'Species', '9606', (0, 8))	('SARS-CoV-2 infection', 'Disease', 'MESH:C000657245', (90, 110))	('hematological disorders', 'Disease', 'MESH:D006402', (14, 37))
11	35673599	In large cohorts, mortality rates were found to be 39% (95% CI: [34;44]) for hospitalized patients with hematologic malignancies versus 22% (95% CI: [21;23]) for hospitalized patients without malignancies.	('malignancies', 'Disease', (192, 204))	('hematologic malignancies', 'Disease', (104, 128))	('malignancies', 'Disease', (116, 128))	('mortality', 'Disease', (18, 27))	('malignancies', 'Disease', 'MESH:D009369', (116, 128))	('malignancies', 'Disease', 'MESH:D009369', (192, 204))	('mortality', 'Disease', 'MESH:D003643', (18, 27))	('patients', 'Species', '9606', (90, 98))	('hematologic malignancies', 'Disease', 'MESH:D019337', (104, 128))	('patients', 'Species', '9606', (175, 183))
12	35673599	Indeed, myelotoxic drugs, immunosuppressive therapies and, consequently, the immune dysfunction seem to contribute to the worst prognosis in patients with hematological diseases and COVID-19.	('COVID-19', 'Disease', (182, 190))	('hematological diseases', 'Disease', (155, 177))	('immune', 'CPA', (77, 83))	('myelotoxic', 'Disease', (8, 18))	('myelotoxic', 'Disease', 'MESH:D001855', (8, 18))	('COVID-19', 'Disease', 'MESH:C000657245', (182, 190))	('hematological diseases', 'Disease', 'MESH:D006402', (155, 177))	('patients', 'Species', '9606', (141, 149))
13	35673599	Patients with malignancies and COVID-19 admitted to the hospital showed a wide range of clinical manifestations and laboratory abnormalities, usually presenting with cytopenias and higher levels of inflammatory biomarkers than the patients without cancer.	('COVID-19', 'Disease', (31, 39))	('presenting', 'Reg', (150, 160))	('levels of inflammatory biomarkers', 'MPA', (188, 221))	('malignancies', 'Disease', (14, 26))	('cancer', 'Disease', (248, 254))	('higher', 'PosReg', (181, 187))	('cytopenias', 'Disease', (166, 176))	('malignancies', 'Disease', 'MESH:D009369', (14, 26))	('cancer', 'Disease', 'MESH:D009369', (248, 254))	('Patients', 'Species', '9606', (0, 8))	('cytopenias', 'Disease', 'MESH:D006402', (166, 176))	('COVID-19', 'Disease', 'MESH:C000657245', (31, 39))	('patients', 'Species', '9606', (231, 239))
15	35673599	Furthermore, the heterogeneous clinical manifestation of COVID-19 in patients with hematological disorders may not be exclusively related to COVID-19, but may also be due to the wide clinical spectrum of underlying hematological disorders.	('related', 'Reg', (130, 137))	('COVID-19', 'Disease', (141, 149))	('COVID-19', 'Disease', (57, 65))	('hematological disorders', 'Disease', (83, 106))	('hematological disorders', 'Disease', (215, 238))	('patients', 'Species', '9606', (69, 77))	('hematological disorders', 'Disease', 'MESH:D006402', (83, 106))	('COVID-19', 'Disease', 'MESH:C000657245', (57, 65))	('hematological disorders', 'Disease', 'MESH:D006402', (215, 238))	('COVID-19', 'Disease', 'MESH:C000657245', (141, 149))
16	35673599	The identification of patterns and clinical manifestations experienced by hematological patients during the moderate or severe SARS-CoV-2 infection might be helpful in deciphering interactions between the hematological disease and the COVID-19 infection, or in the allocation of scarce resources and care management, in areas of the world where it is relevant.	('infection', 'Disease', (138, 147))	('infection', 'Disease', (244, 253))	('SARS-CoV-2 infection', 'Disease', (127, 147))	('COVID-19', 'Disease', (235, 243))	('interactions', 'Interaction', (180, 192))	('hematological disease', 'Disease', (205, 226))	('hematological disease', 'Disease', 'MESH:D006402', (205, 226))	('infection', 'Disease', 'MESH:D007239', (138, 147))	('patients', 'Species', '9606', (88, 96))	('infection', 'Disease', 'MESH:D007239', (244, 253))	('COVID-19', 'Disease', 'MESH:C000657245', (235, 243))	('SARS-CoV-2 infection', 'Disease', 'MESH:C000657245', (127, 147))
17	35673599	In the last few years, the use of unsupervised or supervised learning methods has been boosted by the COVID-19 pandemic and the need to analyze a huge amount of data in an emergency scenario.	('COVID-19', 'Disease', (102, 110))	('boosted', 'PosReg', (87, 94))	('COVID-19', 'Disease', 'MESH:C000657245', (102, 110))
18	35673599	However, to the best of our knowledge, there have been no reports about specific clinical profiles of patients with COVID-19 and underlying hematological diseases from two different countries with demographic and socioeconomic disparities.	('COVID-19', 'Disease', (116, 124))	('hematological diseases', 'Disease', (140, 162))	('COVID-19', 'Disease', 'MESH:C000657245', (116, 124))	('hematological diseases', 'Disease', 'MESH:D006402', (140, 162))	('patients', 'Species', '9606', (102, 110))
19	35673599	The main objective of the study was to identify the profiles of hospitalized hematological patients with moderate or severe COVID-19, using the clinical information and patient survival outcomes from 2 different countries.	('sur', 'Gene', (177, 180))	('COVID-19', 'Disease', (124, 132))	('sur', 'Gene', '6833', (177, 180))	('COVID-19', 'Disease', 'MESH:C000657245', (124, 132))	('patient', 'Species', '9606', (169, 176))	('patients', 'Species', '9606', (91, 99))	('patient', 'Species', '9606', (91, 98))
20	35673599	Patients were enrolled either in Sao Paulo, Brazil, or Paris, France, from two prospective independent databases of in-hospital COVID-19 patients and underlying hematological diseases.	('hematological diseases', 'Disease', (161, 183))	('COVID-19', 'Disease', (128, 136))	('hematological diseases', 'Disease', 'MESH:D006402', (161, 183))	('Patients', 'Species', '9606', (0, 8))	('COVID-19', 'Disease', 'MESH:C000657245', (128, 136))	('patients', 'Species', '9606', (137, 145))
21	35673599	Hospitalization was indicated for patients with respiratory distress signs (accessory muscles use, nasal wing beat and respiratory rate >= 24 bpm) or capillary oxygen saturation < 93%.	('respiratory distress signs', 'Disease', (48, 74))	('nasal', 'CPA', (99, 104))	('oxygen', 'Chemical', 'MESH:D010100', (160, 166))	('respiratory distress signs', 'Disease', 'MESH:D012128', (48, 74))	('patients', 'Species', '9606', (34, 42))
22	35673599	The ICU admission was considered if there was no improvement in respiratory distress, despite the oxygen supply (6 L/min), or hemodynamic instability.	('hemodynamic instability', 'CPA', (126, 149))	('respiratory distress', 'Disease', (64, 84))	('respiratory distress', 'Disease', 'MESH:D012128', (64, 84))	('oxygen', 'Chemical', 'MESH:D010100', (98, 104))
24	35673599	Systematic thromboembolic prophylaxis was first heterogeneous, then higher doses were used from April 4 onward, following the Groupe d'interet en Hemostase Perioperatoire (GIHP) and Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT) recommendations.	('thromboembolic', 'Disease', (11, 25))	('sur', 'Gene', (207, 210))	('sur', 'Gene', '6833', (207, 210))	('thromboembolic', 'Disease', 'MESH:D013923', (11, 25))
30	35673599	COVID-19 cases were defined by SARS-CoV-2 positive real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) and/or very suggestive clinical and radiological findings of COVID-19 or even, additionally, a positive serological test.	('COVID-19', 'Disease', (180, 188))	('COVID-19', 'Disease', (0, 8))	('COVID-19', 'Disease', 'MESH:C000657245', (0, 8))	('COVID-19', 'Disease', 'MESH:C000657245', (180, 188))	('SARS-CoV-2', 'Species', '2697049', (31, 41))
31	35673599	According to the institutional protocols, hospitalization was indicated for patients with respiratory distress signs or low levels of capillary oxygen saturation.	('respiratory distress signs', 'Disease', (90, 116))	('low', 'NegReg', (120, 123))	('patients', 'Species', '9606', (76, 84))	('oxygen', 'Chemical', 'MESH:D010100', (144, 150))	('respiratory distress signs', 'Disease', 'MESH:D012128', (90, 116))
32	35673599	The ICU admission was considered if there was no improvement in respiratory distress, despite the oxygen supply, or hemodynamic instability.	('hemodynamic instability', 'CPA', (116, 139))	('respiratory distress', 'Disease', (64, 84))	('respiratory distress', 'Disease', 'MESH:D012128', (64, 84))	('oxygen', 'Chemical', 'MESH:D010100', (98, 104))
36	35673599	Data on the clinical presentation of COVID-19, type of admission (ward or ICU), comorbidities (diabetes mellitus, high blood pressure, cardiovascular diseases, kidney failure or obesity) and laboratory tests (complete blood count, creatinine, C-reactive protein (CRP), Lactate Dehydrogenase (LDH) and D-dimer) were captured at hospital admission.	('CRP', 'Gene', (263, 266))	('cardiovascular diseases', 'Disease', (135, 158))	('obesity', 'Disease', (178, 185))	('kidney failure', 'Disease', (160, 174))	('COVID-19', 'Disease', (37, 45))	('C-reactive protein', 'Gene', (243, 261))	('diabetes mellitus', 'Disease', (95, 112))	('sur', 'Gene', (129, 132))	('obesity', 'Disease', 'MESH:D009765', (178, 185))	('COVID-19', 'Disease', 'MESH:C000657245', (37, 45))	('CRP', 'Gene', '1401', (263, 266))	('sur', 'Gene', '6833', (129, 132))	('cardiovascular diseases', 'Disease', 'MESH:D002318', (135, 158))	('kidney failure', 'Disease', 'MESH:D051437', (160, 174))	('diabetes mellitus', 'Disease', 'MESH:D003920', (95, 112))	('C-reactive protein', 'Gene', '1401', (243, 261))	('creatinine', 'Chemical', 'MESH:D003404', (231, 241))
38	35673599	The study's primary outcome was the patient overall survival time after hospital admission, whatever the cause of death.	('sur', 'Gene', (52, 55))	('death', 'Disease', (114, 119))	('patient', 'Species', '9606', (36, 43))	('death', 'Disease', 'MESH:D003643', (114, 119))	('sur', 'Gene', '6833', (52, 55))
40	35673599	Categorical variables (symptoms of fever, dyspnea, cough or a rapid hospitalization (within 7 days of symptoms appearance), a high blood pressure comorbidity, a diagnosis of chronic lymphoid disease and an intermediate type of chemotherapy treatment) were modeled into a continuous archetype score, using a generalized low-rank model (GLRM) (Supplementary Fig.	('cough', 'Disease', (51, 56))	('dyspnea', 'Disease', (42, 49))	('chronic lymphoid disease', 'Disease', (174, 198))	('fever', 'Disease', (35, 40))	('sur', 'Gene', (141, 144))	('cough', 'Disease', 'MESH:D003371', (51, 56))	('sur', 'Gene', '6833', (141, 144))	('chronic lymphoid disease', 'Disease', 'MESH:D002908', (174, 198))	('dyspnea', 'Disease', 'MESH:D004417', (42, 49))	('fever', 'Disease', 'MESH:D005334', (35, 40))
41	35673599	The MI model included age, C-reactive Protein (CRP), D-dimers, LDH, neutrophils, lymphocytes, platelets, creatinine level, number of comorbidities, the archetype and patient gender, as well as the Nelson-Aalen estimator and death indicator, as recommended.	('CRP', 'Gene', (47, 50))	('LDH', 'MPA', (63, 66))	('death', 'Disease', (224, 229))	('C-reactive Protein', 'Gene', (27, 45))	('D-dimers', 'MPA', (53, 61))	('creatinine', 'MPA', (105, 115))	('CRP', 'Gene', '1401', (47, 50))	('C-reactive Protein', 'Gene', '1401', (27, 45))	('death', 'Disease', 'MESH:D003643', (224, 229))	('patient', 'Species', '9606', (166, 173))	('creatinine', 'Chemical', 'MESH:D003404', (105, 115))
47	35673599	The prevalence of comorbidities was high, mainly high blood pressure (39.5%), cardiac failure (20.5%) and diabetes mellitus (16.7%).	('sur', 'Gene', (64, 67))	('cardiac failure', 'Disease', (78, 93))	('diabetes mellitus', 'Disease', (106, 123))	('diabetes mellitus', 'Disease', 'MESH:D003920', (106, 123))	('sur', 'Gene', '6833', (64, 67))	('cardiac failure', 'Disease', 'MESH:D006333', (78, 93))
48	35673599	Cough, fever and dyspnea were the most common symptoms at admission and most of the patients had hematological malignancies (86.7%).	('dyspnea', 'Disease', (17, 24))	('fever', 'Disease', (7, 12))	('Cough', 'Disease', (0, 5))	('malignancies', 'Disease', (111, 123))	('patients', 'Species', '9606', (84, 92))	('dyspnea', 'Disease', 'MESH:D004417', (17, 24))	('malignancies', 'Disease', 'MESH:D009369', (111, 123))	('Cough', 'Disease', 'MESH:D003371', (0, 5))	('fever', 'Disease', 'MESH:D005334', (7, 12))
49	35673599	Non-Hodgkin Lymphoma (29.3%) and multiple myeloma (19.4%) were the most frequent hematological disorders.	('myeloma', 'Disease', (42, 49))	('hematological disorders', 'Disease', (81, 104))	('Non-Hodgkin Lymphoma', 'Disease', (0, 20))	('hematological disorders', 'Disease', 'MESH:D006402', (81, 104))	('Non-Hodgkin Lymphoma', 'Disease', 'MESH:D008228', (0, 20))	('myeloma', 'Disease', 'MESH:D009101', (42, 49))
51	35673599	The prevalence of comorbidities was higher among French (78% vs. 56%, p = 0.0002), mainly cardiac failure and COPD.	('cardiac failure', 'Disease', (90, 105))	('higher', 'PosReg', (36, 42))	('COPD', 'Disease', (110, 114))	('COPD', 'Disease', 'MESH:D029424', (110, 114))	('cardiac failure', 'Disease', 'MESH:D006333', (90, 105))
52	35673599	The clinical presentation at admission was similar in the two countries (all p > 0.18), except fever, that was more frequent in the French cohort (78.9% vs. 58.5%, p = 0.0005), and myalgia, that was more evident in the Brazilian group (16.3% vs. 7.8%, p = 0.039)).	('myalgia', 'Disease', (181, 188))	('fever', 'Disease', (95, 100))	('myalgia', 'Disease', 'MESH:D063806', (181, 188))	('fever', 'Disease', 'MESH:D005334', (95, 100))
53	35673599	The proportion of benign diseases was higher in the Brazilian cohort (p = 0.001).	('benign diseases', 'Disease', (18, 33))	('higher', 'PosReg', (38, 44))	('benign diseases', 'Disease', 'MESH:D009369', (18, 33))
55	35673599	A total of 60 deaths in the Brazilian cohort and 55 deaths among French patients were observed, with no evidence of different overall survival across countries (p = 0.54, Figure 1 ).	('deaths', 'Disease', (14, 20))	('sur', 'Gene', (134, 137))	('deaths', 'Disease', (52, 58))	('deaths', 'Disease', 'MESH:D003643', (14, 20))	('patients', 'Species', '9606', (72, 80))	('sur', 'Gene', '6833', (134, 137))	('deaths', 'Disease', 'MESH:D003643', (52, 58))
57	35673599	The ICU admission (56% versus 25%) and invasive ventilation (42% versus 19%) rates were notably higher among Brazilian patients due to scarce ICU beds during the peak of the transmission in France.	('invasive ventilation', 'CPA', (39, 59))	('higher', 'PosReg', (96, 102))	('patients', 'Species', '9606', (119, 127))
58	35673599	Parameters associated with a poor survival were (i) patient-related, namely, age, number of comorbidities, cardiovascular disease, chronic renal disease and smoking status; (ii) related to their hematological disease, namely, malignancies, and; (iii) biology-related, namely, low platelet count, high creatinine, C-reactive protein, D-dimers and LDH levels (Supplementary Table SI).	('D-dimers', 'MPA', (333, 341))	('low', 'NegReg', (276, 279))	('malignancies', 'Disease', (226, 238))	('high', 'MPA', (296, 300))	('C-reactive protein', 'Gene', (313, 331))	('LDH levels', 'MPA', (346, 356))	('sur', 'Gene', (34, 37))	('chronic renal disease', 'Disease', (131, 152))	('cardiovascular disease', 'Disease', (107, 129))	('hematological disease', 'Disease', (195, 216))	('patient', 'Species', '9606', (52, 59))	('malignancies', 'Disease', 'MESH:D009369', (226, 238))	('creatinine', 'Chemical', 'MESH:D003404', (301, 311))	('C-reactive protein', 'Gene', '1401', (313, 331))	('chronic renal disease', 'Disease', 'MESH:D051436', (131, 152))	('sur', 'Gene', '6833', (34, 37))	('cardiovascular disease', 'Disease', 'MESH:D002318', (107, 129))	('hematological disease', 'Disease', 'MESH:D006402', (195, 216))
59	35673599	As expected, blood cell counts were highly correlated, while age correlated with the number of comorbidities and creatinine levels (Supplementary Fig.	('creatinine levels', 'MPA', (113, 130))	('blood cell counts', 'CPA', (13, 30))	('creatinine', 'Chemical', 'MESH:D003404', (113, 123))
61	35673599	Similarly, patients overlapped whatever their hematological diagnosis, except for acute leukemia (AL) patients who exhibited low blood cell counts, likely illustrating their treatment-related aplasia (Supplementary Fig.	('aplasia', 'Disease', (192, 199))	('acute leukemia', 'Disease', (82, 96))	('AL', 'Disease', 'MESH:D009101', (98, 100))	('patients', 'Species', '9606', (102, 110))	('acute leukemia', 'Disease', 'MESH:D015470', (82, 96))	('patients', 'Species', '9606', (11, 19))	('aplasia', 'Disease', 'MESH:C563261', (192, 199))
65	35673599	A semi-supervised prognosis-driven learning analysis identified two profiles, further labeled Surv.+ and Surv.-, regrouping 162 and 86 patients, respectively (Figure 2 A).	('Surv.+', 'Var', (94, 100))	('Surv.-', 'Var', (105, 111))	('patients', 'Species', '9606', (135, 143))
66	35673599	The Surv.- profile regrouped older patients with increased prevalence of comorbidities, high CRP, LDH, D-dimers and creatinine levels (Figure 2 B) and a large proportion of male, myeloma and non-Hodgkin lymphoma (NHL) (Figure 2 C).	('non-Hodgkin lymphoma', 'Disease', (191, 211))	('myeloma', 'Disease', (179, 186))	('CRP', 'Gene', (93, 96))	('D-dimers', 'MPA', (103, 111))	('LDH', 'MPA', (98, 101))	('creatinine levels', 'MPA', (116, 133))	('male', 'Disease', (173, 177))	('non-Hodgkin lymphoma', 'Disease', 'MESH:D008228', (191, 211))	('creatinine', 'Chemical', 'MESH:D003404', (116, 126))	('patients', 'Species', '9606', (35, 43))	('myeloma', 'Disease', 'MESH:D009101', (179, 186))	('CRP', 'Gene', '1401', (93, 96))
67	35673599	Similar COVID-19 initial presentation was observed in both profiles, except dyspnea, that was more prevalent in the Surv.- profile (71% vs. 57%).	('dyspnea', 'Disease', (76, 83))	('COVID-19', 'Disease', (8, 16))	('COVID-19', 'Disease', 'MESH:C000657245', (8, 16))	('dyspnea', 'Disease', 'MESH:D004417', (76, 83))
68	35673599	The two profiles did not differ on the country origin and included similar proportions of non-malignancies, asymptomatic COVID-19e patients, as well as time from symptoms onset and the hospitalization.	('COVID-19', 'Disease', (121, 129))	('malignancies', 'Disease', (94, 106))	('malignancies', 'Disease', 'MESH:D009369', (94, 106))	('COVID-19', 'Disease', 'MESH:C000657245', (121, 129))	('patients', 'Species', '9606', (131, 139))
69	35673599	Patients from the two profiles markedly differed in survival outcome (HR 2.72 [1.84; 4.02]; p < 0.0001), with the Surv.- profile being of poor prognosis (Figure 2 D).	('sur', 'Gene', (52, 55))	('poor', 'NegReg', (138, 142))	('Patients', 'Species', '9606', (0, 8))	('sur', 'Gene', '6833', (52, 55))
70	35673599	Even after adjusting for well-known poor prognosis factors in the COVID-19 pandemic, such as the patient age, the prognostic value of the two profiles persisted (HR 2.19 [1.45; 3.31]; p = 0.0002), denoting the clinical implications of these profiles.	('COVID-19', 'Disease', (66, 74))	('prognostic value', 'MPA', (114, 130))	('patient', 'Species', '9606', (97, 104))	('COVID-19', 'Disease', 'MESH:C000657245', (66, 74))
73	35673599	These patients were quite old, with high CRP and D-dimers levels, but with low creatinine levels and a low number of comorbidities (Table 1).	('CRP', 'Gene', (41, 44))	('D-dimers levels', 'MPA', (49, 64))	('high', 'PosReg', (36, 40))	('creatinine', 'Chemical', 'MESH:D003404', (79, 89))	('patients', 'Species', '9606', (6, 14))	('CRP', 'Gene', '1401', (41, 44))
76	35673599	The baseline predictors consecutively selected by the model were the number of comorbidities, creatinine, C-reactive protein, a continuous regimen of chemotherapy, platelets and lymphocytes counts, a symptom of ageusia, dyspnea, malignancy of the hematological disease, high blood pressure and symptom of myalgia (Table 3 ).	('symptom', 'Disease', (294, 301))	('dyspnea', 'Disease', (220, 227))	('C-reactive protein', 'Gene', (106, 124))	('creatinine', 'MPA', (94, 104))	('ageusia', 'Disease', (211, 218))	('sur', 'Gene', (285, 288))	('myalgia', 'Disease', (305, 312))	('malignancy of the hematological disease', 'Disease', (229, 268))	('malignancy of the hematological disease', 'Disease', 'MESH:D019337', (229, 268))	('creatinine', 'Chemical', 'MESH:D003404', (94, 104))	('sur', 'Gene', '6833', (285, 288))	('ageusia', 'Disease', 'MESH:D000370', (211, 218))	('dyspnea', 'Disease', 'MESH:D004417', (220, 227))	('C-reactive protein', 'Gene', '1401', (106, 124))	('myalgia', 'Disease', 'MESH:D063806', (305, 312))
78	35673599	In this paper, we analyzed a binational cohort of hospitalized patients with a hematological disorder and a COVID-19 infection.	('hematological disorder', 'Disease', (79, 101))	('infection', 'Disease', (117, 126))	('COVID-19', 'Disease', (108, 116))	('hematological disorder', 'Disease', 'MESH:D006402', (79, 101))	('infection', 'Disease', 'MESH:D007239', (117, 126))	('COVID-19', 'Disease', 'MESH:C000657245', (108, 116))	('patients', 'Species', '9606', (63, 71))
82	35673599	Another difference was that the proportion of benign hematological diseases was higher in the Brazilian cohort.	('benign hematological diseases', 'Disease', (46, 75))	('higher', 'PosReg', (80, 86))	('benign hematological diseases', 'Disease', 'MESH:D006402', (46, 75))
83	35673599	Those baseline differences could have induced a higher mortality rate among French patients.	('mortality', 'Disease', (55, 64))	('higher', 'PosReg', (48, 54))	('mortality', 'Disease', 'MESH:D003643', (55, 64))	('patients', 'Species', '9606', (83, 91))
85	35673599	However, some studies have speculated that demographics, including ethnicity and socioeconomic factors, may influence COVID-19 mortality rates in Brazil, which possibly counterbalanced the pejorative effect of age and comorbidities in France.	('COVID-19', 'Disease', (118, 126))	('mortality', 'Disease', (127, 136))	('influence', 'Reg', (108, 117))	('mortality', 'Disease', 'MESH:D003643', (127, 136))	('COVID-19', 'Disease', 'MESH:C000657245', (118, 126))
86	35673599	Despite those differences and because of them, we aimed to provide patient profiles of COVID-19 patients with hematological diseases, to better understand their presentation and outcome, using those two cohorts.	('COVID-19', 'Disease', (87, 95))	('hematological diseases', 'Disease', (110, 132))	('patients', 'Species', '9606', (96, 104))	('patient', 'Species', '9606', (67, 74))	('patient', 'Species', '9606', (96, 103))	('hematological diseases', 'Disease', 'MESH:D006402', (110, 132))	('COVID-19', 'Disease', 'MESH:C000657245', (87, 95))
87	35673599	Based on a semi-supervised learning approach, we found two distinct profiles involving age, comorbidities and biological parameters previously identified as being associated with COVID-19 severity in the literature, such as CRP, D-dimers, LDH and creatinine levels.	('LDH', 'MPA', (239, 242))	('creatinine levels', 'MPA', (247, 264))	('D-dimers', 'MPA', (229, 237))	('CRP', 'Gene', (224, 227))	('COVID-19', 'Disease', (179, 187))	('creatinine', 'Chemical', 'MESH:D003404', (247, 257))	('CRP', 'Gene', '1401', (224, 227))	('COVID-19', 'Disease', 'MESH:C000657245', (179, 187))
88	35673599	Regarding the hematological diseases, most of the information was obtained from lymphomas, as opposed to myelomas.	('lymphomas', 'Disease', (80, 89))	('myelomas', 'Disease', (105, 113))	('hematological diseases', 'Disease', (14, 36))	('myelomas', 'Disease', 'MESH:D009101', (105, 113))	('hematological diseases', 'Disease', 'MESH:D006402', (14, 36))	('lymphomas', 'Disease', 'MESH:D008223', (80, 89))
92	35673599	Interestingly, these country-dependent specificities faded at the population level, as the profiles identified with the whole cohort mostly relied on parameters, such as the CRP level or the number of comorbidities, independently of the country origin.	('CRP', 'Gene', (174, 177))	('relied', 'Reg', (140, 146))	('CRP', 'Gene', '1401', (174, 177))
94	35673599	Nevertheless, we focused on patients with a hematological disease, a population in which the SARS-CoV-2 infection was not widely studied, and mostly within large and broad cancer cohorts.	('cancer', 'Disease', (172, 178))	('hematological disease', 'Disease', (44, 65))	('SARS-CoV-2 infection', 'Disease', (93, 113))	('patients', 'Species', '9606', (28, 36))	('hematological disease', 'Disease', 'MESH:D006402', (44, 65))	('SARS-CoV-2 infection', 'Disease', 'MESH:C000657245', (93, 113))	('cancer', 'Disease', 'MESH:D009369', (172, 178))
95	35673599	The data collection used two different databases, though recorded information was largely standardized across the two countries, regarding both the SARS-CoV-2 infection and the hematological disease.	('SARS-CoV-2 infection', 'Disease', (148, 168))	('hematological disease', 'Disease', (177, 198))	('SARS-CoV-2 infection', 'Disease', 'MESH:C000657245', (148, 168))	('hematological disease', 'Disease', 'MESH:D006402', (177, 198))
96	35673599	However, identifying profiles from a survival analysis would not ensure the accountability of the variability and heterogeneity in the original data.	('not', 'NegReg', (61, 64))	('sur', 'Gene', (37, 40))	('sur', 'Gene', (67, 70))	('sur', 'Gene', '6833', (67, 70))	('sur', 'Gene', '6833', (37, 40))
99	35673599	Second, all collected data relate to patients who contracted the SARS-CoV-2 in the first year of the COVID-19 pandemic, that is, to the first wave and part of the second wave, in both countries studied.	('COVID-19', 'Disease', (101, 109))	('SARS-CoV-2', 'Gene', (65, 75))	('SARS-CoV-2', 'Species', '2697049', (65, 75))	('COVID-19', 'Disease', 'MESH:C000657245', (101, 109))	('patients', 'Species', '9606', (37, 45))
100	35673599	The situation related to the COVID-19 infection evolves rapidly and treatments and care strategies have also evolved, notably with the availability of vaccines.	('COVID-19', 'Disease', (29, 37))	('infection', 'Disease', (38, 47))	('COVID-19', 'Disease', 'MESH:C000657245', (29, 37))	('infection', 'Disease', 'MESH:D007239', (38, 47))
101	35673599	This study brings insights on the prognostic value of standard laboratory markers for patients with a hematological disorder and affected by COVID-19, which may be directly relevant in countries with low vaccination rates.	('COVID-19', 'Disease', (141, 149))	('affected', 'Reg', (129, 137))	('hematological disorder', 'Disease', (102, 124))	('hematological disorder', 'Disease', 'MESH:D006402', (102, 124))	('patients', 'Species', '9606', (86, 94))	('COVID-19', 'Disease', 'MESH:C000657245', (141, 149))
103	35673599	This analysis framework could be applied to other cohorts of COVID-19-affected patients, or to any other severe infections.	('COVID-19', 'Disease', (61, 69))	('infections', 'Disease', (112, 122))	('infections', 'Disease', 'MESH:D007239', (112, 122))	('COVID-19', 'Disease', 'MESH:C000657245', (61, 69))	('patients', 'Species', '9606', (79, 87))
104	35673599	In conclusion, in this study, a novel analysis strategy was used, which consisted in identifying clinical-based patient profiles that directly relate to a survival outcome.	('sur', 'Gene', (155, 158))	('relate', 'Reg', (143, 149))	('patient', 'Species', '9606', (112, 119))	('sur', 'Gene', '6833', (155, 158))
105	35673599	We were thus able to identify two profiles of hospitalized hematological patients infected with SARS-CoV-2 who differed in outcomes.	('infected', 'Disease', (82, 90))	('SARS-CoV-2', 'Var', (96, 106))	('infected', 'Disease', 'MESH:D007239', (82, 90))	('SARS-CoV-2', 'Species', '2697049', (96, 106))	('patients', 'Species', '9606', (73, 81))
106	35673599	These profiles mainly differed on age, number of comorbidities and four standard biology markers: CRP, D-dimers, LDH and creatinine.	('differed', 'Reg', (22, 30))	('D-dimers', 'MPA', (103, 111))	('CRP', 'Gene', (98, 101))	('creatinine', 'MPA', (121, 131))	('LDH', 'MPA', (113, 116))	('CRP', 'Gene', '1401', (98, 101))	('creatinine', 'Chemical', 'MESH:D003404', (121, 131))
109	35673599	Projection of the patients, with color according to country (B), hematological diagnosis (C) ICU admission (D), survival status of the patient, and; (E) aplasia (F).	('sur', 'Gene', (112, 115))	('aplasia', 'Disease', (153, 160))	('ICU', 'Disease', (93, 96))	('patient', 'Species', '9606', (135, 142))	('patient', 'Species', '9606', (18, 25))	('patients', 'Species', '9606', (18, 26))	('sur', 'Gene', '6833', (112, 115))	('aplasia', 'Disease', 'MESH:C563261', (153, 160))
110	35673599	Interpretation can be made according to panel A, for example, patients in aplasia (panel F) are the ones with low neutrophils, lymphocytes and platelets counts.	('aplasia', 'Disease', (74, 81))	('low', 'NegReg', (110, 113))	('aplasia', 'Disease', 'MESH:C563261', (74, 81))	('patients', 'Species', '9606', (62, 70))
112	35371214	Emotional Experience and Psychological Intervention of Depression Patients Based on SOM Depression is a severe mental illness with an unknown pathogenesis.	('Depression', 'Disease', (55, 65))	('mental illness', 'Disease', (111, 125))	('Depression', 'Disease', (88, 98))	('Depression', 'Disease', 'MESH:D000275', (55, 65))	('Depression', 'Disease', 'MESH:D000275', (88, 98))	('mental illness', 'Disease', 'MESH:D002908', (111, 125))	('Patients', 'Species', '9606', (66, 74))
113	35371214	The SOM (self-organizing feature mapping) model was used to identify the depression tendency of users in order to investigate the emotional experience and psychological intervention of patients with depression.	('depression', 'Disease', (199, 209))	('depression', 'Disease', (73, 83))	('depression', 'Disease', 'MESH:D000275', (73, 83))	('patients', 'Species', '9606', (185, 193))	('depression', 'Disease', 'MESH:D000275', (199, 209))
114	35371214	On this foundation, the concept of depression index is developed further, and the relationship between depression index and the severity of depression in patients is thoroughly investigated.	('depression', 'Disease', (103, 113))	('depression', 'Disease', (140, 150))	('depression', 'Disease', (35, 45))	('patients', 'Species', '9606', (154, 162))	('depression', 'Disease', 'MESH:D000275', (103, 113))	('depression', 'Disease', 'MESH:D000275', (140, 150))	('depression', 'Disease', 'MESH:D000275', (35, 45))
115	35371214	The system can accurately and quickly identify the depression state by applying it directly to the original EEG signals, without any preprocessing or feature extraction.	('depression', 'Disease', (51, 61))	('EEG signals', 'MPA', (108, 119))	('depression', 'Disease', 'MESH:D000275', (51, 61))
116	35371214	When combined with traditional classifiers, the analysis and comparison results show that SOM can not only effectively select features but also improve the accuracy of depression classification.	('depression', 'Disease', (168, 178))	('improve', 'PosReg', (144, 151))	('accuracy', 'MPA', (156, 164))	('depression', 'Disease', 'MESH:D000275', (168, 178))
117	35371214	Depression is a common emotional disorder with a high occurrence rate, a high recurrence rate, a high suicide rate, a high rate of disability, and a high social burden.	('Depression', 'Disease', (0, 10))	('emotional disorder', 'Disease', (23, 41))	('emotional disorder', 'Disease', 'MESH:D030342', (23, 41))	('Depression', 'Disease', 'MESH:D000275', (0, 10))
118	35371214	Currently, the rate of depression recognition is low, and the proportion of patients who can be identified and treated in a timely, sufficient, and adequate manner is even lower.	('depression', 'Disease', (23, 33))	('low', 'NegReg', (49, 52))	('lower', 'NegReg', (172, 177))	('patients', 'Species', '9606', (76, 84))	('depression', 'Disease', 'MESH:D000275', (23, 33))
120	35371214	The six mental disorders (mood disorders, anxiety disorders, alcohol/drug addiction disorders, schizophrenia and related mental disorders, eating disorders, and impulse control disorders) accounted for 9.3% of the total, with mood disorders accounting for the majority of the cases.	('schizophrenia', 'Disease', (95, 108))	('mental disorders', 'Disease', (121, 137))	('mood disorders', 'Disease', (226, 240))	('drug addiction disorders', 'Disease', (69, 93))	('eating disorders', 'Disease', (139, 155))	('anxiety disorders', 'Disease', (42, 59))	('mood disorders', 'Disease', (26, 40))	('mental disorders', 'Disease', (8, 24))	('mental disorders', 'Disease', 'MESH:D001523', (8, 24))	('eating disorders', 'Disease', 'MESH:D001068', (139, 155))	('mood disorders', 'Disease', 'MESH:D019964', (26, 40))	('schizophrenia', 'Disease', 'MESH:D012559', (95, 108))	('mood disorders', 'Disease', 'MESH:D019964', (226, 240))	('drug addiction disorders', 'Disease', 'MESH:D019966', (69, 93))	('mental disorders', 'Disease', 'MESH:D001523', (121, 137))	('anxiety disorders', 'Disease', 'MESH:D001007', (42, 59))
126	35371214	Personalized nursing pays more attention to the patient's own characteristics, and a reasonable nursing plan is tailored according to the patient's condition, age, education level, etc., and comprehensive in-depth nursing is implemented to improve the recovery speed of patients.	('improve', 'PosReg', (240, 247))	('recovery', 'MPA', (252, 260))	('patient', 'Species', '9606', (48, 55))	('patient', 'Species', '9606', (138, 145))	('patient', 'Species', '9606', (270, 277))	('patients', 'Species', '9606', (270, 278))
128	35371214	At this time, research indicates that the mechanism of depression is primarily related to abnormal activity in emotional regulation brain regions, and a large number of studies have focused on specific brain regions and neural circuits, such as the prefrontal cortex, anterior cingulate cortex, and subcortical amygdala, hippocampus, habenular nucleus, and hypothalamus.	('depression', 'Disease', (55, 65))	('activity', 'MPA', (99, 107))	('hypothalamus', 'Disease', (357, 369))	('hypothalamus', 'Disease', 'MESH:D007029', (357, 369))	('depression', 'Disease', 'MESH:D000275', (55, 65))
129	35371214	Long-term use of antidepressants causes damage to the liver, kidneys, extravertebral system, and other organs, and the recurrence rate is very high after stopping antidepressants, so the psychological state of patients has not improved significantly, and patients frequently cannot receive appropriate treatment, and their prognosis is poor.	('not', 'NegReg', (223, 226))	('psychological', 'MPA', (187, 200))	('recurrence', 'CPA', (119, 129))	('patients', 'Species', '9606', (210, 218))	('patients', 'Species', '9606', (255, 263))
130	35371214	The purpose of this study is to understand the emotional experience and psychological intervention of patients with depression, explore the effect of psychological intervention on their negative emotional experience, provide suggestions for clinical nursing, and provide reference for the majority of clinical medical staff to implement intervention measures for patients with depression.	('negative', 'MPA', (186, 194))	('depression', 'Disease', (116, 126))	('depression', 'Disease', (377, 387))	('depression', 'Disease', 'MESH:D000275', (377, 387))	('patients', 'Species', '9606', (102, 110))	('patients', 'Species', '9606', (363, 371))	('depression', 'Disease', 'MESH:D000275', (116, 126))
133	35371214	In, studies show that depression is a high-cost disease.	('depression', 'Disease', (22, 32))	('high-cost disease', 'Disease', (38, 55))	('depression', 'Disease', 'MESH:D000275', (22, 32))	('high-cost disease', 'Disease', 'MESH:D052456', (38, 55))
134	35371214	Early detection and treatment, especially, early diagnosis and effective treatment by physicians in general hospitals, can reduce the course of depression and suicide and can significantly reduce functional impairment and medical resource consumption, thus reducing the total burden of depression.	('depression', 'Disease', (144, 154))	('reducing', 'NegReg', (257, 265))	('depression', 'Disease', (286, 296))	('reduce', 'NegReg', (123, 129))	('course', 'MPA', (134, 140))	('functional', 'MPA', (196, 206))	('suicide', 'Disease', (159, 166))	('reduce', 'NegReg', (189, 195))	('depression', 'Disease', 'MESH:D000275', (286, 296))	('depression', 'Disease', 'MESH:D000275', (144, 154))
136	35371214	Literature holds that it is necessary to encourage the patient's spirit of tenacious struggle against the disease, mobilize the patient's subjective initiative to fight against the disease, and work with doctors to obtain the patient's cooperation and improve the curative effect.	('encourage', 'PosReg', (41, 50))	('mobilize', 'PosReg', (115, 123))	('curative effect', 'CPA', (264, 279))	('improve', 'PosReg', (252, 259))	('patient', 'Species', '9606', (226, 233))	('patient', 'Species', '9606', (128, 135))	('patient', 'Species', '9606', (55, 62))
137	35371214	According to, identifying the harbinger of disease recurrence can encourage patients to see a doctor sooner rather than later, thereby controlling symptoms, significantly improving discharged mental patients' compliance, and effectively lowering the recurrence rate.	('lowering', 'NegReg', (237, 245))	('discharged mental patients', 'MPA', (181, 207))	('recurrence rate', 'CPA', (250, 265))	('improving', 'PosReg', (171, 180))	('compliance', 'MPA', (209, 219))	('encourage', 'PosReg', (66, 75))	('patients', 'Species', '9606', (76, 84))	('patients', 'Species', '9606', (199, 207))
139	35371214	In, the relatives of 56 anxiety disorder inpatients were followed for 9 months, and it was discovered that the recurrence rate of patients in the high emotional experience family group was significantly higher than that of the low emotional experience family group.	('higher', 'PosReg', (203, 209))	('anxiety disorder', 'Disease', (24, 40))	('recurrence rate', 'CPA', (111, 126))	('patients', 'Species', '9606', (130, 138))	('patients', 'Species', '9606', (43, 51))	('anxiety disorder', 'Disease', 'MESH:D001007', (24, 40))
140	35371214	In, the results of a study of 86 psychotic patients and their relatives revealed that patients with a lot of emotional experience had higher depression and anxiety scores, but no significant difference in psychotic symptoms.	('anxiety', 'Disease', (156, 163))	('psychotic', 'Disease', (205, 214))	('higher', 'PosReg', (134, 140))	('psychotic', 'Disease', (33, 42))	('depression', 'Disease', (141, 151))	('psychotic symptoms', 'Disease', (205, 223))	('patients', 'Species', '9606', (86, 94))	('psychotic', 'Disease', 'MESH:D011618', (205, 214))	('psychotic symptoms', 'Disease', 'MESH:D011605', (205, 223))	('psychotic', 'Disease', 'MESH:D011618', (33, 42))	('anxiety', 'Disease', 'MESH:D001007', (156, 163))	('depression', 'Disease', 'MESH:D000275', (141, 151))	('patients', 'Species', '9606', (43, 51))
141	35371214	This study suggests that emotional experience may be more reliable than schizophrenia in predicting depression outcomes.	('depression', 'Disease', (100, 110))	('schizophrenia', 'Disease', (72, 85))	('schizophrenia', 'Disease', 'MESH:D012559', (72, 85))	('depression', 'Disease', 'MESH:D000275', (100, 110))
143	35371214	Family intervention can help patients with schizophrenia have fewer relapses and improve their social functioning.	('schizophrenia', 'Disease', (43, 56))	('social functioning', 'CPA', (95, 113))	('schizophrenia', 'Disease', 'MESH:D012559', (43, 56))	('patients', 'Species', '9606', (29, 37))
144	35371214	Early brain imaging studies based on voxel morphological measurement found that patients with unipolar depression had reduced gray matter volume, which was related to their psychopathology and cognitive dysfunction.	('cognitive dysfunction', 'Disease', (193, 214))	('reduced', 'NegReg', (118, 125))	('gray matter volume', 'MPA', (126, 144))	('unipolar depression', 'Disease', (94, 113))	('related', 'Reg', (156, 163))	('unipolar depression', 'Disease', 'MESH:D000275', (94, 113))	('patients', 'Species', '9606', (80, 88))	('cognitive dysfunction', 'Disease', 'MESH:D003072', (193, 214))
147	35371214	Literature has built an intermediary model, which shows that depression factors in families are influenced by family identity factors and insomnia factors.	('influenced', 'Reg', (96, 106))	('depression', 'Disease', (61, 71))	('insomnia', 'Disease', (138, 146))	('depression', 'Disease', 'MESH:D000275', (61, 71))	('insomnia', 'Disease', 'MESH:D007319', (138, 146))
148	35371214	Thus, sleep quality, study, family identity, and other dimensions all have an important influence on depression, indicating that the diversity of dimensions also has a positive effect on the identification of depression.	('positive effect', 'PosReg', (168, 183))	('depression', 'Disease', (101, 111))	('depression', 'Disease', (209, 219))	('depression', 'Disease', 'MESH:D000275', (209, 219))	('depression', 'Disease', 'MESH:D000275', (101, 111))
150	35371214	Literature classifies patients into different types for the purpose of using online healthy communities, analyzes the patients' network information behaviors, and finds that there are significant differences in personal health information management behaviors of patients with depression in online healthy communities.	('personal health information management behaviors', 'MPA', (211, 259))	('depression', 'Disease', (277, 287))	('patients', 'Species', '9606', (118, 126))	('depression', 'Disease', 'MESH:D000275', (277, 287))	('patients', 'Species', '9606', (22, 30))	('patients', 'Species', '9606', (263, 271))
153	35371214	The widespread negative emotional experience of depression patients has had a significant impact on their rehabilitation and quality of life and is a roadblock in the development of health care.	('depression', 'Disease', (48, 58))	('negative', 'NegReg', (15, 23))	('depression', 'Disease', 'MESH:D000275', (48, 58))	('patients', 'Species', '9606', (59, 67))
157	35371214	The family emotional experience of depression can be improved, the mental health of family members can be improved, family harmony can be promoted, and depression patients' symptoms can be alleviated through targeted group counseling for family members, which can meet the actual needs of family intervention for depression patients more economically and effectively.	('depression', 'Disease', (35, 45))	('mental', 'CPA', (67, 73))	('depression', 'Disease', (152, 162))	('depression', 'Disease', (313, 323))	('family', 'CPA', (116, 122))	('improved', 'PosReg', (53, 61))	('promoted', 'PosReg', (138, 146))	('improved', 'PosReg', (106, 114))	('patients', 'Species', '9606', (324, 332))	('patients', 'Species', '9606', (163, 171))	('depression', 'Disease', 'MESH:D000275', (313, 323))	('depression', 'Disease', 'MESH:D000275', (152, 162))	('depression', 'Disease', 'MESH:D000275', (35, 45))
159	35371214	To explore the characteristics of brain activation in patients with depression under the task of positive and negative emotion induction and to test the hypothesis of emotional background insensitivity, during the experiment, each picture is presented as an experiment.	('depression', 'Disease', (68, 78))	('brain activation', 'MPA', (34, 50))	('depression', 'Disease', 'MESH:D000275', (68, 78))	('patients', 'Species', '9606', (54, 62))
160	35371214	After the experiment, the degree of instruction execution was checked, and all the subjects could understand the instruction and implement the instruction requirements during the experiment, including the distribution characteristics of family emotional experience of depression patients, the proportion of high emotional experience and low emotional experience, the mental health status of depression patients and their families, coping styles, and social support,.	('depression', 'Disease', (391, 401))	('depression', 'Disease', (268, 278))	('patients', 'Species', '9606', (279, 287))	('patients', 'Species', '9606', (402, 410))	('depression', 'Disease', 'MESH:D000275', (268, 278))	('depression', 'Disease', 'MESH:D000275', (391, 401))
161	35371214	Carry out group counseling research on family emotional experience intervention of depression patients, and design targeted group counseling implementation scheme based on the investigation of family emotional experience status of depression patients.	('depression', 'Disease', (83, 93))	('depression', 'Disease', (231, 241))	('depression', 'Disease', 'MESH:D000275', (83, 93))	('patients', 'Species', '9606', (242, 250))	('patients', 'Species', '9606', (94, 102))	('depression', 'Disease', 'MESH:D000275', (231, 241))
163	35371214	Negative life events and independent events may be important factors for the occurrence or recurrence of depression, while positive life events are obviously related to the occurrence or recurrence of mania.	('mania', 'Disease', (201, 206))	('related', 'Reg', (158, 165))	('depression', 'Disease', (105, 115))	('mania', 'Disease', 'MESH:D001714', (201, 206))	('depression', 'Disease', 'MESH:D000275', (105, 115))
166	35371214	As a subconscious response to conflict, a defense mechanism is a set of habitual adaptive behaviors that people use to avoid and relieve mental stress such as anxiety when confronted with a variety of frustrating situations.	('mental stress', 'Disease', (137, 150))	('anxiety', 'Disease', (159, 166))	('relieve', 'NegReg', (129, 136))	('people', 'Species', '9606', (105, 111))	('mental stress', 'Disease', 'MESH:D000079225', (137, 150))	('anxiety', 'Disease', 'MESH:D001007', (159, 166))
168	35371214	Neurosis patients, including neurotic depression patients, use immature defense mechanisms more than mature defense mechanisms, according to a comprehensive study.	('Neurosis', 'Disease', (0, 8))	('neurotic depression', 'Disease', (29, 48))	('Neurosis', 'Disease', 'MESH:D009449', (0, 8))	('patients', 'Species', '9606', (49, 57))	('neurotic depression', 'Disease', 'MESH:D000275', (29, 48))	('patients', 'Species', '9606', (9, 17))
175	35371214	When judging the depression tendency of online users from the perspective of text analysis, the depression index of users is calculated by the proportion of depression Weibo to the total Weibo number of users, so as to measure the depression tendency of users in a certain period of time.	('depression', 'Disease', (231, 241))	('depression', 'Disease', (96, 106))	('depression', 'Disease', (157, 167))	('depression', 'Disease', (17, 27))	('depression', 'Disease', 'MESH:D000275', (157, 167))	('depression', 'Disease', 'MESH:D000275', (96, 106))	('depression', 'Disease', 'MESH:D000275', (17, 27))	('depression', 'Disease', 'MESH:D000275', (231, 241))
176	35371214	A depression index based on online healthy community is proposed, and the calculation formula is as follows:where Ncd refers to the number of Weibo posts with depression tendency published by users in other accounts within a certain period of time, Nct refers to the number of Weibo posts published by users in other accounts within a certain period of time, Nmd refers to the number of Weibo posts with depression tendency distributed and forwarded by users in personal accounts within a certain period of time, Nmt refers to the number of Weibo posts distributed and forwarded by users in personal accounts within a certain period of time, and DI is the depression index.	('depression', 'Disease', (159, 169))	('Nmt', 'Gene', (513, 516))	('depression', 'Disease', (656, 666))	('depression', 'Disease', (2, 12))	('depression', 'Disease', (404, 414))	('depression', 'Disease', 'MESH:D000275', (404, 414))	('depression', 'Disease', 'MESH:D000275', (2, 12))	('depression', 'Disease', 'MESH:D000275', (656, 666))	('depression', 'Disease', 'MESH:D000275', (159, 169))	('Nmt', 'Gene', '4836', (513, 516))
178	35371214	Besides text information, there are other types of feature information that can be used in the analysis of depression tendency prediction to help improve the recognition rate.	('depression', 'Disease', (107, 117))	('recognition', 'MPA', (158, 169))	('depression', 'Disease', 'MESH:D000275', (107, 117))
179	35371214	Excel calculates the arousal rating of depression patients and normal CG emotions (1-4 grades, representing "almost no feeling," "weak," "strong," and "very strong"), as well as the average value for each group.	('depression', 'Disease', (39, 49))	('arousal', 'MPA', (21, 28))	('CG', 'Gene', '1511', (70, 72))	('patients', 'Species', '9606', (50, 58))	('depression', 'Disease', 'MESH:D000275', (39, 49))
180	35371214	There was no significant difference in arousal degree evaluation of neutral, positive, and negative emotional materials and CG in patients with depression, according to the findings (Figure 5).	('depression', 'Disease', (144, 154))	('arousal', 'MPA', (39, 46))	('CG', 'Gene', '1511', (124, 126))	('patients', 'Species', '9606', (130, 138))	('depression', 'Disease', 'MESH:D000275', (144, 154))
181	35371214	Independent double sample T test was used to compare the brain activation areas and their intensity of emotional stimulation materials with a different potency in depression group and normal CG emotional evaluation task.	('depression', 'Disease', (163, 173))	('intensity', 'MPA', (90, 99))	('brain activation areas', 'MPA', (57, 79))	('CG', 'Gene', '1511', (191, 193))	('depression', 'Disease', 'MESH:D000275', (163, 173))
182	35371214	The differences in brain activation of negative emotional stimulus materials between the two groups are as follows: the activation of right posterior cingulate gyrus, anterior cingulate gyrus, and right anterior wedge lobe in depression group are less than that in normal CG.	('activation', 'MPA', (120, 130))	('depression', 'Disease', (226, 236))	('brain activation', 'MPA', (19, 35))	('less', 'NegReg', (247, 251))	('CG', 'Gene', '1511', (272, 274))	('depression', 'Disease', 'MESH:D000275', (226, 236))
183	35371214	The descriptive statistics of behavioral results show that the arousal degree of positive, medium, and negative emotional materials in the patient group is lower than CG, in which the arousal degree of positive and negative emotions is consistent and higher than that of neutral emotions, and the arousal degree of positive emotions is slightly lower than that of negative emotions.	('higher', 'PosReg', (251, 257))	('lower', 'NegReg', (156, 161))	('arousal', 'MPA', (297, 304))	('arousal', 'MPA', (184, 191))	('lower', 'NegReg', (345, 350))	('arousal', 'MPA', (63, 70))	('CG', 'Gene', '1511', (167, 169))	('patient', 'Species', '9606', (139, 146))
184	35371214	Only the activated and weakened brain regions were discovered in the patient group when positive emotion induction was used, and only the activated and enhanced brain regions were discovered when negative emotion induction was used.	('brain regions', 'MPA', (161, 174))	('enhanced', 'PosReg', (152, 160))	('brain regions', 'MPA', (32, 45))	('patient', 'Species', '9606', (69, 76))
185	35371214	Patients with depression may have a negative bias in their emotional responses, but this hypothesis must be tested against normal CG.	('negative', 'NegReg', (36, 44))	('depression', 'Disease', (14, 24))	('emotional responses', 'MPA', (59, 78))	('CG', 'Gene', '1511', (130, 132))	('Patients', 'Species', '9606', (0, 8))	('depression', 'Disease', 'MESH:D000275', (14, 24))
187	35371214	It was found that the activation of anterior and posterior cingulate gyrus and right anterior cuneiform lobe was weakened under the condition of negative emotion induction in patients with depression.	('activation', 'MPA', (22, 32))	('weakened', 'NegReg', (113, 121))	('depression', 'Disease', (189, 199))	('depression', 'Disease', 'MESH:D000275', (189, 199))	('patients', 'Species', '9606', (175, 183))
189	35371214	As can be seen from Figure 8, the immature defense style and intermediate defense style of depression group are significantly higher than those of CG, but there is no significant difference between mature defense style and masking factor.	('intermediate', 'MPA', (61, 73))	('higher', 'PosReg', (126, 132))	('depression', 'Disease', (91, 101))	('immature', 'MPA', (34, 42))	('CG', 'Gene', '1511', (147, 149))	('depression', 'Disease', 'MESH:D000275', (91, 101))
191	35371214	The results show that the frequency of negative life events and the total intensity of life events in depression group are higher than those in CG, and there are significant differences.	('higher', 'PosReg', (123, 129))	('depression', 'Disease', (102, 112))	('intensity', 'MPA', (74, 83))	('CG', 'Gene', '1511', (144, 146))	('depression', 'Disease', 'MESH:D000275', (102, 112))
193	35371214	Some people in the CG have a higher frequency of negative life events and a higher total intensity of life events, whereas some people in the depression group have a lower frequency of negative life events and a lower total intensity of life events, suggesting that the occurrence of negative life events can help us predict or explain the occurrence of depression in general.	('depression', 'Disease', (354, 364))	('depression', 'Disease', (142, 152))	('lower', 'NegReg', (166, 171))	('total intensity', 'MPA', (218, 233))	('depression', 'Disease', 'MESH:D000275', (142, 152))	('depression', 'Disease', 'MESH:D000275', (354, 364))	('people', 'Species', '9606', (128, 134))	('people', 'Species', '9606', (5, 11))	('CG', 'Gene', '1511', (19, 21))
196	35371214	Even in depression patients, mature defense mechanisms will be used, but the frequency that depression patients may use immature and intermediate defense mechanisms is much higher than that of them.	('depression', 'Disease', (92, 102))	('depression', 'Disease', (8, 18))	('higher', 'PosReg', (173, 179))	('depression', 'Disease', 'MESH:D000275', (92, 102))	('depression', 'Disease', 'MESH:D000275', (8, 18))	('patients', 'Species', '9606', (19, 27))	('patients', 'Species', '9606', (103, 111))
197	35371214	Psychological problems such as depression are not caused by the obstacles in the use of certain defense mechanisms, but related to the imbalance in the use of immature defense mechanisms, intermediate defense mechanisms, and mature defense mechanisms.	('depression', 'Disease', (31, 41))	('Psychological', 'Disease', (0, 13))	('imbalance', 'MPA', (135, 144))	('depression', 'Disease', 'MESH:D000275', (31, 41))
198	35371214	The F1-score of four variants of SOM and the control model in different depression grades are shown in Figure 9.	('depression', 'Disease', (72, 82))	('F1-score', 'MPA', (4, 12))	('depression', 'Disease', 'MESH:D000275', (72, 82))
199	35371214	The classification performance of SOM in this study has obvious advantages over CG.	('advantages', 'PosReg', (64, 74))	('classification', 'CPA', (4, 18))	('CG', 'Gene', '1511', (80, 82))
200	35371214	Compared with other models, SOM (especially mul + add) can better and more accurately identify people with severe depression, which is very valuable in the screening of depression.	('depression', 'Disease', (114, 124))	('depression', 'Disease', (169, 179))	('depression', 'Disease', 'MESH:D000275', (169, 179))	('people', 'Species', '9606', (95, 101))	('depression', 'Disease', 'MESH:D000275', (114, 124))
203	35371214	Hospital administrators should allocate medical human resources appropriately so that medical staff have enough time to sit down and communicate with patients, provide appropriate opportunities for patients to talk about their inner pain, patiently listen to their inner voice when they need it, provide emotional comfort when they are in pain, and truly enter their hearts and earn trust.	('pain', 'Disease', (339, 343))	('pain', 'Disease', (233, 237))	('inner pain', 'Disease', (227, 237))	('patient', 'Species', '9606', (239, 246))	('patients', 'Species', '9606', (198, 206))	('patients', 'Species', '9606', (150, 158))	('patient', 'Species', '9606', (198, 205))	('pain', 'Disease', 'MESH:D010146', (233, 237))	('inner pain', 'Disease', 'MESH:D010146', (227, 237))	('pain', 'Disease', 'MESH:D010146', (339, 343))	('patient', 'Species', '9606', (150, 157))	('human', 'Species', '9606', (48, 53))
204	35371214	They walk alongside them to help them overcome depression and pain, stay away from death's edge, and rediscover the meaning and value of life.	('depression', 'Disease', (47, 57))	('death', 'Disease', (83, 88))	('pain', 'Disease', (62, 66))	('pain', 'Disease', 'MESH:D010146', (62, 66))	('death', 'Disease', 'MESH:D003643', (83, 88))	('depression', 'Disease', 'MESH:D000275', (47, 57))
206	35371214	In the face of depression-scale big data, the SOM algorithm of PC projection automatically selects the optimal feature subset on the basis of retaining the original feature space, thereby eliminating redundant information in depression-scale big data.	('depression', 'Disease', (15, 25))	('depression', 'Disease', (225, 235))	('eliminating', 'NegReg', (188, 199))	('redundant information', 'MPA', (200, 221))	('PC', 'Gene', '5091', (63, 65))	('depression', 'Disease', 'MESH:D000275', (225, 235))	('depression', 'Disease', 'MESH:D000275', (15, 25))
207	35371214	The identification of the user's depression emotional state is divided into the judgment of the depression emotional tendency of a single text and the judgment of the user's depression state to measure the user's depression and depression.	('depression', 'Disease', (96, 106))	('depression', 'Disease', (33, 43))	('depression', 'Disease', (174, 184))	('depression', 'Disease', (228, 238))	('depression', 'Disease', (213, 223))	('depression', 'Disease', 'MESH:D000275', (213, 223))	('depression', 'Disease', 'MESH:D000275', (228, 238))	('depression', 'Disease', 'MESH:D000275', (174, 184))	('depression', 'Disease', 'MESH:D000275', (33, 43))	('depression', 'Disease', 'MESH:D000275', (96, 106))
209	35371214	The abnormal emotion regulation in patients with depression is mainly manifested in two aspects: one is that it is difficult to use cognitive resources needed to enhance positive emotions through cognitive reappraisal, and the cognitive control ability declines; secondly, cognitive reappraisal weakens negative emotions.	('depression', 'Disease', (49, 59))	('weakens', 'NegReg', (295, 302))	('cognitive control ability', 'MPA', (227, 252))	('abnormal', 'MPA', (4, 12))	('positive emotions', 'MPA', (170, 187))	('enhance', 'PosReg', (162, 169))	('negative emotions', 'MPA', (303, 320))	('declines', 'NegReg', (253, 261))	('depression', 'Disease', 'MESH:D000275', (49, 59))	('patients', 'Species', '9606', (35, 43))
210	35323341	Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt's lymphoma.	("Burkitt's lymphoma", 'Disease', (158, 176))	('Cancer', 'Disease', (40, 46))	('effect', 'Reg', (148, 154))	('Cancer', 'Disease', 'MESH:D009369', (40, 46))	("Burkitt's lymphoma", 'Disease', 'MESH:D002051', (158, 176))
213	35323341	Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator.	('inhibitor', 'MPA', (36, 45))	('autophagy', 'CPA', (88, 97))	('Pevonedistat', 'Var', (0, 12))	('neddylation pathway', 'Pathway', (58, 77))	('Pevonedistat', 'Chemical', 'MESH:C539933', (0, 12))
215	35323341	Autophagy is a potential therapeutic target for a variety of diseases and was brought to light by results of a study on endemic Burkitt's lymphoma in Africa, where remission of the disease was linked to wide administration of chloroquine.	("Burkitt's lymphoma", 'Disease', (128, 146))	('Autophagy', 'CPA', (0, 9))	('linked', 'Reg', (193, 199))	("Burkitt's lymphoma", 'Disease', 'MESH:D002051', (128, 146))	('chloroquine', 'Chemical', 'MESH:D002738', (226, 237))
217	35323341	Among all three forms, macroautophagy has been the focus of clinical research since it has been linked to numerous vital processes such as antigen presentation, immunity, drug resistance, exosomes secretion, apoptosis, inflammation, and oncogenesis.	('apoptosis', 'CPA', (208, 217))	('linked', 'Reg', (96, 102))	('macroautophagy', 'CPA', (23, 37))	('oncogenesis', 'Disease', (237, 248))	('inflammation', 'Disease', (219, 231))	('inflammation', 'Disease', 'MESH:D007249', (219, 231))
218	35323341	The hypothesis of adding these agents is to minimize cancer cell stress adaptive mechanisms and drug resistance.	('minimize', 'NegReg', (44, 52))	('cancer', 'Disease', (53, 59))	('drug resistance', 'CPA', (96, 111))	('cancer', 'Disease', 'MESH:D009369', (53, 59))
219	35323341	This paper reviews the current FDA-approved autophagy agents chloroquine and hydroxychloroquine, along with a new and novel pro-apoptotic and autophagy inducer, Pevonedistat, in current clinical trials.	('autophagy', 'CPA', (142, 151))	('autophagy', 'CPA', (44, 53))	('Pevonedistat', 'Chemical', 'MESH:C539933', (161, 173))	('chloroquine', 'Chemical', 'MESH:D002738', (61, 72))	('hydroxychloroquine', 'Chemical', 'MESH:D006886', (77, 95))	('chloroquine', 'Chemical', 'MESH:D002738', (84, 95))
224	35323341	There are multiple mechanisms of autophagy dysregulation that may be conducive to cancer growth.	('cancer', 'Disease', (82, 88))	('autophagy', 'CPA', (33, 42))	('dysregulation', 'Var', (43, 56))	('cancer', 'Disease', 'MESH:D009369', (82, 88))
225	35323341	As stated previously, stress in the microenvironment along with reactive oxygen species (ROS) and ischemia can upregulate autophagocytic genes to promote autophagy.	('promote', 'PosReg', (146, 153))	('autophagy', 'CPA', (154, 163))	('autophagocytic', 'Protein', (122, 136))	('upregulate', 'PosReg', (111, 121))	('ischemia', 'Disease', (98, 106))	('ischemia', 'Disease', 'MESH:D007511', (98, 106))	('reactive oxygen species', 'Chemical', 'MESH:D017382', (64, 87))	('ROS', 'Chemical', 'MESH:D017382', (89, 92))
226	35323341	Interestingly enough in cancer cells, despite their presence in these high cellular stress environments, they do not upregulate autophagy.	('cancer', 'Disease', (24, 30))	('upregulate', 'PosReg', (117, 127))	('autophagy', 'CPA', (128, 137))	('cancer', 'Disease', 'MESH:D009369', (24, 30))
227	35323341	The disruption and inhibition of this upregulated environment for the cancer cells has become a novel discussion in recent years as a potential target.	('cancer', 'Disease', (70, 76))	('upregulated', 'PosReg', (38, 49))	('inhibition', 'NegReg', (19, 29))	('cancer', 'Disease', 'MESH:D009369', (70, 76))
228	35323341	The lysosomal pathway is an important potential therapeutic target because of its role in upregulation during cancer formation and growth.	('cancer', 'Disease', (110, 116))	('lysosomal pathway', 'Pathway', (4, 21))	('upregulation', 'PosReg', (90, 102))	('cancer', 'Disease', 'MESH:D009369', (110, 116))
230	35323341	Bafilomycin A1, through inhibition of the lysosomal V-ATPase, prevents acidification, causing autophagosomes that are engulfed by lysosomes of the vesicular organelles in its lumen, leading to cell death.	('acidification', 'MPA', (71, 84))	('autophagosomes', 'MPA', (94, 108))	('cell death', 'CPA', (193, 203))	('causing', 'Reg', (86, 93))	('prevents', 'NegReg', (62, 70))	('leading to', 'Reg', (182, 192))	('inhibition', 'NegReg', (24, 34))	('Bafilomycin A1', 'Chemical', 'MESH:C040929', (0, 14))
231	35323341	Neddylation has become an increasingly novel focus over the past few years as a target for anti-cancer therapy.	('cancer', 'Disease', (96, 102))	('Neddylation', 'Protein', (0, 11))	('cancer', 'Disease', 'MESH:D009369', (96, 102))
232	35323341	This process has been shown to be overactive in a variety of human cancers, thus making it a desirable choice of therapeutic targeting.	('overactive', 'PosReg', (34, 44))	('cancers', 'Disease', (67, 74))	('human', 'Species', '9606', (61, 66))	('cancers', 'Disease', 'MESH:D009369', (67, 74))
234	35323341	The novel therapeutic Pevonedistat (MLN4924) has been shown to significantly increase cell apoptosis and autophagy via neddylation.	('cell apoptosis', 'CPA', (86, 100))	('increase', 'PosReg', (77, 85))	('neddylation', 'MPA', (119, 130))	('MLN4924', 'Var', (36, 43))	('autophagy', 'CPA', (105, 114))	('Pevonedistat', 'Chemical', 'MESH:C539933', (22, 34))	('MLN4924', 'Chemical', 'MESH:C539933', (36, 43))
235	35323341	Neddylation may be an increased therapeutic benefit, as it also has other effects on the tumor microenvironment in comparison with other pathways.	('tumor', 'Disease', (89, 94))	('Neddylation', 'Var', (0, 11))	('effects', 'Reg', (74, 81))	('therapeutic benefit', 'MPA', (32, 51))	('tumor', 'Disease', 'MESH:D009369', (89, 94))
237	35323341	This blocks a survival mechanism that allows cancer cells to proliferate.	('survival', 'CPA', (14, 22))	('cancer', 'Disease', (45, 51))	('blocks', 'NegReg', (5, 11))	('cancer', 'Disease', 'MESH:D009369', (45, 51))
238	35323341	The variability in effect of these therapies in different cancer lines can vary greatly, partly attributable to differing cancer types relying more on autophagy than others.	('cancer', 'Disease', (58, 64))	('cancer', 'Disease', (122, 128))	('effect', 'MPA', (19, 25))	('cancer', 'Disease', 'MESH:D009369', (58, 64))	('cancer', 'Disease', 'MESH:D009369', (122, 128))
241	35323341	The most studied cancer types in chloroquine trials were brain and breast, followed by lung and GI.	('brain', 'Disease', (57, 62))	('breast', 'Disease', (67, 73))	('cancer', 'Disease', (17, 23))	('lung', 'Disease', (87, 91))	('cancer', 'Disease', 'MESH:D009369', (17, 23))	('chloroquine', 'Chemical', 'MESH:D002738', (33, 44))
244	35323341	The only phase III trial showed an enhanced response in glioblastoma multiforme.	('enhanced', 'PosReg', (35, 43))	('glioblastoma multiforme', 'Disease', (56, 79))	('response', 'MPA', (44, 52))	('glioblastoma multiforme', 'Disease', 'MESH:D005909', (56, 79))
245	35323341	Chloroquine coadministration with Carmustine enhanced activity in resistant clones during radio and chemotherapy.	('enhanced', 'PosReg', (45, 53))	('activity', 'MPA', (54, 62))	('Carmustine', 'Chemical', 'MESH:D002330', (34, 44))	('Chloroquine', 'Chemical', 'MESH:D002738', (0, 11))
248	35323341	In a phase II randomized control trial (RCT) trial by Arnaout, KI67 index was demonstrated to not be lowered with use of Chloroquine supplementation as a mono therapy compared with placebo.	('KI67 index', 'MPA', (63, 73))	('lowered', 'NegReg', (101, 108))	('Chloroquine', 'Chemical', 'MESH:D002738', (121, 132))
249	35323341	It was speculated that autophagy inhibitors may be more beneficial in combination therapy and more synergistically beneficial when tumor cells are placed under stress.	('beneficial', 'PosReg', (56, 66))	('tumor', 'Disease', (131, 136))	('combination', 'Interaction', (70, 81))	('autophagy inhibitors', 'CPA', (23, 43))	('tumor', 'Disease', 'MESH:D009369', (131, 136))
250	35323341	This highlights the overall generality seen, in which combination therapy with antineoplastic agents in coadministration with Chloroquine sees better response, specifically with proliferation, in the clinical trials presented.	('response', 'MPA', (150, 158))	('better', 'PosReg', (143, 149))	('proliferation', 'CPA', (178, 191))	('combination', 'Interaction', (54, 65))	('Chloroquine', 'Chemical', 'MESH:D002738', (126, 137))
252	35323341	High-dose HCQ and dose-intense temozolomide were found to be safe and tolerable and were associated with autophagy modulation in patients with melanoma.	('modulation', 'MPA', (115, 125))	('associated', 'Reg', (89, 99))	('autophagy', 'CPA', (105, 114))	('melanoma', 'Disease', (143, 151))	('HCQ', 'Chemical', 'MESH:D006886', (10, 13))	('melanoma', 'Disease', 'MESH:D008545', (143, 151))	('temozolomide', 'Chemical', 'MESH:D000077204', (31, 43))	('patients', 'Species', '9606', (129, 137))
254	35323341	Further phase II trials have shown promising effects in Kras-mutated lung cancers, opening up the possibilities of further therapeutic options in chemoresistant cancers.	('Kras', 'Gene', (56, 60))	('lung cancers', 'Disease', (69, 81))	('chemoresistant cancers', 'Disease', (146, 168))	('effects', 'MPA', (45, 52))	('chemoresistant cancers', 'Disease', 'MESH:D009369', (146, 168))	('Kras', 'Gene', '3845', (56, 60))	('lung cancers', 'Disease', 'MESH:D008175', (69, 81))
255	35323341	The only other lung cancer trial, phase I, showed a safe toxicity and tolerability profile when given with erlotinib.	('tolerability', 'CPA', (70, 82))	('toxicity', 'Disease', (57, 65))	('lung cancer', 'Disease', (15, 26))	('toxicity', 'Disease', 'MESH:D064420', (57, 65))	('erlotinib', 'Chemical', 'MESH:D000069347', (107, 116))	('lung cancer', 'Disease', 'MESH:D008175', (15, 26))
256	35323341	Other monotherapy trials demonstrated safe toxicity profiles but were not clinically significant and showed no difference in outcomes with p53 status of individual patients.	('toxicity', 'Disease', (43, 51))	('p53', 'Gene', (139, 142))	('toxicity', 'Disease', 'MESH:D064420', (43, 51))	('patients', 'Species', '9606', (164, 172))	('p53', 'Gene', '7157', (139, 142))
257	35323341	These trials contrasted with combination therapy including gemcitabine and nab-paclitaxel, in which greater pathologic and biomarker response increased, along with autophagy inhabitation and immune activity.	('increased', 'PosReg', (142, 151))	('autophagy', 'CPA', (164, 173))	('immune activity', 'CPA', (191, 206))	('gemcitabine', 'Chemical', 'MESH:C056507', (59, 70))
263	35323341	Another phase I trial with IL-2 (no chemotherapy) also demonstrated a PFS of 17 months with a 600 mg dose monotherapy.	('PFS', 'MPA', (70, 73))	('IL-2', 'Gene', (27, 31))	('IL-2', 'Gene', '3558', (27, 31))
265	35323341	The addition of mammalian target of rampiclin (mTOR) and autophagy inhibition with cyclophosphamide yields a regimen with low toxicity that is tolerable in heavily pretreated patients.	('low toxicity', 'Disease', (122, 134))	('mTOR', 'Gene', (47, 51))	('autophagy', 'CPA', (57, 66))	('mammalian target of rampiclin', 'Gene', (16, 45))	('inhibition', 'NegReg', (67, 77))	('cyclophosphamide', 'Chemical', 'MESH:D003520', (83, 99))	('mTOR', 'Gene', '2475', (47, 51))	('low toxicity', 'Disease', 'MESH:D009800', (122, 134))	('mammalian target of rampiclin', 'Gene', '2475', (16, 45))	('patients', 'Species', '9606', (175, 183))
267	35323341	A more recent drug that has sparked clinical interest is Pevonedistat, with a more novel pathway of NEDD-9 inhibition leading to autophagy activation.	('activation', 'PosReg', (139, 149))	('NEDD-9', 'Gene', (100, 106))	('autophagy', 'CPA', (129, 138))	('inhibition', 'NegReg', (107, 117))	('Pevonedistat', 'Chemical', 'MESH:C539933', (57, 69))	('NEDD-9', 'Gene', '4739', (100, 106))
268	35323341	Pevonedistat differs in terms of CQ/HCQ in that it is a pro-apoptotic and autophagy inducer, rather than inhibitor.	('pro-apoptotic', 'CPA', (56, 69))	('autophagy inducer', 'CPA', (74, 91))	('HCQ', 'Chemical', 'MESH:D006886', (36, 39))	('CQ', 'Chemical', 'MESH:D002738', (33, 35))	('CQ', 'Chemical', 'MESH:D002738', (37, 39))	('Pevonedistat', 'Chemical', 'MESH:C539933', (0, 12))
270	35323341	Trial NCT02610777, involving Pevonedistat plus azacytidine vs. azacytidine alone, had promising OS, EFS, ORR, and OS, with similar patient side effect profiles.	('EFS', 'MPA', (100, 103))	('ORR', 'MPA', (105, 108))	('EFS', 'CellLine', 'CVCL:5I29', (100, 103))	('Pevonedistat', 'Chemical', 'MESH:C539933', (29, 41))	('patient', 'Species', '9606', (131, 138))	('azacytidine', 'Chemical', 'MESH:D001374', (63, 74))	('azacytidine', 'Chemical', 'MESH:D001374', (47, 58))
272	35323341	In cancer cells, multiple studies have demonstrated that autophagy suppression along with creating a cytotoxic environment with chemotherapy can disrupt cancer homeostasis far greater than either agent alone.	('disrupt', 'NegReg', (145, 152))	('cancer', 'Disease', (3, 9))	('suppression', 'NegReg', (67, 78))	('cancer', 'Disease', (153, 159))	('cancer', 'Disease', 'MESH:D009369', (153, 159))	('cancer', 'Disease', 'MESH:D009369', (3, 9))
274	35323341	Theories have been proposed as to why combination may have seemingly more clinically efficacious results:the main theory being oxidation with use from antineoplastic therapy creates intracellular stress, ROS, and invokes starvation creating cytotoxic environments.	('starvation', 'MPA', (221, 231))	('cytotoxic', 'MPA', (241, 250))	('ROS', 'MPA', (204, 207))	('creates', 'Reg', (174, 181))	('intracellular stress', 'MPA', (182, 202))	('ROS', 'Chemical', 'MESH:D017382', (204, 207))
275	35323341	The upregulated autophagocytic process normally present at a basal level in cancer cells is unable to function properly when antiautophagocytic agents are present.	('cancer', 'Disease', (76, 82))	('autophagocytic process', 'CPA', (16, 38))	('upregulated', 'PosReg', (4, 15))	('unable', 'NegReg', (92, 98))	('nab', 'Chemical', '-', (93, 96))	('cancer', 'Disease', 'MESH:D009369', (76, 82))
276	35323341	Another is autophagy inhibitors and pro-apoptotic agents' ability to enhance cancer cell radiosensitivity.	('autophagy', 'CPA', (11, 20))	('cancer', 'Disease', (77, 83))	('enhance', 'PosReg', (69, 76))	('cancer', 'Disease', 'MESH:D009369', (77, 83))
277	35323341	While not widely studied, autophagy inhibitors and activators (mTOR inhibitors) have been used with synergistic results.	('autophagy', 'CPA', (26, 35))	('mTOR', 'Gene', (63, 67))	('mTOR', 'Gene', '2475', (63, 67))
278	35323341	This could lead to novel pathways in mTOR-resistant cancers.	('mTOR-resistant cancers', 'Disease', (37, 59))	('lead to', 'Reg', (11, 18))	('mTOR-resistant cancers', 'Disease', 'MESH:D009369', (37, 59))
279	35323341	Although these may be used as a tumor suppressor and may aid in malignant therapeutics, considerations must be taken into effect on potentiating other diseases, such neurodegenerative diseases in which autophagy can be protective.	('tumor', 'Disease', (32, 37))	('neurodegenerative diseases', 'Disease', (166, 192))	('potentiating', 'PosReg', (132, 144))	('neurodegenerative diseases', 'Disease', 'MESH:D019636', (166, 192))	('tumor', 'Disease', 'MESH:D009369', (32, 37))
281	35323341	Side effects associated with use were mainly GI related, with nausea, emesis, and diarrhea.	('emesis', 'Disease', (70, 76))	('diarrhea', 'Disease', (82, 90))	('nausea', 'Disease', (62, 68))	('nausea', 'Disease', 'MESH:D009325', (62, 68))	('emesis', 'Disease', 'MESH:D014839', (70, 76))	('diarrhea', 'Disease', 'MESH:D003967', (82, 90))
282	35323341	A randomized control trial that included 70 breast cancer patients was designed to evaluate effects on tumor of daily CQ supplementation at a dose of 500 mg daily.	('effects', 'MPA', (92, 99))	('breast cancer', 'Disease', (44, 57))	('tumor', 'Disease', (103, 108))	('tumor', 'Disease', 'MESH:D009369', (103, 108))	('CQ', 'Chemical', 'MESH:D002738', (118, 120))	('patients', 'Species', '9606', (58, 66))	('breast cancer', 'Disease', 'MESH:D001943', (44, 57))
283	35323341	It was found that there was no significant difference in tumor Ki-67 index between both CQ and placebo groups.	('tumor', 'Disease', (57, 62))	('Ki-67 index', 'MPA', (63, 74))	('CQ', 'Chemical', 'MESH:D002738', (88, 90))	('tumor', 'Disease', 'MESH:D009369', (57, 62))
284	35323341	Similarly, a phase II randomized clinical trial found that HCQ combination with gemcitabine and nab-paclitaxel did not improve 12-month overall survival among patients with metastatic pancreatic cancer.	('pancreatic cancer', 'Disease', (184, 201))	('improve', 'PosReg', (119, 126))	('not', 'NegReg', (115, 118))	('HCQ', 'Chemical', 'MESH:D006886', (59, 62))	('pancreatic cancer', 'Disease', 'MESH:D010190', (184, 201))	('gemcitabine', 'Chemical', 'MESH:C056507', (80, 91))	('patients', 'Species', '9606', (159, 167))
285	35323341	However, in the same study, overall response rate of advanced tumors showed improvement with continuous addition of 600 mg HCQ twice daily that may permit resection of tumor.	('resection', 'CPA', (155, 164))	('response', 'MPA', (36, 44))	('tumors', 'Disease', (62, 68))	('improvement', 'PosReg', (76, 87))	('tumor', 'Disease', (168, 173))	('tumor', 'Disease', (62, 67))	('tumor', 'Disease', 'MESH:D009369', (62, 67))	('tumors', 'Disease', 'MESH:D009369', (62, 68))	('HCQ', 'Chemical', 'MESH:D006886', (123, 126))	('tumor', 'Disease', 'MESH:D009369', (168, 173))
287	35323341	This study employed 64 patients and found administration of HCQ correlated with an increase in the means of patients with the tumor.	('means of patients', 'MPA', (99, 116))	('increase', 'PosReg', (83, 91))	('tumor', 'Disease', (126, 131))	('HCQ', 'Chemical', 'MESH:D006886', (60, 63))	('patients', 'Species', '9606', (108, 116))	('tumor', 'Disease', 'MESH:D009369', (126, 131))	('patients', 'Species', '9606', (23, 31))
288	35323341	This immune system alteration in the resected tumor correlated with improved overall survival in recurrence-free survival.	('immune system', 'CPA', (5, 18))	('improved', 'PosReg', (68, 76))	('alteration', 'Reg', (19, 29))	('tumor', 'Disease', (46, 51))	('overall', 'MPA', (77, 84))	('tumor', 'Disease', 'MESH:D009369', (46, 51))
290	35323341	While Chloroquine does impact intracellular pH in acidic parts of the cell, it is limited in its ability to permeate the cellular membrane in the presence of an acidic environment.	('impact', 'Reg', (23, 29))	('ability', 'MPA', (97, 104))	('limited', 'NegReg', (82, 89))	('permeate', 'MPA', (108, 116))	('Chloroquine', 'Chemical', 'MESH:D002738', (6, 17))
292	35323341	This can be attributed to the Warburg effect in which cancer cells use glycolysis in lieu of anaerobic respiration.	('cancer', 'Disease', (54, 60))	('glycolysis', 'MPA', (71, 81))	('cancer', 'Disease', 'MESH:D009369', (54, 60))
293	35323341	As discussed previously, effects of autophagy inhibitors can inadvertently promote antitumor mechanisms.	('autophagy', 'Protein', (36, 45))	('promote', 'PosReg', (75, 82))	('tumor', 'Disease', (87, 92))	('tumor', 'Disease', 'MESH:D009369', (87, 92))
294	35323341	This mechanism occurs through pathways such as the promotion of T-regs that can damper down the innate immune system alarm for tumor escape and upregulation in transcription factors in conjunction with other anti-neoplastic therapies due to cellular stress.	('promotion', 'PosReg', (51, 60))	('innate immune system alarm for', 'MPA', (96, 126))	('transcription factors', 'MPA', (160, 181))	('damper down', 'NegReg', (80, 91))	('upregulation', 'PosReg', (144, 156))	('T-regs', 'Protein', (64, 70))	('tumor', 'Disease', (127, 132))	('tumor', 'Disease', 'MESH:D009369', (127, 132))
295	35323341	For example, alkylating agents activate ataxia telangiectasis-mutated kinase (ATM), which increases cancer cells upregulation of autophagy to help in survival.	('ataxia telangiectasis-mutated kinase', 'Gene', (40, 76))	('survival', 'CPA', (150, 158))	('increases', 'PosReg', (90, 99))	('upregulation', 'PosReg', (113, 125))	('activate', 'PosReg', (31, 39))	('cancer', 'Disease', (100, 106))	('ATM', 'Gene', (78, 81))	('autophagy', 'CPA', (129, 138))	('ATM', 'Gene', '472', (78, 81))	('cancer', 'Disease', 'MESH:D009369', (100, 106))	('ataxia telangiectasis-mutated kinase', 'Gene', '472', (40, 76))
296	35323341	In turn, this increases a protective effect in regular glycolysis, resulting in increasing lactate creating the acidic environment that may be detrimental to Chloroquine/Hydroxychloroquine effects.	('increasing', 'PosReg', (80, 90))	('acidic environment', 'MPA', (112, 130))	('protective', 'MPA', (26, 36))	('lactate creating', 'MPA', (91, 107))	('regular glycolysis', 'MPA', (47, 65))	('increases', 'PosReg', (14, 23))	('Hydroxychloroquine', 'Chemical', 'MESH:D006886', (170, 188))	('lactate', 'Chemical', 'MESH:D019344', (91, 98))	('Chloroquine', 'Chemical', 'MESH:D002738', (158, 169))
297	35323341	This can be seen by immunological response of CQ-immune cancer antigens.	('cancer', 'Disease', (56, 62))	('immunological', 'MPA', (20, 33))	('CQ', 'Chemical', 'MESH:D002738', (46, 48))	('cancer', 'Disease', 'MESH:D009369', (56, 62))
298	35323341	In immunocompetent mice, CQ decreased acidification into lysosomes, which in turn has been shown to hinder CD4 positive T cells.	('CD4', 'Gene', (107, 110))	('hinder', 'NegReg', (100, 106))	('decreased', 'NegReg', (28, 37))	('acidification into lysosomes', 'MPA', (38, 66))	('CD4', 'Gene', '12504', (107, 110))	('CQ', 'Chemical', 'MESH:D002738', (25, 27))	('mice', 'Species', '10090', (19, 23))
299	35323341	Conversely, in the T cell deficient, most Chloroquine has been demonstrated to increase NK cells and upregulate TNF, leading to more antitumor response.	('increase', 'PosReg', (79, 87))	('more', 'PosReg', (128, 132))	('upregulate', 'PosReg', (101, 111))	('tumor', 'Disease', (137, 142))	('TNF', 'Gene', (112, 115))	('tumor', 'Disease', 'MESH:D009369', (137, 142))	('TNF', 'Gene', '7124', (112, 115))	('Chloroquine', 'Chemical', 'MESH:D002738', (42, 53))
300	35323341	These limitations have also been seen with mTOR inhibitors' ability to slow progression but limited cell death.	('slow', 'NegReg', (71, 75))	('limited', 'NegReg', (92, 99))	('mTOR', 'Gene', (43, 47))	('cell death', 'CPA', (100, 110))	('progression', 'CPA', (76, 87))	('mTOR', 'Gene', '2475', (43, 47))
301	35323341	Both Chloroquine and Hydroxychloroquine demonstrate inhibitory effects on autophagy, making them potential targets for future cancer therapies.	('cancer', 'Disease', (126, 132))	('inhibitory effects', 'NegReg', (52, 70))	('autophagy', 'CPA', (74, 83))	('Chloroquine', 'Chemical', 'MESH:D002738', (5, 16))	('cancer', 'Disease', 'MESH:D009369', (126, 132))	('Hydroxychloroquine', 'Chemical', 'MESH:D006886', (21, 39))
303	35323341	Given that Chloroquine and Hydroxychloroquine are autophagy inhibitors, while Pevonedistat is a pro-apoptotic agent, this has potential to lead to more interesting results used in combination to approach multiple sites of therapeutic significance.	('autophagy', 'CPA', (50, 59))	('inhibitors', 'NegReg', (60, 70))	('Pevonedistat', 'Chemical', 'MESH:C539933', (78, 90))	('Hydroxychloroquine', 'Chemical', 'MESH:D006886', (27, 45))	('Chloroquine', 'Chemical', 'MESH:D002738', (11, 22))
304	35323341	There are limitations to use of autophagy inhibitors, and these can also be seen with mTOR inhibitors, as discussed previously.	('autophagy', 'CPA', (32, 41))	('limitations', 'MPA', (10, 21))	('mTOR', 'Gene', (86, 90))	('mTOR', 'Gene', '2475', (86, 90))
305	35323341	While Chloroquine and Hydroxychloroquine are the only FDA-approved autophagy inhibitors, there are promising results in terms of toxicity in early phase studies, but further clinical trials are needed to see clinical benefit with other therapies.	('autophagy', 'CPA', (67, 76))	('toxicity', 'Disease', (129, 137))	('toxicity', 'Disease', 'MESH:D064420', (129, 137))	('Hydroxychloroquine', 'Chemical', 'MESH:D006886', (22, 40))	('Chloroquine', 'Chemical', 'MESH:D002738', (6, 17))
312	35246200	In Canada, the shortest median duration (in months) from regulatory approval to reimbursement was in British Columbia (17.3), Quebec (19.6) and Manitoba (19.6), while the longest duration was in P.E.I (38.5), followed by Nova Scotia (25.9), and Newfoundland (25.1).	('British Columbia', 'Disease', (101, 117))	('Nova Scotia', 'Disease', (221, 232))	('Nova Scotia', 'Disease', 'MESH:D052556', (221, 232))	('British Columbia', 'Disease', 'OMIM:176500', (101, 117))
347	35246200	There was one instance where, despite a positive CADTH recommendation, a pricing agreement was not reached with pCPA (Eliglustat (Cerdelga) for Gaucher Disease).	('not', 'NegReg', (95, 98))	('Gaucher Disease', 'Disease', (144, 159))	('Gaucher Disease', 'Disease', 'MESH:D005776', (144, 159))	('pCPA', 'Chemical', '-', (112, 116))
352	35246200	Of the 63 drugs approved by the EMA, 20/63 (32%) were for cancer indications and 43/63 (68%) were for non-cancer indications.	('cancer', 'Disease', (58, 64))	('cancer', 'Disease', (106, 112))	('EMA', 'Chemical', '-', (32, 35))	('cancer', 'Disease', 'MESH:D009369', (58, 64))	('cancer', 'Disease', 'MESH:D009369', (106, 112))
353	35246200	Proportionally more drugs for cancer indications were submitted for Health Canada approval: 15/20 (75%) compared to 26/43 (60%) drugs for non-cancer indications.	('cancer', 'Disease', (142, 148))	('cancer', 'Disease', (30, 36))	('cancer', 'Disease', 'MESH:D009369', (142, 148))	('cancer', 'Disease', 'MESH:D009369', (30, 36))
354	35246200	Twelve of the 15 drugs for cancer indications with Health Canada approval received a positive HTA recommendation from CADTH compared to 18/26 (69%) of the drugs for non-cancer indications (Fig.	('cancer', 'Disease', (27, 33))	('cancer', 'Disease', (169, 175))	('cancer', 'Disease', 'MESH:D009369', (169, 175))	('cancer', 'Disease', 'MESH:D009369', (27, 33))
357	35246200	We also compared the percentage of drugs publicly reimbursed in European countries by EMA approval to public reimbursement in each province by Health Canada and found that the proportion of public reimbursement for orphan drugs in Europe was generally higher than for Health Canada approved drugs in Canadian provinces (Fig.	('public reimbursement', 'MPA', (190, 210))	('higher', 'PosReg', (252, 258))	('EMA', 'Chemical', '-', (86, 89))
361	35246200	When we compared the difference in regulatory approval timelines between EMA, FDA, and Health Canada, we observed closer timelines between the EMA and FDA, compared to Health Canada and EMA or Health Canada and FDA.	('timelines', 'MPA', (121, 130))	('closer', 'PosReg', (114, 120))	('EMA', 'Chemical', '-', (186, 189))	('EMA', 'Chemical', '-', (73, 76))	('EMA', 'Chemical', '-', (143, 146))
377	35246200	Other studies have demonstrated similar trends in which fewer drugs were submitted to Canada for regulatory approval compared with other countries in other disease areas, including cancer and antibacterials.	('fewer', 'NegReg', (56, 61))	('cancer', 'Disease', (181, 187))	('cancer', 'Disease', 'MESH:D009369', (181, 187))
378	35246200	noted that variation in availability to cancer drugs across countries was partially due to different willingness-to-pay thresholds.	('cancer', 'Disease', (40, 46))	('availability', 'MPA', (24, 36))	('cancer', 'Disease', 'MESH:D009369', (40, 46))
386	35246200	If we can understand the positive and negative pressure points in the pathway, there is an opportunity to develop solutions or mechanisms to increase the availability to effective therapies for patients in Canada.	('increase', 'PosReg', (141, 149))	('availability', 'MPA', (154, 166))	('patients', 'Species', '9606', (194, 202))
387	35246200	This balance, which further depends on a sustainable, fair access funding program, emphasizes the importance of a rare disease strategy that provides optimal therapy for patients so that they, like those with common disorders such as cardiovascular disease, chronic respiratory diseases, and diabetes, have an equal opportunity to live their best lives.	('cardiovascular disease', 'Disease', (234, 256))	('respiratory diseases', 'Disease', (266, 286))	('diabetes', 'Disease', (292, 300))	('respiratory diseases', 'Disease', 'MESH:D012140', (266, 286))	('cardiovascular disease', 'Disease', 'MESH:D002318', (234, 256))	('diabetes', 'Disease', 'MESH:D003920', (292, 300))	('patients', 'Species', '9606', (170, 178))
396	35216362	Overcoming Radiation Resistance in Gliomas by Targeting Metabolism and DNA Repair Pathways Gliomas represent a wide spectrum of brain tumors characterized by their high invasiveness, resistance to chemoradiotherapy, and both intratumoral and intertumoral heterogeneity.	('Gliomas by Targeting Metabolism', 'Disease', (35, 66))	('tumor', 'Disease', (134, 139))	('brain tumors', 'Disease', (128, 140))	('tumor', 'Disease', (247, 252))	('Gliomas', 'Disease', (35, 42))	('tumor', 'Disease', (230, 235))	('Gliomas', 'Disease', (91, 98))	('Gliomas', 'Disease', 'MESH:D005910', (35, 42))	('tumor', 'Disease', 'MESH:D009369', (230, 235))	('tumor', 'Disease', 'MESH:D009369', (134, 139))	('tumor', 'Disease', 'MESH:D009369', (247, 252))	('Gliomas', 'Disease', 'MESH:D005910', (91, 98))	('brain tumors', 'Disease', 'MESH:D001932', (128, 140))	('Gliomas by Targeting Metabolism', 'Disease', 'MESH:D005910', (35, 66))
397	35216362	Recent advances in transomics studies revealed that enormous abnormalities exist in different biological layers of glioma cells, which include genetic/epigenetic alterations, RNA expressions, protein expression/modifications, and metabolic pathways, which provide opportunities for development of novel targeted therapeutic agents for gliomas.	('gliomas', 'Disease', (335, 342))	('glioma', 'Disease', (115, 121))	('metabolic pathways', 'Pathway', (230, 248))	('enormous abnormalities', 'Disease', (52, 74))	('protein', 'Protein', (192, 199))	('genetic/epigenetic alterations', 'Var', (143, 173))	('RNA expressions', 'MPA', (175, 190))	('glioma', 'Disease', (335, 341))	('glioma', 'Disease', 'MESH:D005910', (115, 121))	('glioma', 'Disease', 'MESH:D005910', (335, 341))	('gliomas', 'Disease', 'MESH:D005910', (335, 342))	('enormous abnormalities', 'Disease', 'MESH:D018376', (52, 74))
398	35216362	Metabolic reprogramming is one of the hallmarks of cancer cells, as well as one of the oldest fields in cancer biology research.	('cancer', 'Disease', (104, 110))	('cancer', 'Disease', (51, 57))	('Metabolic reprogramming', 'CPA', (0, 23))	('cancer', 'Disease', 'MESH:D009369', (51, 57))	('cancer', 'Disease', 'MESH:D009369', (104, 110))
399	35216362	Altered cancer cell metabolism not only provides energy and metabolites to support tumor growth, but also mediates the resistance of tumor cells to antitumor therapies.	('tumor', 'Disease', (83, 88))	('mediates', 'Reg', (106, 114))	('tumor', 'Disease', (152, 157))	('resistance', 'CPA', (119, 129))	('tumor', 'Disease', (133, 138))	('Altered cancer', 'Disease', (0, 14))	('Altered cancer', 'Disease', 'MESH:D009369', (0, 14))	('tumor', 'Disease', 'MESH:D009369', (83, 88))	('tumor', 'Disease', 'MESH:D009369', (133, 138))	('tumor', 'Disease', 'MESH:D009369', (152, 157))
400	35216362	The interactions between cancer metabolism and DNA repair pathways, and the enhancement of radiotherapy sensitivity and assessment of radiation response by modulation of glioma metabolism are discussed herein.	('cancer', 'Disease', (25, 31))	('radiotherapy sensitivity', 'CPA', (91, 115))	('enhancement', 'PosReg', (76, 87))	('glioma metabolism', 'Disease', (170, 187))	('interactions', 'Interaction', (4, 16))	('cancer', 'Disease', 'MESH:D009369', (25, 31))	('glioma metabolism', 'Disease', 'MESH:D005910', (170, 187))
401	35216362	Glioma is a broad category of central nervous system (CNS) tumors, which are one of the deadliest types of human cancers.	('Glioma', 'Disease', (0, 6))	('tumors', 'Disease', (59, 65))	('cancers', 'Disease', (113, 120))	('cancers', 'Disease', 'MESH:D009369', (113, 120))	('Glioma', 'Disease', 'MESH:D005910', (0, 6))	('tumors', 'Disease', 'MESH:D009369', (59, 65))	('human', 'Species', '9606', (107, 112))
402	35216362	Neomorphic mutations in isocitrate dehydrogenase (IDH) enzymes (arginine 132 for IDH1 and arginine 172 for IDH2) are found in 70% of gliomas and are highly associated with favorable outcomes of glioma patients.	('Neomorphic', 'Var', (0, 10))	('arginine 172', 'Var', (90, 102))	('gliomas', 'Disease', (133, 140))	('found', 'Reg', (117, 122))	('IDH', 'Gene', (50, 53))	('glioma', 'Disease', (133, 139))	('isocitrate dehydrogenase', 'Gene', (24, 48))	('glioma', 'Disease', (194, 200))	('associated', 'Reg', (156, 166))	('IDH', 'Gene', (107, 110))	('IDH', 'Gene', (81, 84))	('arginine 132', 'Var', (64, 76))	('glioma', 'Disease', 'MESH:D005910', (133, 139))	('isocitrate dehydrogenase', 'Gene', '3417', (24, 48))	('arginine 132', 'Mutation', 'rs121913500', (64, 76))	('IDH', 'Gene', '3417', (81, 84))	('arginine', 'Chemical', 'MESH:D001120', (64, 72))	('patients', 'Species', '9606', (201, 209))	('arginine', 'Chemical', 'MESH:D001120', (90, 98))	('gliomas', 'Disease', 'MESH:D005910', (133, 140))	('glioma', 'Disease', 'MESH:D005910', (194, 200))	('IDH', 'Gene', '3417', (50, 53))	('IDH', 'Gene', '3417', (107, 110))	('IDH1', 'CellLine', '9606', (81, 85))
403	35216362	By contrast, IDH1/2 wild-type glioma (IDHwt; without either of the mutations) is the most aggressive form of glioma, and IDHwt patients only have a short 6-12-month survival time.	('glioma', 'Disease', (109, 115))	('IDH', 'Gene', (38, 41))	('IDH', 'Gene', (13, 16))	('IDH', 'Gene', (121, 124))	('glioma', 'Disease', (30, 36))	('IDH', 'Gene', '3417', (13, 16))	('glioma', 'Disease', 'MESH:D005910', (30, 36))	('IDH', 'Gene', '3417', (38, 41))	('glioma', 'Disease', 'MESH:D005910', (109, 115))	('IDH', 'Gene', '3417', (121, 124))	('IDH1', 'CellLine', '9606', (13, 17))	('patients', 'Species', '9606', (127, 135))
404	35216362	Due to intratumoral heterogeneity and infiltrative nature, glioblastoma (GBM) is the most aggressive tumor, and it is notoriously resistant to chemoradiation therapy.	('aggressive tumor', 'Disease', (90, 106))	('glioblastoma', 'Disease', (59, 71))	('tumor', 'Disease', (12, 17))	('tumor', 'Disease', (101, 106))	('aggressive tumor', 'Disease', 'MESH:D001523', (90, 106))	('glioblastoma', 'Disease', 'MESH:D005909', (59, 71))	('tumor', 'Disease', 'MESH:D009369', (101, 106))	('tumor', 'Disease', 'MESH:D009369', (12, 17))
406	35216362	Warburg's study indicated that cancer cells can uptake a tremendous amount of glucose under normoxic conditions and produce lactic acid through aerobic glycolysis, the well-known Warburg effect.	('cancer', 'Disease', (31, 37))	('lactic acid', 'MPA', (124, 135))	('uptake', 'MPA', (48, 54))	('aerobic glycolysis', 'MPA', (144, 162))	('glucose', 'Chemical', 'MESH:D005947', (78, 85))	('lactic acid', 'Chemical', 'MESH:D019344', (124, 135))	('cancer', 'Disease', 'MESH:D009369', (31, 37))
407	35216362	Cancer cells gain proliferative advantages by increasing glucose uptake and aerobic glycolysis.	('glucose', 'MPA', (57, 64))	('increasing', 'PosReg', (46, 56))	('Cancer', 'Disease', (0, 6))	('gain', 'PosReg', (13, 17))	('aerobic glycolysis', 'MPA', (76, 94))	('proliferative advantages', 'CPA', (18, 42))	('Cancer', 'Disease', 'MESH:D009369', (0, 6))	('glucose', 'Chemical', 'MESH:D005947', (57, 64))
408	35216362	Here, we review the interplay between cancer cell metabolism and DNA repair activities in brain tumors and the therapeutic potential of enhancing radiation sensitivity through cancer metabolic reprogramming.	('brain tumors', 'Disease', (90, 102))	('cancer', 'Disease', (176, 182))	('radiation sensitivity', 'CPA', (146, 167))	('cancer', 'Disease', (38, 44))	('enhancing', 'PosReg', (136, 145))	('brain tumors', 'Disease', 'MESH:D001932', (90, 102))	('cancer', 'Disease', 'MESH:D009369', (176, 182))	('cancer', 'Disease', 'MESH:D009369', (38, 44))
409	35216362	Irradiation can cause DNA damage in mammalian cells, which was first shown in a microelectrophoretic study almost four decades ago.	('DNA damage', 'MPA', (22, 32))	('cause', 'Reg', (16, 21))	('mammalian', 'Species', '9606', (36, 45))
411	35216362	Although DSBs arise less frequently than SSBs after radiation exposure, DSBs are arguably more lethal to cancer cells because DSB repair and G2/M checkpoint cannot guarantee genomic integrity and chromosomal stability.	('genomic integrity', 'CPA', (174, 191))	('cancer', 'Disease', (105, 111))	('DSB', 'Var', (126, 129))	('not', 'NegReg', (160, 163))	('chromosomal stability', 'CPA', (196, 217))	('G2/M checkpoint', 'MPA', (141, 156))	('DSBs', 'Chemical', 'MESH:C007563', (72, 76))	('SSBs', 'Chemical', 'MESH:C016118', (41, 45))	('cancer', 'Disease', 'MESH:D009369', (105, 111))	('DSBs', 'Chemical', 'MESH:C007563', (9, 13))
412	35216362	In addition to DNA damage, radiation can also produce a variety of cellular perturbations and oxidative stress caused by reactive free radicals as one of the most significant consequences.	('cellular perturbations', 'MPA', (67, 89))	('produce', 'Reg', (46, 53))	('oxidative', 'MPA', (94, 103))	('reactive free radicals', 'Chemical', '-', (121, 143))
413	35216362	In normal cellular metabolism, reactive oxygen species (ROS) are generated in aerobic cells, but cells can utilize multiple mechanisms to balance the redox homeostasis and eliminate oxidative stress such as glutathione (GSH), superoxide dismutase (SOD) and catalase, etc.	('eliminate oxidative stress', 'MPA', (172, 198))	('catalase', 'Enzyme', (257, 265))	('redox homeostasis', 'MPA', (150, 167))	('balance', 'MPA', (138, 145))	('reactive oxygen species', 'Chemical', 'MESH:D017382', (31, 54))	('ROS', 'Chemical', 'MESH:D017382', (56, 59))	('glutathione', 'Chemical', 'MESH:D005978', (207, 218))	('GSH', 'Chemical', 'MESH:D005978', (220, 223))
414	35216362	However, in many tumors and cancer cell lines, these protective mechanisms can be either shifted or made incapable of eliminating ROS generated from the actively proliferating cancer cells.	('cancer', 'Disease', (176, 182))	('cancer', 'Disease', (28, 34))	('tumors', 'Disease', (17, 23))	('shifted', 'PosReg', (89, 96))	('ROS generated', 'MPA', (130, 143))	('incapable', 'NegReg', (105, 114))	('ROS', 'Chemical', 'MESH:D017382', (130, 133))	('tumors', 'Disease', 'MESH:D009369', (17, 23))	('cancer', 'Disease', 'MESH:D009369', (176, 182))	('cancer', 'Disease', 'MESH:D009369', (28, 34))
415	35216362	For radiation treatment of cancer, the cellular redox system may be a critical determinant to enhance cancer cell killing while protecting normal tissues because ROS can oxidize cellular biomolecules such as proteins and lipids and activate many pathological processes.	('enhance', 'PosReg', (94, 101))	('cancer', 'Disease', (27, 33))	('cancer', 'Disease', (102, 108))	('activate', 'PosReg', (232, 240))	('oxidize', 'MPA', (170, 177))	('ROS', 'Var', (162, 165))	('ROS', 'Chemical', 'MESH:D017382', (162, 165))	('cancer', 'Disease', 'MESH:D009369', (27, 33))	('lipids', 'Chemical', 'MESH:D008055', (221, 227))	('cancer', 'Disease', 'MESH:D009369', (102, 108))
416	35216362	While this mechanism has largely remained uncharted, ROS generation can become one of the primary weapons of radiotherapy for radiation-induced death of cancer cells.	('cancer', 'Disease', (153, 159))	('death', 'Disease', (144, 149))	('cancer', 'Disease', 'MESH:D009369', (153, 159))	('ROS', 'Chemical', 'MESH:D017382', (53, 56))	('death', 'Disease', 'MESH:D003643', (144, 149))
419	35216362	The number of gammaH2AX foci shows specific temporal and spatial relationships with cellular DNA damages.	('cellular', 'CPA', (84, 92))	('H2AX', 'Gene', (19, 23))	('H2AX', 'Gene', '3014', (19, 23))
420	35216362	The MRN complex (Mre11, Rad50, and Nbs1) can be independent from the H2AX-mediated DNA repair-signaling pathway by recruiting 53BP1 and BRCA1 to DSB sites and promote homologous recombination (HR) pathway.	('Rad50', 'Gene', (24, 29))	('53BP1', 'Gene', (126, 131))	('Mre11', 'Gene', (17, 22))	('recruiting', 'PosReg', (115, 125))	('promote', 'PosReg', (159, 166))	('BRCA1', 'Gene', (136, 141))	('Nbs1', 'Gene', (35, 39))	('H2AX', 'Gene', (69, 73))	('BRCA1', 'Gene', '672', (136, 141))	('H2AX', 'Gene', '3014', (69, 73))	('53BP1', 'Gene', '7158', (126, 131))	('Nbs1', 'Gene', '4683', (35, 39))	('Rad50', 'Gene', '10111', (24, 29))	('Mre11', 'Gene', '4361', (17, 22))
421	35216362	Loss of MRN complex member (Mre11, Rad50, and Nbs1) can significantly sensitize the radiation treatment.	('Rad50', 'Gene', (35, 40))	('Mre11', 'Gene', (28, 33))	('Loss', 'NegReg', (0, 4))	('Nbs1', 'Gene', (46, 50))	('sensitize', 'MPA', (70, 79))	('radiation treatment', 'CPA', (84, 103))	('Mre11', 'Gene', '4361', (28, 33))	('Rad50', 'Gene', '10111', (35, 40))	('Nbs1', 'Gene', '4683', (46, 50))
422	35216362	Ku70/Ku80 heterodimer is composed of 70-kDa (Ku70) and 80-kDa (Ku80) subunits.	('Ku70', 'Gene', (0, 4))	('Ku70', 'Gene', (45, 49))	('Ku80', 'Gene', (5, 9))	('Ku80', 'Gene', (63, 67))	('Ku70', 'Gene', '2547', (45, 49))	('Ku80', 'Gene', '7520', (63, 67))	('Ku80', 'Gene', '7520', (5, 9))	('Ku70', 'Gene', '2547', (0, 4))
423	35216362	In combination with DNA-dependent protein kinase (DNA-PK), Ku70/Ku80 form a multisubunit DNA repair machinery to repair DSBs through Non-homologous end joining (NHEJ) pathway.	('Ku70', 'Gene', (59, 63))	('Non-homologous end joining', 'Pathway', (133, 159))	('DNA-PK', 'Gene', (50, 56))	('Ku80', 'Gene', (64, 68))	('repair DSBs', 'MPA', (113, 124))	('DNA-dependent protein kinase', 'Gene', (20, 48))	('DNA-dependent protein kinase', 'Gene', '5591', (20, 48))	('DSBs', 'Chemical', 'MESH:C007563', (120, 124))	('Ku70', 'Gene', '2547', (59, 63))	('DNA-PK', 'Gene', '5591', (50, 56))	('Ku80', 'Gene', '7520', (64, 68))
424	35216362	It has been demonstrated that Ku70/Ku80 heterodimer's DNA end-binding activity can dictate the radiosensitivity in human glioma, cervical cancer, and leukemia.	('DNA end-binding', 'Interaction', (54, 69))	('heterodimer', 'Protein', (40, 51))	('Ku70', 'Gene', (30, 34))	('activity', 'MPA', (70, 78))	('glioma', 'Disease', (121, 127))	('Ku80', 'Gene', (35, 39))	('cancer', 'Disease', (138, 144))	('radiosensitivity', 'CPA', (95, 111))	('leukemia', 'Disease', (150, 158))	('dictate', 'Reg', (83, 90))	('glioma', 'Disease', 'MESH:D005910', (121, 127))	('Ku80', 'Gene', '7520', (35, 39))	('Ku70', 'Gene', '2547', (30, 34))	('human', 'Species', '9606', (115, 120))	('cancer', 'Disease', 'MESH:D009369', (138, 144))	('leukemia', 'Disease', 'MESH:D007938', (150, 158))
427	35216362	For example, human apurinic/apyrimidinic endonuclease/redox factor-1 (APE1/Ref-1) is a dual function protein functioning as the major AP endonuclease in BER pathway as well as in the transcriptional regulation.	('Ref-1', 'Gene', (75, 80))	('BER pathway', 'Pathway', (153, 164))	('APE1', 'Gene', (70, 74))	('human', 'Species', '9606', (13, 18))	('BER', 'CellLine', '9606', (153, 156))	('APE1', 'Gene', '328', (70, 74))	('Ref-1', 'Gene', '328', (75, 80))
428	35216362	The expression of human APE1 increases after the G1-S transition and peaks at the S phase, which has a direct impact on the cytotoxic effects of radiation and temozolomide treatment in glioblastoma cells.	('glioblastoma', 'Disease', (185, 197))	('increases', 'PosReg', (29, 38))	('impact', 'Reg', (110, 116))	('temozolomide treatment', 'CPA', (159, 181))	('APE1', 'Gene', (24, 28))	('G1-S', 'MPA', (49, 53))	('cytotoxic effects of radiation', 'CPA', (124, 154))	('expression', 'MPA', (4, 14))	('APE1', 'Gene', '328', (24, 28))	('glioblastoma', 'Disease', 'MESH:D005909', (185, 197))	('human', 'Species', '9606', (18, 23))	('temozolomide', 'Chemical', 'MESH:D000077204', (159, 171))
429	35216362	A 24 to 32 nucleotide-long oligomer is excised by endonuclease XPG (ERCC5).Then, polymerase and replication proteins fill in the gap followed by ligation.	('XPG', 'Gene', (63, 66))	('ligation', 'MPA', (145, 153))	('polymerase', 'Protein', (81, 91))	('replication proteins', 'Protein', (96, 116))	('ERCC5', 'Gene', (68, 73))	('ERCC5', 'Gene', '2073', (68, 73))	('XPG', 'Gene', '2073', (63, 66))
430	35216362	DNA excision repair protein ERCC2 and ERCC1 are important components of the NER pathway.	('ERCC2', 'Gene', (28, 33))	('NER pathway', 'Pathway', (76, 87))	('ERCC1', 'Gene', (38, 43))	('ERCC2', 'Gene', '2068', (28, 33))	('ERCC1', 'Gene', '2067', (38, 43))
431	35216362	The polymorphism of ERCC1 and ERCC2 genes showed a significant association with the incidence of primary malignant brain tumors in a meta-analysis study.	('ERCC1', 'Gene', (20, 25))	('primary malignant brain tumors', 'Disease', (97, 127))	('ERCC2', 'Gene', (30, 35))	('significant association', 'Reg', (51, 74))	('polymorphism', 'Var', (4, 16))	('ERCC1', 'Gene', '2067', (20, 25))	('primary malignant brain tumors', 'Disease', 'MESH:D001932', (97, 127))	('ERCC2', 'Gene', '2068', (30, 35))
433	35216362	Once the MRN complex is activated, ataxia-telangiectasia (ATM) kinase is recruited to trigger the DSB-signaling cascade and coordinate DNA repair processes.	('ataxia-telangiectasia', 'Disease', (35, 56))	('MRN', 'Protein', (9, 12))	('trigger', 'PosReg', (86, 93))	('DSB-signaling', 'MPA', (98, 111))	('DNA repair', 'CPA', (135, 145))	('recruited', 'PosReg', (73, 82))	('ataxia-telangiectasia', 'Disease', 'MESH:D001260', (35, 56))
434	35216362	Furthermore, ATM mutations confer enhanced radiation sensitivity and potentially develop late toxicity from cancer radiotherapy.	('enhanced', 'PosReg', (34, 42))	('toxicity', 'Disease', (94, 102))	('cancer', 'Disease', (108, 114))	('late', 'MPA', (89, 93))	('radiation', 'MPA', (43, 52))	('mutations', 'Var', (17, 26))	('ATM', 'Gene', (13, 16))	('develop', 'PosReg', (81, 88))	('toxicity', 'Disease', 'MESH:D064420', (94, 102))	('cancer', 'Disease', 'MESH:D009369', (108, 114))
435	35216362	5' AMP-activated protein kinase (AMPK) is a highly conserved metabolic stress sensor protein which is phosphorylated by ATM in response to chemo- and radiotherapy-induced DNA damages in cancer cells.	('cancer', 'Disease', (186, 192))	('AMPK', 'Gene', (33, 37))	('AMP-activated protein kinase', 'Gene', (3, 31))	('AMP-activated protein kinase', 'Gene', '5562', (3, 31))	('AMPK', 'Gene', '5562', (33, 37))	('cancer', 'Disease', 'MESH:D009369', (186, 192))
436	35216362	The intracellular ATP level needs to be maintained to conduct the repairing processes of DNA damages, responding to the increased ATP consumption.	('ATP consumption', 'MPA', (130, 145))	('repairing', 'CPA', (66, 75))	('increased', 'PosReg', (120, 129))	('ATP', 'Chemical', 'MESH:D000255', (130, 133))	('ATP', 'Chemical', 'MESH:D000255', (18, 21))
437	35216362	The active AMPK can downregulate ATP-consuming biosynthetic processes and upregulate ATP-producing pathways to balance energy consumption and genomic integrity.	('downregulate', 'NegReg', (20, 32))	('balance energy consumption', 'MPA', (111, 137))	('ATP-consuming biosynthetic processes', 'MPA', (33, 69))	('upregulate', 'PosReg', (74, 84))	('AMPK', 'Gene', (11, 15))	('ATP-producing pathways', 'Pathway', (85, 107))	('genomic', 'MPA', (142, 149))	('ATP-', 'Chemical', 'MESH:D000255', (33, 37))	('ATP-', 'Chemical', 'MESH:D000255', (85, 89))	('AMPK', 'Gene', '5562', (11, 15))
440	35216362	Glucose enters into cells via glucose transporters (GLUT), then gets phosphorylated by hexokinase (HK) to form glucose 6-phosphate.	('GLUT', 'Gene', (52, 56))	('hexokinase', 'Gene', (87, 97))	('glucose 6-phosphate', 'MPA', (111, 130))	('HK', 'Gene', '3098', (99, 101))	('glucose', 'Chemical', 'MESH:D005947', (30, 37))	('Glucose', 'Chemical', 'MESH:D005947', (0, 7))	('glucose', 'Chemical', 'MESH:D005947', (111, 118))	('GLUT', 'Gene', '6513', (52, 56))	('hexokinase', 'Gene', '3098', (87, 97))
443	35216362	Under an anaerobic setting, the TCA cycle is not active, and glycolysis becomes the only option that cells can have for the production of ATP from glucose.	('production of ATP from glucose', 'MPA', (124, 154))	('glycolysis', 'MPA', (61, 71))	('TCA', 'MPA', (32, 35))	('TCA', 'Chemical', 'MESH:D014233', (32, 35))	('glucose', 'Chemical', 'MESH:D005947', (147, 154))	('ATP', 'Chemical', 'MESH:D000255', (138, 141))
444	35216362	This process is not very efficient and only produces 6-8 ATPs per glucose molecule, and the end product is lactic acid which is the main cause of exercise-induced muscle fatigue.	('muscle fatigue', 'Disease', (163, 177))	('lactic acid', 'MPA', (107, 118))	('glucose', 'Chemical', 'MESH:D005947', (66, 73))	('lactic acid', 'Chemical', 'MESH:D019344', (107, 118))	('muscle fatigue', 'Disease', 'MESH:D005221', (163, 177))	('ATPs', 'Chemical', 'MESH:D000255', (57, 61))
445	35216362	Here we review the key enzymes found to be essential for the uptake of glucose in cancer cells and their roles in radiation resistance.	('cancer', 'Disease', (82, 88))	('radiation resistance', 'CPA', (114, 134))	('roles', 'Reg', (105, 110))	('uptake of glucose', 'MPA', (61, 78))	('glucose', 'Chemical', 'MESH:D005947', (71, 78))	('cancer', 'Disease', 'MESH:D009369', (82, 88))
446	35216362	The three isocitrate dehydrogenase (IDHs) isoforms have a prominent place in cellular metabolism, which catalyzes the reversible oxidative decarboxylation reaction converting isocitrate to alpha-ketoglutarate to generate NADPH from NADP+.	('IDH', 'Gene', (36, 39))	('reversible', 'MPA', (118, 128))	('isocitrate dehydrogenase', 'Gene', (10, 34))	('NADPH from NADP+', 'MPA', (221, 237))	('catalyzes', 'MPA', (104, 113))	('NADP+', 'Chemical', 'MESH:D009249', (232, 237))	('isocitrate', 'Chemical', 'MESH:C034219', (175, 185))	('alpha-ketoglutarate', 'Chemical', 'MESH:D007656', (189, 208))	('isocitrate', 'Chemical', 'MESH:C034219', (10, 20))	('NADPH', 'Chemical', 'MESH:D009249', (221, 226))	('isocitrate dehydrogenase', 'Gene', '3417', (10, 34))	('IDH', 'Gene', '3417', (36, 39))
447	35216362	However, only mutations in IDH1 and 2 are considered to be the drivers of tumor initiation.	('tumor initiation', 'Disease', (74, 90))	('mutations', 'Var', (14, 23))	('tumor initiation', 'Disease', 'MESH:D009369', (74, 90))	('IDH1 and 2', 'Gene', '3417;3418', (27, 37))
448	35216362	IDH1 R132 or IDH2 R172 mutant gliomas usually arise in a younger patient population, and patients with low grade gliomas (LGG) typically have a long overall survival time (5-10 years).	('IDH', 'Gene', (0, 3))	('gliomas', 'Disease', (113, 120))	('gliomas', 'Disease', (30, 37))	('IDH', 'Gene', (13, 16))	('IDH', 'Gene', '3417', (13, 16))	('IDH1', 'CellLine', '9606', (0, 4))	('gliomas', 'Disease', 'MESH:D005910', (113, 120))	('patients', 'Species', '9606', (89, 97))	('gliomas', 'Disease', 'MESH:D005910', (30, 37))	('patient', 'Species', '9606', (89, 96))	('patient', 'Species', '9606', (65, 72))	('IDH', 'Gene', '3417', (0, 3))	('R132', 'Mutation', 'rs121913500', (5, 9))
449	35216362	On the other hand, IDH1 wild-type glioma is the most aggressive form of glioma, and IDHwt patients only have a short survival time (6-12-months).	('IDH', 'Gene', (84, 87))	('glioma', 'Disease', (34, 40))	('IDH', 'Gene', (19, 22))	('glioma', 'Disease', (72, 78))	('IDH1', 'CellLine', '9606', (19, 23))	('glioma', 'Disease', 'MESH:D005910', (72, 78))	('IDH', 'Gene', '3417', (84, 87))	('patients', 'Species', '9606', (90, 98))	('glioma', 'Disease', 'MESH:D005910', (34, 40))	('IDH', 'Gene', '3417', (19, 22))
450	35216362	Mutant IDH1 proteins gain a new enzymatic activity at the cellular level compared to wild-type IDH proteins, leading to accumulation of oncometabolite d-2-hydroxyglutarate (2HG) in cancer cells.	('proteins', 'Protein', (12, 20))	('gain', 'PosReg', (21, 25))	('cancer', 'Disease', (181, 187))	('enzymatic', 'MPA', (32, 41))	('IDH', 'Gene', (7, 10))	('IDH', 'Gene', (95, 98))	('Mutant', 'Var', (0, 6))	('accumulation', 'PosReg', (120, 132))	('d-2-hydroxyglutarate', 'Chemical', 'MESH:C019417', (151, 171))	('cancer', 'Disease', 'MESH:D009369', (181, 187))	('IDH', 'Gene', '3417', (95, 98))	('IDH1', 'CellLine', '9606', (7, 11))	('IDH', 'Gene', '3417', (7, 10))
451	35216362	2HG causes global accumulation of cytosine and histone methylations and drives chromatin to a closed structure, which reduces the activities of oncogenic signaling pathways.	('cytosine', 'MPA', (34, 42))	('drives', 'Reg', (72, 78))	('oncogenic signaling pathways', 'Pathway', (144, 172))	('activities', 'MPA', (130, 140))	('methylations', 'MPA', (55, 67))	('reduces', 'NegReg', (118, 125))	('accumulation', 'PosReg', (18, 30))	('histone', 'Reg', (47, 54))	('cytosine', 'Chemical', 'MESH:D003596', (34, 42))
452	35216362	Mutations in IDH1 and IDH2 have frequently been found in acute myeloid leukemia patients, 7% for IDH1 and 14% for IDH2, separately.	('IDH', 'Gene', (114, 117))	('acute myeloid leukemia', 'Disease', (57, 79))	('Mutations', 'Var', (0, 9))	('IDH', 'Gene', (22, 25))	('IDH', 'Gene', (13, 16))	('IDH', 'Gene', (97, 100))	('found', 'Reg', (48, 53))	('IDH', 'Gene', '3417', (97, 100))	('IDH', 'Gene', '3417', (13, 16))	('patients', 'Species', '9606', (80, 88))	('acute myeloid leukemia', 'Disease', 'MESH:D015470', (57, 79))	('IDH1', 'CellLine', '9606', (13, 17))	('IDH', 'Gene', '3417', (22, 25))	('IDH1', 'CellLine', '9606', (97, 101))	('IDH', 'Gene', '3417', (114, 117))
453	35216362	IDH2 R140 patients usually have a favorable outcome, however IDH2 R172 patients had a poor outcome suggesting these two mutations drive tumorigenesis in opposite directions.	('tumor', 'Disease', (136, 141))	('IDH', 'Gene', (0, 3))	('IDH', 'Gene', (61, 64))	('R172', 'Var', (66, 70))	('IDH', 'Gene', '3417', (61, 64))	('patients', 'Species', '9606', (10, 18))	('IDH', 'Gene', '3417', (0, 3))	('tumor', 'Disease', 'MESH:D009369', (136, 141))	('patients', 'Species', '9606', (71, 79))
454	35216362	Pyruvate dehydrogenase (PDH) oxidizes pyruvate to form the two-carbon unit acetyl-CoA which joins the metabolic pathways between glycolysis and TCA cycle.	('Pyruvate dehydrogenase', 'Gene', (0, 22))	('TCA cycle', 'MPA', (144, 153))	('metabolic pathways', 'MPA', (102, 120))	('acetyl-CoA', 'MPA', (75, 85))	('glycolysis', 'MPA', (129, 139))	('PDH', 'Gene', (24, 27))	('PDH', 'Gene', '54704', (24, 27))	('pyruvate', 'Chemical', 'MESH:D019289', (38, 46))	('TCA', 'Chemical', 'MESH:D014233', (144, 147))	('carbon', 'Chemical', 'MESH:D002244', (63, 69))	('Pyruvate dehydrogenase', 'Gene', '54704', (0, 22))	('acetyl-CoA', 'Chemical', 'MESH:D000105', (75, 85))
455	35216362	Pyruvate dehydrogenase exerts its functions by forming a large complex with dihydrolipoyl transacetylase and dihydrolipoyl dehydrogenase.	('dihydrolipoyl transacetylase', 'Enzyme', (76, 104))	('Pyruvate dehydrogenase', 'Gene', (0, 22))	('dihydrolipoyl dehydrogenase', 'Enzyme', (109, 136))	('functions', 'MPA', (34, 43))	('complex', 'Interaction', (63, 70))	('Pyruvate dehydrogenase', 'Gene', '54704', (0, 22))
456	35216362	It has been demonstrated that PDH component X (PDHX) is an essential gene for the cell growth of esophageal squamous cell carcinoma (ESCC) through metabolic regulations.	('esophageal squamous cell carcinoma', 'Disease', (97, 131))	('PDHX', 'Gene', (47, 51))	('cell growth', 'CPA', (82, 93))	('PDH component X', 'Gene', (30, 45))	('PDH component X', 'Gene', '8050', (30, 45))	('PDHX', 'Gene', '8050', (47, 51))	('esophageal squamous cell carcinoma', 'Disease', 'MESH:D000077277', (97, 131))
457	35216362	The upregulated PDH function can be attributed to the co-amplification of PDHX and CD44 genes which are known markers of cancer stem cells in several different malignancies.	('PDH', 'Gene', (74, 77))	('upregulated', 'PosReg', (4, 15))	('cancer', 'Disease', (121, 127))	('CD44 genes', 'Gene', (83, 93))	('malignancies', 'Disease', (160, 172))	('PDH', 'Gene', (16, 19))	('function', 'MPA', (20, 28))	('PDHX', 'Gene', (74, 78))	('cancer', 'Disease', 'MESH:D009369', (121, 127))	('PDH', 'Gene', '54704', (74, 77))	('malignancies', 'Disease', 'MESH:D009369', (160, 172))	('PDH', 'Gene', '54704', (16, 19))	('PDHX', 'Gene', '8050', (74, 78))
459	35216362	CPI-613, a PDH inhibitor has been shown to inhibit the proliferation of cancer stem cells (CSCs) in vitro and the growth of ESCC xenograft tumors in vivo.	('tumors', 'Disease', (139, 145))	('proliferation', 'CPA', (55, 68))	('ESCC', 'Disease', (124, 128))	('growth', 'CPA', (114, 120))	('inhibit', 'NegReg', (43, 50))	('PDH', 'Gene', (11, 14))	('cancer', 'Disease', (72, 78))	('CPI-613', 'Var', (0, 7))	('PDH', 'Gene', '54704', (11, 14))	('CPI-613', 'Chemical', 'MESH:C568850', (0, 7))	('tumors', 'Disease', 'MESH:D009369', (139, 145))	('cancer', 'Disease', 'MESH:D009369', (72, 78))
460	35216362	Pyruvate kinase is the last enzyme in glycolysis process, and its end-product, pyruvate, enters the TCA cycle to form ATP.	('Pyruvate', 'Enzyme', (0, 8))	('pyruvate', 'MPA', (79, 87))	('TCA cycle', 'MPA', (100, 109))	('pyruvate', 'Chemical', 'MESH:D019289', (79, 87))	('TCA', 'Chemical', 'MESH:D014233', (100, 103))	('ATP', 'Chemical', 'MESH:D000255', (118, 121))
461	35216362	There are four pyruvate kinase isoforms, but only Pyruvate Kinase Muscle 2 (PKM2) has been found to be oncogenic.	('Pyruvate Kinase Muscle 2', 'Gene', (50, 74))	('oncogenic', 'CPA', (103, 112))	('PKM2', 'Gene', (76, 80))	('PKM2', 'Gene', '5315', (76, 80))	('Pyruvate Kinase Muscle 2', 'Gene', '5315', (50, 74))	('pyruvate', 'Chemical', 'MESH:D019289', (15, 23))
462	35216362	Glucose Transporter (GLUT) family proteins are encoded by the SLC2 genes and contain 14 members of the GLUT family in human, which actively transport monosaccharides across the lipid bilayers.	('Glucose Transporter', 'Gene', (0, 19))	('GLUT', 'Gene', (103, 107))	('GLUT', 'Gene', (21, 25))	('GLUT', 'Gene', '6513', (21, 25))	('lipid', 'Chemical', 'MESH:D008055', (177, 182))	('Glucose Transporter', 'Gene', '6513', (0, 19))	('monosaccharides', 'Chemical', 'MESH:D009005', (150, 165))	('human', 'Species', '9606', (118, 123))	('GLUT', 'Gene', '6513', (103, 107))
463	35216362	Over-expression of the facilitative GLUT1 protein has been observed in a large array of human cancer types suggesting that it likely plays a role in tumor initiation, progression and modulation of tumor immune microenvironment (TME).	('cancer', 'Disease', (94, 100))	('GLUT1', 'Gene', (36, 41))	('tumor', 'Disease', (197, 202))	('tumor initiation', 'Disease', (149, 165))	('tumor', 'Disease', (149, 154))	('Over-expression', 'MPA', (0, 15))	('plays', 'Reg', (133, 138))	('cancer', 'Disease', 'MESH:D009369', (94, 100))	('tumor', 'Disease', 'MESH:D009369', (149, 154))	('human', 'Species', '9606', (88, 93))	('tumor initiation', 'Disease', 'MESH:D009369', (149, 165))	('tumor', 'Disease', 'MESH:D009369', (197, 202))	('GLUT1', 'Gene', '6513', (36, 41))
464	35216362	Radiation therapy can induce GLUT1 expression and upregulate glucose metabolism in MDA-MB-231 and MCF-7 breast cancer cells.	('induce', 'PosReg', (22, 28))	('glucose metabolism', 'Disease', (61, 79))	('expression', 'MPA', (35, 45))	('MCF-7 breast cancer', 'Disease', (98, 117))	('GLUT1', 'Gene', (29, 34))	('upregulate', 'PosReg', (50, 60))	('glucose metabolism', 'Disease', 'MESH:D044882', (61, 79))	('GLUT1', 'Gene', '6513', (29, 34))	('MCF-7 breast cancer', 'Disease', 'MESH:D001943', (98, 117))
465	35216362	Thus, inhibition of GLUT1 may enhance the radiation sensitivity through increasing ROS production.	('increasing', 'PosReg', (72, 82))	('GLUT1', 'Gene', (20, 25))	('enhance', 'PosReg', (30, 37))	('radiation sensitivity', 'CPA', (42, 63))	('inhibition', 'Var', (6, 16))	('ROS production', 'MPA', (83, 97))	('ROS', 'Chemical', 'MESH:D017382', (83, 86))	('GLUT1', 'Gene', '6513', (20, 25))
466	35216362	The transient inhibition of GLUT1 in laryngeal CSCs can increase radiosensitivity by downregulating the levels of RAD51 and DNA-PKcs.	('increase', 'PosReg', (56, 64))	('DNA-PKcs', 'Gene', (124, 132))	('inhibition', 'NegReg', (14, 24))	('RAD51', 'Gene', (114, 119))	('radiosensitivity', 'CPA', (65, 81))	('downregulating', 'NegReg', (85, 99))	('GLUT1', 'Gene', (28, 33))	('RAD51', 'Gene', '5888', (114, 119))	('DNA-PKcs', 'Gene', '5591', (124, 132))	('GLUT1', 'Gene', '6513', (28, 33))
467	35216362	Cancer cells treated with WZB117, a GLUT1 inhibitor, display downregulation of GLUT1 expression and glucose uptake.	('downregulation', 'NegReg', (61, 75))	('GLUT1', 'Gene', (36, 41))	('GLUT1', 'Gene', (79, 84))	('glucose uptake', 'CPA', (100, 114))	('WZB117', 'Var', (26, 32))	('Cancer', 'Disease', (0, 6))	('expression', 'MPA', (85, 95))	('Cancer', 'Disease', 'MESH:D009369', (0, 6))	('WZB117', 'Chemical', 'MESH:C576807', (26, 32))	('glucose', 'Chemical', 'MESH:D005947', (100, 107))	('GLUT1', 'Gene', '6513', (79, 84))	('GLUT1', 'Gene', '6513', (36, 41))
468	35216362	A combination of radiation therapy and a GLUT1 inhibitor demonstrated synergistic inhibition effect in the breast cancer cells.	('GLUT1', 'Gene', (41, 46))	('inhibition', 'NegReg', (82, 92))	('synergistic', 'MPA', (70, 81))	('breast cancer', 'Disease', (107, 120))	('breast cancer', 'Disease', 'MESH:D001943', (107, 120))	('GLUT1', 'Gene', '6513', (41, 46))
469	35216362	GLUT1 inhibition not only alters the tumor metabolism, but also influences the tumor TME.	('alters', 'Reg', (26, 32))	('influences', 'Reg', (64, 74))	('GLUT1', 'Gene', (0, 5))	('inhibition', 'NegReg', (6, 16))	('TME', 'MPA', (85, 88))	('tumor', 'Disease', (37, 42))	('tumor', 'Disease', (79, 84))	('tumor metabolism', 'Disease', (37, 53))	('tumor', 'Disease', 'MESH:D009369', (79, 84))	('tumor metabolism', 'Disease', 'MESH:D008659', (37, 53))	('tumor', 'Disease', 'MESH:D009369', (37, 42))	('GLUT1', 'Gene', '6513', (0, 5))
470	35216362	Tumor-associated neutrophils (TANs) also rely on GLUT1 and glucose metabolism to support tumor growth.	('tumor', 'Disease', (89, 94))	('GLUT1', 'Gene', (49, 54))	('glucose metabolism', 'Disease', (59, 77))	('tumor', 'Disease', 'MESH:D009369', (89, 94))	('GLUT1', 'Gene', '6513', (49, 54))	('glucose metabolism', 'Disease', 'MESH:D044882', (59, 77))
471	35216362	Hexokinase (HK) phosphorylates six-carbon glucose to glucose-6-phosphate, which is the first enzymatic reaction in glycolysis.	('Hexokinase', 'Gene', (0, 10))	('glucose-6-phosphate', 'MPA', (53, 72))	('glucose', 'Chemical', 'MESH:D005947', (53, 60))	('carbon', 'Chemical', 'MESH:D002244', (35, 41))	('Hexokinase', 'Gene', '3098', (0, 10))	('glucose', 'Chemical', 'MESH:D005947', (42, 49))	('HK', 'Gene', '3098', (12, 14))
472	35216362	One glucose analog, 2-Deoxy-glucose (2-DG), can also be phosphorylated by hexokinase to form 2-deoxy-glucose-6-phosphate.	('hexokinase', 'Gene', (74, 84))	('2-deoxy-glucose-6-phosphate', 'MPA', (93, 120))	('glucose', 'Chemical', 'MESH:D005947', (101, 108))	('glucose', 'Chemical', 'MESH:D005947', (28, 35))	('hexokinase', 'Gene', '3098', (74, 84))	('glucose', 'Chemical', 'MESH:D005947', (4, 11))	('2-DG', 'Chemical', 'MESH:D003847', (37, 41))
473	35216362	However, this compound cannot be further processed by the enzymes in cells providing an opportunity to block glucose uptake.	('block', 'NegReg', (103, 108))	('not', 'NegReg', (26, 29))	('glucose uptake', 'MPA', (109, 123))	('glucose', 'Chemical', 'MESH:D005947', (109, 116))
474	35216362	The addition of dietary 2-DG alone has been shown to inhibit Lewis lung carcinoma and its associated lung metastases and radiation-induced angiogenesis in a mouse model.	('radiation-induced angiogenesis', 'CPA', (121, 151))	('lung metastases', 'Disease', (101, 116))	('inhibit', 'NegReg', (53, 60))	('lung carcinoma', 'Disease', (67, 81))	('lung metastases', 'Disease', 'MESH:D009362', (101, 116))	('2-DG', 'Chemical', 'MESH:D003847', (24, 28))	('lung carcinoma', 'Disease', 'MESH:D008175', (67, 81))	('mouse', 'Species', '10090', (157, 162))
475	35216362	Succinate dehydrogenase (SDH) converts succinate to fumarate in the TCA cycle facilitating electron transport in the respiratory chain complex.	('succinate to fumarate', 'MPA', (39, 60))	('Succinate dehydrogenase', 'Gene', (0, 23))	('SDH', 'Gene', (25, 28))	('TCA cycle', 'MPA', (68, 77))	('succinate', 'Chemical', 'MESH:D019802', (39, 48))	('SDH', 'Gene', '6390', (25, 28))	('TCA', 'Chemical', 'MESH:D014233', (68, 71))	('Succinate dehydrogenase', 'Gene', '6390', (0, 23))	('fumarate', 'Chemical', 'MESH:D005650', (52, 60))
476	35216362	Despite the rare occurrence of SDH mutations in humans, mutations in any SDH subunits can damage SDH complex assembly.	('SDH', 'Gene', (31, 34))	('SDH', 'Gene', (97, 100))	('damage', 'NegReg', (90, 96))	('mutations', 'Var', (56, 65))	('SDH', 'Gene', (73, 76))	('SDH', 'Gene', '6390', (97, 100))	('SDH', 'Gene', '6390', (73, 76))	('SDH', 'Gene', '6390', (31, 34))	('humans', 'Species', '9606', (48, 54))
477	35216362	Hereditary paraganglioma and pheochromocytoma syndrome (PGL/PCC) results from the mutations in SDH subunits revealed the relationship between mitochondrial deficiency and tumor initiation.	('SDH', 'Gene', (95, 98))	('mitochondrial deficiency', 'Disease', (142, 166))	('mutations', 'Var', (82, 91))	('relationship', 'Reg', (121, 133))	('PCC', 'Gene', (60, 63))	('tumor initiation', 'Disease', (171, 187))	('PCC', 'Gene', '1421', (60, 63))	('Hereditary paraganglioma and pheochromocytoma syndrome', 'Disease', 'MESH:D010673', (0, 54))	('tumor initiation', 'Disease', 'MESH:D009369', (171, 187))	('SDH', 'Gene', '6390', (95, 98))	('mitochondrial deficiency', 'Disease', 'MESH:D028361', (142, 166))
478	35216362	The significant consequence of loss of SDH function is the accumulation of succinate, like neomorphic production of d-2HG in IDH1 mutant cancer, which causes the hypermethylation of DNA and histone 3.	('SDH', 'Gene', (39, 42))	('IDH1', 'Gene', (125, 129))	('hypermethylation', 'MPA', (162, 178))	('d-2HG', 'MPA', (116, 121))	('DNA', 'Protein', (182, 185))	('cancer', 'Disease', (137, 143))	('accumulation', 'PosReg', (59, 71))	('loss', 'NegReg', (31, 35))	('causes', 'Reg', (151, 157))	('succinate', 'MPA', (75, 84))	('histone 3', 'Protein', (190, 199))	('production', 'MPA', (102, 112))	('mutant', 'Var', (130, 136))	('cancer', 'Disease', 'MESH:D009369', (137, 143))	('SDH', 'Gene', '6390', (39, 42))	('succinate', 'Chemical', 'MESH:D019802', (75, 84))	('IDH1', 'CellLine', '9606', (125, 129))
479	35216362	Fumarate Hydratase (FH) catalyzes the formation of malate from fumarate and the gene encoding this enzyme is located on chromosome 1p43.	('Fumarate Hydratase', 'Gene', (0, 18))	('formation of malate from fumarate', 'MPA', (38, 71))	('fumarate', 'Chemical', 'MESH:D005650', (63, 71))	('FH', 'Gene', '2271', (20, 22))	('Fumarate Hydratase', 'Gene', '2271', (0, 18))	('malate', 'Chemical', 'MESH:C030298', (51, 57))
480	35216362	Heterozygous germline mutations of the FH gene have been found to relate to inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.	('uterine fibroids', 'Disease', (86, 102))	('Heterozygous germline mutations', 'Var', (0, 31))	('skin leiomyomata', 'Disease', (104, 120))	('relate', 'Reg', (66, 72))	('papillary renal cell cancer', 'Disease', (125, 152))	('FH', 'Gene', '2271', (39, 41))	('papillary renal cell cancer', 'Disease', 'MESH:C538614', (125, 152))	('skin leiomyomata', 'Disease', 'MESH:C535516', (104, 120))
482	35216362	FH-deficient cells accumulate intracellular fumarate, display hypermethylation phenotype, and exhibit the hypoxic gene expression profiles even under normoxic conditions.	('hypoxic', 'Disease', (106, 113))	('exhibit', 'Reg', (94, 101))	('hypermethylation', 'CPA', (62, 78))	('FH-deficient', 'Disease', (0, 12))	('accumulate', 'PosReg', (19, 29))	('intracellular fumarate', 'MPA', (30, 52))	('FH-deficient', 'Disease', 'MESH:D006938', (0, 12))	('hypoxic', 'Disease', 'MESH:D000860', (106, 113))	('fumarate', 'Chemical', 'MESH:D005650', (44, 52))
483	35216362	Genetic inhibition of GLUT1 expression in TANs can significantly alleviate tumor growth and increase radiotherapy efficacy.	('GLUT1', 'Gene', (22, 27))	('expression', 'MPA', (28, 38))	('radiotherapy efficacy', 'CPA', (101, 122))	('alleviate', 'NegReg', (65, 74))	('tumor', 'Disease', (75, 80))	('increase', 'PosReg', (92, 100))	('inhibition', 'NegReg', (8, 18))	('tumor', 'Disease', 'MESH:D009369', (75, 80))	('GLUT1', 'Gene', '6513', (22, 27))
484	35216362	Increased radiosensitization of IDH1 mutant glioma cells was found in in vitro models through increasing apoptosis and upregulating ROS generation.	('radiosensitization', 'CPA', (10, 28))	('Increased', 'PosReg', (0, 9))	('IDH1', 'Gene', (32, 36))	('apoptosis', 'CPA', (105, 114))	('upregulating', 'PosReg', (119, 131))	('glioma', 'Disease', (44, 50))	('mutant', 'Var', (37, 43))	('ROS generation', 'MPA', (132, 146))	('IDH1', 'CellLine', '9606', (32, 36))	('ROS', 'Chemical', 'MESH:D017382', (132, 135))	('glioma', 'Disease', 'MESH:D005910', (44, 50))
485	35216362	The crosstalk between DNA damage response and IDH1 mutation in the context of TP53 and ATRX loss indicated that IDH1 R132H acts as a tumor suppressor in glioma by epigenetically upregulating the ATM signaling pathway in mouse model and patient-derived xenograft model.	('epigenetically', 'NegReg', (163, 177))	('ATRX', 'Gene', (87, 91))	('ATM signaling pathway', 'Pathway', (195, 216))	('upregulating', 'PosReg', (178, 190))	('IDH1', 'Gene', (112, 116))	('TP53', 'Gene', (78, 82))	('tumor', 'Disease', (133, 138))	('R132H', 'Var', (117, 122))	('glioma', 'Disease', (153, 159))	('glioma', 'Disease', 'MESH:D005910', (153, 159))	('IDH1', 'CellLine', '9606', (112, 116))	('IDH1', 'CellLine', '9606', (46, 50))	('patient', 'Species', '9606', (236, 243))	('ATRX', 'Gene', '22589', (87, 91))	('TP53', 'Gene', '22059', (78, 82))	('mouse', 'Species', '10090', (220, 225))	('R132H', 'Mutation', 'rs121913500', (117, 122))	('tumor', 'Disease', 'MESH:D009369', (133, 138))
486	35216362	However, clinical trial suggested that IDH1 mutation glioma patients appeared to be sensitive to conventional chemoradiation therapy.	('glioma', 'Disease', (53, 59))	('IDH1', 'Gene', (39, 43))	('sensitive', 'CPA', (84, 93))	('mutation', 'Var', (44, 52))	('glioma', 'Disease', 'MESH:D005910', (53, 59))	('patients', 'Species', '9606', (60, 68))	('IDH1', 'CellLine', '9606', (39, 43))
487	35216362	PDH complex plays an important role in citric acid cycle and aerobic glycolysis.	('citric acid cycle', 'MPA', (39, 56))	('PDH', 'Gene', (0, 3))	('aerobic glycolysis', 'MPA', (61, 79))	('PDH', 'Gene', '54704', (0, 3))	('citric acid', 'Chemical', 'MESH:D019343', (39, 50))
488	35216362	A recent study suggested that reduced PDH activity can promote cancer cells to repair DNA damages through mitochondrial retrograde signaling.	('PDH', 'Gene', (38, 41))	('activity', 'MPA', (42, 50))	('promote', 'PosReg', (55, 62))	('mitochondrial retrograde signaling', 'MPA', (106, 140))	('reduced', 'NegReg', (30, 37))	('cancer', 'Disease', (63, 69))	('repair DNA damages', 'MPA', (79, 97))	('cancer', 'Disease', 'MESH:D009369', (63, 69))	('PDH', 'Gene', '54704', (38, 41))
489	35216362	It has recently been found that PKM2 is highly expressed in cancer cells and reshapes cancer metabolic programming.	('cancer', 'Disease', (60, 66))	('PKM2', 'Gene', (32, 36))	('cancer', 'Disease', (86, 92))	('reshapes', 'Reg', (77, 85))	('PKM2', 'Gene', '5315', (32, 36))	('cancer', 'Disease', 'MESH:D009369', (60, 66))	('cancer', 'Disease', 'MESH:D009369', (86, 92))
490	35216362	Phosphorylation of PKM2 at T328 by ATM, a key member of the DNA repair pathway, attenuates the response to ionizing radiation.	('attenuates', 'NegReg', (80, 90))	('PKM2', 'Gene', (19, 23))	('response to ionizing radiation', 'MPA', (95, 125))	('PKM2', 'Gene', '5315', (19, 23))
491	35216362	2-DG enhancing cytotoxicity and radiosensitization in tumor cells does not only depend on the glucose metabolism, but also decreases intracellular total glutathione content.	('decreases', 'NegReg', (123, 132))	('2-DG', 'Var', (0, 4))	('glucose metabolism', 'Disease', (94, 112))	('radiosensitization', 'CPA', (32, 50))	('enhancing', 'PosReg', (5, 14))	('cytotoxicity', 'Disease', (15, 27))	('tumor', 'Disease', (54, 59))	('intracellular total glutathione content', 'MPA', (133, 172))	('tumor', 'Disease', 'MESH:D009369', (54, 59))	('cytotoxicity', 'Disease', 'MESH:D064420', (15, 27))	('glutathione', 'Chemical', 'MESH:D005978', (153, 164))	('2-DG', 'Chemical', 'MESH:D003847', (0, 4))	('glucose metabolism', 'Disease', 'MESH:D044882', (94, 112))
492	35216362	The mechanism was demonstrated in the rescue experiment by adding thiol antioxidant N-acetylcysteine to the HeLa cells, which partially reversed the radiation-induced toxicity.	('toxicity', 'Disease', (167, 175))	('reversed', 'NegReg', (136, 144))	('toxicity', 'Disease', 'MESH:D064420', (167, 175))	('N-acetylcysteine', 'Chemical', 'MESH:D000111', (84, 100))	('thiol', 'Chemical', 'MESH:D013438', (66, 71))
493	35216362	The results from the in vitro and in vivo models suggest that HK2, but not HK1 or HK3, determines the sensitivity of glioma cells to chemotherapy and/or radiation therapy through modulating the DNA damage responses.	('HK3', 'Gene', (82, 85))	('DNA damage responses', 'MPA', (194, 214))	('HK1', 'Gene', (75, 78))	('sensitivity', 'MPA', (102, 113))	('determines', 'Reg', (87, 97))	('HK2', 'Gene', (62, 65))	('modulating', 'Reg', (179, 189))	('glioma', 'Disease', (117, 123))	('HK1', 'Gene', '3098', (75, 78))	('glioma', 'Disease', 'MESH:D005910', (117, 123))	('HK2', 'Gene', '3099', (62, 65))	('HK3', 'Gene', '3101', (82, 85))
494	35216362	Enhance radiation sensitivity was found in hamster B9 fibroblasts expressing a mutation in the gene coding for SDH subunit C. Disruption of mitochondrial metabolism can result in the elevation of intracellular ROS levels, which can dictate the biological effects of radiation.	('SDH', 'Gene', (111, 114))	('intracellular ROS levels', 'MPA', (196, 220))	('mitochondrial metabolism', 'MPA', (140, 164))	('dictate', 'Reg', (232, 239))	('elevation', 'PosReg', (183, 192))	('biological effects of radiation', 'CPA', (244, 275))	('result in', 'Reg', (169, 178))	('Disruption', 'MPA', (126, 136))	('SDH', 'Gene', '6390', (111, 114))	('ROS', 'Chemical', 'MESH:D017382', (210, 213))	('hamster', 'Species', '10034', (43, 50))	('B9', 'CellLine', 'CVCL:W349', (51, 53))
495	35216362	One recently published study shed light on FH as a DNA repair factor in NHEJ by producing fumarate locally.	('fumarate', 'MPA', (90, 98))	('NHEJ', 'Disease', (72, 76))	('producing', 'Reg', (80, 89))	('FH', 'Gene', '2271', (43, 45))	('fumarate', 'Chemical', 'MESH:D005650', (90, 98))
496	35216362	FH-deficient cells gain resistance to the radiation-induced DNA damage by promoting rapid mitotic entry and fumarate-dependent promotion of NHEJ.	('promotion', 'PosReg', (127, 136))	('gain', 'PosReg', (19, 23))	('rapid mitotic entry', 'CPA', (84, 103))	('resistance', 'CPA', (24, 34))	('fumarate-dependent', 'MPA', (108, 126))	('promoting', 'PosReg', (74, 83))	('NHEJ', 'MPA', (140, 144))	('FH-deficient', 'Disease', (0, 12))	('FH-deficient', 'Disease', 'MESH:D006938', (0, 12))	('fumarate', 'Chemical', 'MESH:D005650', (108, 116))
497	35216362	Glutamine is also recognized as a non-essential amino acid because the magnesium-dependent glutamine synthetase (GS) catalyzes the reaction by condensing glutamate and ammonia to form glutamine.	('glutamine synthetase', 'Gene', (91, 111))	('reaction', 'MPA', (131, 139))	('condensing glutamate', 'MPA', (143, 163))	('catalyzes', 'MPA', (117, 126))	('glutamine synthetase', 'Gene', '2752', (91, 111))	('ammonia', 'Chemical', 'MESH:D000641', (168, 175))	('glutamine', 'Chemical', 'MESH:D005973', (184, 193))	('glutamate', 'Chemical', 'MESH:D018698', (154, 163))	('glutamine', 'Chemical', 'MESH:D005973', (91, 100))	('Glutamine', 'Chemical', 'MESH:D005973', (0, 9))	('magnesium', 'Chemical', 'MESH:D008274', (71, 80))
498	35216362	Cancer cells with specific genetic alterations such as MYC amplification can reprogram mitochondrial metabolism and upregulate glutaminolysis to support the production of energy and building blocks for cell division.	('MYC', 'Gene', (55, 58))	('glutaminolysis to support', 'MPA', (127, 152))	('Cancer', 'Disease', (0, 6))	('reprogram', 'CPA', (77, 86))	('mitochondrial metabolism', 'MPA', (87, 111))	('upregulate', 'PosReg', (116, 126))	('MYC', 'Gene', '4609', (55, 58))	('Cancer', 'Disease', 'MESH:D009369', (0, 6))
499	35216362	The phenomenon can make cancer cells addicted to glutamine as their bioenergetic resource.	('cancer', 'Disease', (24, 30))	('addicted', 'MPA', (37, 45))	('glutamine', 'Chemical', 'MESH:D005973', (49, 58))	('cancer', 'Disease', 'MESH:D009369', (24, 30))
500	35216362	The recently developed glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON, also termed JHU-083) can simultaneously suppress glycolysis and oxidative phosphorylation in cancer cells, which enhanced anticancer immune responses in a preclinical model.	('cancer', 'Disease', (170, 176))	('cancer', 'Disease', (203, 209))	('suppress', 'NegReg', (117, 125))	('enhanced', 'PosReg', (190, 198))	('oxidative phosphorylation', 'MPA', (141, 166))	('glycolysis', 'MPA', (126, 136))	('DON', 'Chemical', 'MESH:D003980', (72, 75))	('JHU-083', 'Chemical', '-', (89, 96))	('glutamine', 'Chemical', 'MESH:D005973', (23, 32))	('cancer', 'Disease', 'MESH:D009369', (170, 176))	('6-diazo-5-oxo-L-norleucine', 'Chemical', 'MESH:D003980', (44, 70))	('cancer', 'Disease', 'MESH:D009369', (203, 209))
501	35216362	To identify patients who will benefit from glutamine deprivation therapy, the synergy between glycolysis and glutaminase inhibition is being actively investigated.	('glycolysis', 'MPA', (94, 104))	('inhibition', 'NegReg', (121, 131))	('glutaminase', 'Gene', (109, 120))	('patients', 'Species', '9606', (12, 20))	('glutamine', 'Chemical', 'MESH:D005973', (43, 52))	('glutaminase', 'Gene', '2744', (109, 120))
503	35216362	The serine synthesis pathway connects many metabolic pathways, including glycolysis, nucleotide synthesis and S-adenosyl methionine cycle.	('serine synthesis pathway', 'Pathway', (4, 28))	('S-adenosyl methionine cycle', 'MPA', (110, 137))	('glycolysis', 'MPA', (73, 83))	('nucleotide synthesis', 'MPA', (85, 105))	('methionine', 'Chemical', 'MESH:D008715', (121, 131))	('serine', 'Chemical', 'MESH:D012694', (4, 10))
505	35216362	Phosphoglycerate dehydrogenase (PHGDH) catalyzes 3PG to 3-phosphohydroxypyruvate (3PHP), then phosphoserine aminotransferase 1 (PSAT1) converts 3PHP into 3-phosphoserine (3PS).	('PSAT1', 'Gene', (128, 133))	('3PG', 'MPA', (49, 52))	('phosphoserine aminotransferase 1', 'Gene', (94, 126))	('PHGDH', 'Gene', (32, 37))	('Phosphoglycerate dehydrogenase', 'Gene', (0, 30))	('Phosphoglycerate dehydrogenase', 'Gene', '26227', (0, 30))	('PHGDH', 'Gene', '26227', (32, 37))	('3-phosphoserine', 'Chemical', 'MESH:D010768', (154, 169))	('3PHP', 'Chemical', 'MESH:C012488', (144, 148))	('3PHP', 'Chemical', 'MESH:C012488', (82, 86))	('PSAT1', 'Gene', '29968', (128, 133))	('phosphoserine aminotransferase 1', 'Gene', '29968', (94, 126))	('3-phosphohydroxypyruvate', 'Chemical', 'MESH:C012488', (56, 80))
506	35216362	Lastly, phosphoserine phosphatase (PSPH) hydrolyzes 3PS to form serine.	('3PS', 'Protein', (52, 55))	('form serine', 'MPA', (59, 70))	('PSPH', 'Gene', (35, 39))	('serine', 'Chemical', 'MESH:D012694', (15, 21))	('PSPH', 'Gene', '5723', (35, 39))	('serine', 'Chemical', 'MESH:D012694', (64, 70))
507	35216362	It has also been demonstrated that the dependence of cancer cells on serine can result from the amplification of the serine synthesis pathway enzymes especially PHGDH encoded by the gene located in chromosome 1p.	('cancer', 'Disease', (53, 59))	('PHGDH', 'Gene', (161, 166))	('serine synthesis pathway', 'Pathway', (117, 141))	('amplification', 'PosReg', (96, 109))	('dependence', 'MPA', (39, 49))	('serine', 'Chemical', 'MESH:D012694', (69, 75))	('cancer', 'Disease', 'MESH:D009369', (53, 59))	('serine', 'Chemical', 'MESH:D012694', (117, 123))	('PHGDH', 'Gene', '26227', (161, 166))
508	35216362	Furthermore, increased serine synthesis activity may present as a therapeutic target in some cancers.	('increased', 'PosReg', (13, 22))	('serine synthesis activity', 'MPA', (23, 48))	('cancers', 'Disease', (93, 100))	('cancers', 'Disease', 'MESH:D009369', (93, 100))	('serine', 'Chemical', 'MESH:D012694', (23, 29))
509	35216362	This observation revealed that the byproducts of de novo serine synthesis are essential for breast cancer by supporting nucleotide synthesis and maintaining cellular redox balance.	('supporting nucleotide synthesis', 'MPA', (109, 140))	('breast cancer', 'Disease', (92, 105))	('cellular redox balance', 'MPA', (157, 179))	('serine', 'Chemical', 'MESH:D012694', (57, 63))	('breast cancer', 'Disease', 'MESH:D001943', (92, 105))
510	35216362	These findings suggest that targeting the enzymes involved in serine synthesis and limiting exogenous serine could be promising therapeutic approaches for cancer therapy.	('limiting', 'NegReg', (83, 91))	('exogenous serine', 'MPA', (92, 108))	('cancer', 'Disease', (155, 161))	('targeting', 'Reg', (28, 37))	('serine', 'Chemical', 'MESH:D012694', (102, 108))	('cancer', 'Disease', 'MESH:D009369', (155, 161))	('serine', 'Chemical', 'MESH:D012694', (62, 68))
511	35216362	NCT-502 and NCT-503 are two small-molecule inhibitors of PHGDH enzyme developed by David Sabatini's group.	('PHGDH', 'Gene', (57, 62))	('NCT-503', 'Var', (12, 19))	('PHGDH', 'Gene', '26227', (57, 62))
512	35216362	Recent data have demonstrated that the biological or chemical inhibition of PHGDH reduces the incorporation of glucose-derived and exogenous serine into nucleotide synthesis by decreasing the activity of cytosolic serine hydroxymethyl transferase (SHMT1).	('inhibition', 'NegReg', (62, 72))	('decreasing', 'NegReg', (177, 187))	('PHGDH', 'Gene', (76, 81))	('SHMT1', 'Gene', (248, 253))	('activity', 'MPA', (192, 200))	('reduces', 'NegReg', (82, 89))	('SHMT1', 'Gene', '6470', (248, 253))	('PHGDH', 'Gene', '26227', (76, 81))	('glucose', 'Chemical', 'MESH:D005947', (111, 118))	('serine', 'Chemical', 'MESH:D012694', (141, 147))	('serine', 'Chemical', 'MESH:D012694', (214, 220))
513	35216362	NCT-503 displayed its ability to reduce the tumor volume of cell lines with high serine synthesis activity in the in vitro and orthotopic xenograft models.	('tumor', 'Disease', (44, 49))	('reduce', 'NegReg', (33, 39))	('NCT-503', 'Var', (0, 7))	('serine', 'Chemical', 'MESH:D012694', (81, 87))	('tumor', 'Disease', 'MESH:D009369', (44, 49))
514	35216362	CBR-5884 is another recently developed small molecular inhibitor of PHGDH, which shows a high selective toxicity to PHGDH-dependent tumor cells.	('selective', 'MPA', (94, 103))	('toxicity', 'Disease', (104, 112))	('CBR-5884', 'Var', (0, 8))	('tumor', 'Disease', (132, 137))	('PHGDH', 'Gene', (116, 121))	('PHGDH', 'Gene', (68, 73))	('PHGDH', 'Gene', '26227', (68, 73))	('CBR-5884', 'Chemical', '-', (0, 8))	('PHGDH', 'Gene', '26227', (116, 121))	('toxicity', 'Disease', 'MESH:D064420', (104, 112))	('tumor', 'Disease', 'MESH:D009369', (132, 137))
515	35216362	This compound is a noncompetitive inhibitor that shows a time-dependent onset of inhibition and attenuates the PHGDH enzymatic activity on its oligomeric state.	('attenuates', 'NegReg', (96, 106))	('PHGDH', 'Gene', (111, 116))	('inhibition', 'MPA', (81, 91))	('PHGDH', 'Gene', '26227', (111, 116))
517	35216362	Arginine, a non-essential amino acid, can be readily acquired from daily food consumption or de novo synthesized through the urea cycle in the normal cells by argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL).	('argininosuccinate lyase', 'Gene', (198, 221))	('ASL', 'Gene', (223, 226))	('ASS', 'Gene', (189, 192))	('ASS', 'Gene', '445', (189, 192))	('succinate', 'Chemical', 'MESH:D019802', (167, 176))	('argininosuccinate lyase', 'Gene', '435', (198, 221))	('urea', 'Chemical', 'MESH:D014508', (125, 129))	('Arginine', 'Chemical', 'MESH:D001120', (0, 8))	('succinate', 'Chemical', 'MESH:D019802', (206, 215))	('ASL', 'Gene', '435', (223, 226))
518	35216362	The most aggressive malignant tumors are usually associated with increased metabolic activities to support their high proliferation rate, metastasis, and invasion.	('malignant tumors', 'Disease', (20, 36))	('metabolic activities', 'MPA', (75, 95))	('metastasis', 'CPA', (138, 148))	('increased', 'PosReg', (65, 74))	('invasion', 'CPA', (154, 162))	('malignant tumors', 'Disease', 'MESH:D009369', (20, 36))
521	35216362	Tumor-infiltrating myeloid cells expressing high levels of arginase can quickly deplete arginine in the tumor TME and promote immune evasion.	('tumor', 'Disease', (104, 109))	('immune evasion', 'CPA', (126, 140))	('promote', 'PosReg', (118, 125))	('arginine', 'Chemical', 'MESH:D001120', (88, 96))	('tumor', 'Disease', 'MESH:D009369', (104, 109))
522	35216362	CB-1158 is a recently developed small-molecule inhibitor of arginase that reverses the myeloid cell-mediated suppression of T cell functions.	('reverses', 'NegReg', (74, 82))	('T cell functions', 'CPA', (124, 140))	('CB-1158', 'Var', (0, 7))	('arginase', 'Enzyme', (60, 68))	('CB-1158', 'Chemical', 'MESH:C000628114', (0, 7))
523	35216362	In vitro and syngeneic mouse models revealed that CB-1158 augmented tumor-infiltrating T cells and NK cells and delayed the tumor growth as a single agent or combined with checkpoint blockade therapy.	('tumor', 'Disease', (124, 129))	('CB-1158', 'Var', (50, 57))	('NK cells', 'CPA', (99, 107))	('delayed', 'NegReg', (112, 119))	('augmented', 'PosReg', (58, 67))	('tumor', 'Disease', (68, 73))	('tumor', 'Disease', 'MESH:D009369', (68, 73))	('mouse', 'Species', '10090', (23, 28))	('CB-1158', 'Chemical', 'MESH:C000628114', (50, 57))	('tumor', 'Disease', 'MESH:D009369', (124, 129))
524	35216362	It is worth noting that 25 Gy irradiation induced mRNA and protein expression of arginase in the syngenic murine prostate cancer model, and, furthermore, tumor-associated macrophages (TAM) were found to be the sources of the elevated arginase expression.	('arginase', 'Enzyme', (81, 89))	('tumor', 'Disease', (154, 159))	('prostate cancer', 'Disease', (113, 128))	('expression', 'MPA', (243, 253))	('protein expression', 'MPA', (59, 77))	('elevated', 'PosReg', (225, 233))	('mRNA', 'MPA', (50, 54))	('induced', 'PosReg', (42, 49))	('arginase', 'Enzyme', (234, 242))	('tumor', 'Disease', 'MESH:D009369', (154, 159))	('prostate cancer', 'Disease', 'MESH:D011471', (113, 128))	('murine', 'Species', '10090', (106, 112))
525	35216362	Myeloid cell-specific ARG deletion in an in vivo model demonstrated an enhanced tumor control after radiation therapy.	('tumor', 'Disease', (80, 85))	('enhanced', 'PosReg', (71, 79))	('ARG', 'Gene', (22, 25))	('deletion', 'Var', (26, 34))	('tumor', 'Disease', 'MESH:D009369', (80, 85))
526	35216362	Glutamine deprivation or pharmacological inhibition of glutaminase can significantly promote radiation-induced apoptosis and sensitized pancreatic CSCs to fractionated radiation.	('pancreatic CSCs', 'Disease', (136, 151))	('radiation-induced apoptosis', 'CPA', (93, 120))	('inhibition', 'NegReg', (41, 51))	('promote', 'PosReg', (85, 92))	('glutaminase', 'Gene', (55, 66))	('sensitized', 'CPA', (125, 135))	('Glutamine', 'Chemical', 'MESH:D005973', (0, 9))	('glutaminase', 'Gene', '2744', (55, 66))	('pancreatic CSCs', 'Disease', 'MESH:D010195', (136, 151))
527	35216362	In addition, the in vitro and xenograft lung cancer models suggest a 30% increase in radiosensitivity after being treated with GLS inhibitors.	('GLS', 'Protein', (127, 130))	('lung cancer', 'Disease', (40, 51))	('radiosensitivity', 'CPA', (85, 101))	('increase', 'PosReg', (73, 81))	('lung cancer', 'Disease', 'MESH:D008175', (40, 51))
528	35216362	After examining 13Carbon metabolism in the GBM tumors and adjacent tissues of an orthotopic mouse model; the study indicated strikingly that a large accumulation of glutamine was found in the tumor tissues, which can only be partially explained by GS enzyme activity.	('tumor', 'Disease', (192, 197))	('tumor', 'Disease', (47, 52))	('GBM tumors', 'Disease', (43, 53))	('accumulation', 'PosReg', (149, 161))	('GBM tumors', 'Disease', 'MESH:D005910', (43, 53))	('tumor', 'Disease', 'MESH:D009369', (47, 52))	('tumor', 'Disease', 'MESH:D009369', (192, 197))	('mouse', 'Species', '10090', (92, 97))	('glutamine', 'Chemical', 'MESH:D005973', (165, 174))	('13Carbon', 'Chemical', '-', (16, 24))
529	35216362	Several studies have demonstrated that the high glutamine synthetase activity is linked with the radiation resistance of cancer cells by modulating nucleotide metabolism, G2/M recovery, and DNA repair.	('DNA repair', 'CPA', (190, 200))	('cancer', 'Disease', (121, 127))	('nucleotide metabolism', 'MPA', (148, 169))	('radiation resistance', 'CPA', (97, 117))	('modulating', 'Reg', (137, 147))	('activity', 'MPA', (69, 77))	('G2/M recovery', 'MPA', (171, 184))	('glutamine synthetase', 'Gene', (48, 68))	('high', 'PosReg', (43, 47))	('linked', 'Reg', (81, 87))	('glutamine synthetase', 'Gene', '2752', (48, 68))	('cancer', 'Disease', 'MESH:D009369', (121, 127))
530	35216362	Moreover, high expression of glutamine synthase can support the proliferation of cancer cells in a novel non-canonical glutamine-independent pathway that, in turn, augment chemoradiation resistance in many cancers.	('proliferation', 'CPA', (64, 77))	('cancers', 'Disease', (206, 213))	('non-canonical glutamine-independent pathway', 'Pathway', (105, 148))	('support', 'PosReg', (52, 59))	('augment', 'PosReg', (164, 171))	('cancer', 'Disease', (206, 212))	('glutamine synthase', 'Gene', (29, 47))	('cancer', 'Disease', (81, 87))	('chemoradiation resistance', 'CPA', (172, 197))	('glutamine synthase', 'Gene', '2752', (29, 47))	('cancer', 'Disease', 'MESH:D009369', (206, 212))	('glutamine', 'Chemical', 'MESH:D005973', (29, 38))	('cancer', 'Disease', 'MESH:D009369', (81, 87))	('glutamine', 'Chemical', 'MESH:D005973', (119, 128))	('cancers', 'Disease', 'MESH:D009369', (206, 213))
531	35216362	Some cancer cells have demonstrated increased de novo serine synthesis through upregulation of PHGDH indicating their survival depends on the sustainable supply of serine.	('cancer', 'Disease', (5, 11))	('survival', 'CPA', (118, 126))	('increased', 'PosReg', (36, 45))	('upregulation', 'PosReg', (79, 91))	('PHGDH', 'Gene', (95, 100))	('de novo serine synthesis', 'MPA', (46, 70))	('PHGDH', 'Gene', '26227', (95, 100))	('cancer', 'Disease', 'MESH:D009369', (5, 11))	('serine', 'Chemical', 'MESH:D012694', (164, 170))	('serine', 'Chemical', 'MESH:D012694', (54, 60))
532	35216362	To the best of our knowledge, the available data investigating the efficacy of the radiotherapy combined with inhibition of PHGDH is very limited.	('PHGDH', 'Gene', (124, 129))	('inhibition', 'NegReg', (110, 120))	('radiotherapy', 'CPA', (83, 95))	('PHGDH', 'Gene', '26227', (124, 129))
533	35216362	ASS is the limiting step of arginine biosynthesis, therefore, some pancreatic, skin, liver, and renal tumors that usually have low expression of ASS have demonstrated the enhanced sensitivity to arginine deprivation therapy in vitro and in vivo.	('enhanced', 'PosReg', (171, 179))	('skin', 'Disease', (79, 83))	('renal tumors', 'Disease', (96, 108))	('pancreatic', 'Disease', (67, 77))	('ASS', 'Gene', (0, 3))	('liver', 'Disease', (85, 90))	('low', 'NegReg', (127, 130))	('ASS', 'Gene', (145, 148))	('sensitivity to arginine deprivation therapy', 'MPA', (180, 223))	('ASS', 'Gene', '445', (145, 148))	('renal tumors', 'Disease', 'MESH:D007674', (96, 108))	('arginine', 'Chemical', 'MESH:D001120', (195, 203))	('arginine', 'Chemical', 'MESH:D001120', (28, 36))	('ASS', 'Gene', '445', (0, 3))	('pancreatic', 'Disease', 'MESH:D010195', (67, 77))
534	35216362	Arginine starvation has been associated with DNA damages and genome instability in breast cancer cells because low arginine level can reduce dNTP pools and affect DNA repair.	('reduce', 'NegReg', (134, 140))	('dNTP pools', 'MPA', (141, 151))	('DNA repair', 'MPA', (163, 173))	('low', 'NegReg', (111, 114))	('affect', 'Reg', (156, 162))	('breast cancer', 'Disease', (83, 96))	('Arginine', 'Chemical', 'MESH:D001120', (0, 8))	('arginine', 'Chemical', 'MESH:D001120', (115, 123))	('dNTP', 'Chemical', '-', (141, 145))	('breast cancer', 'Disease', 'MESH:D001943', (83, 96))
535	35216362	Nucleotide synthesis and DNA replication are the basic requirements for cell proliferation, especially in the case of rapidly proliferating cancer cells.	('cancer', 'Disease', (140, 146))	('DNA', 'MPA', (25, 28))	('Nucleotide', 'MPA', (0, 10))	('cancer', 'Disease', 'MESH:D009369', (140, 146))
537	35216362	Although the salvage pathway can recycle free purines and pyrimidines for nucleoside and nucleotide biosynthesis, most proliferating cells, especially cancer cells, synthesize nucleotides and nucleic acids de novo.	('cancer', 'Disease', (151, 157))	('recycle', 'MPA', (33, 40))	('purines', 'Chemical', 'MESH:D011687', (46, 53))	('pyrimidines', 'Chemical', 'MESH:D011743', (58, 69))	('cancer', 'Disease', 'MESH:D009369', (151, 157))	('nucleoside', 'Chemical', 'MESH:D009705', (74, 84))
538	35216362	Understanding the regulation of the nucleotide salvage pathways by cancer cells can be vital to develop new strategies to target cancer cell proliferation using chemoradiation therapy.	('regulation', 'MPA', (18, 28))	('cancer', 'Disease', (67, 73))	('nucleotide salvage pathways', 'Pathway', (36, 63))	('cancer', 'Disease', (129, 135))	('cancer', 'Disease', 'MESH:D009369', (129, 135))	('cancer', 'Disease', 'MESH:D009369', (67, 73))
541	35216362	Purine analogs 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and 8-Azaguanine (8-AG) were first developed to inhibit several enzymes involved in purine biosynthesis, including PRPP amidotransferase (PPAT).	('PPAT', 'Gene', (199, 203))	('inhibit', 'NegReg', (109, 116))	('PRPP amidotransferase', 'Gene', (176, 197))	('PPAT', 'Gene', '5471', (199, 203))	('8-Azaguanine', 'Chemical', 'MESH:D001375', (65, 77))	('6-MP', 'Chemical', 'MESH:D015122', (33, 37))	('6-TG', 'Chemical', 'MESH:D013866', (55, 59))	('purine', 'Chemical', 'MESH:C030985', (25, 31))	('6-thioguanine', 'Chemical', 'MESH:D013866', (40, 53))	('8-AG', 'Chemical', 'MESH:D001375', (79, 83))	('purine', 'Chemical', 'MESH:C030985', (145, 151))	('Purine', 'Chemical', 'MESH:C030985', (0, 6))	('PRPP amidotransferase', 'Gene', '5471', (176, 197))	('6-mercaptopurine', 'Chemical', 'MESH:D015122', (15, 31))
544	35216362	Additionally, IMPDH is also involved in the GTP salvage pathway though recycling the hypoxanthine.	('involved', 'Reg', (28, 36))	('PDH', 'Gene', (16, 19))	('GTP salvage pathway', 'Pathway', (44, 63))	('recycling the hypoxanthine', 'MPA', (71, 97))	('hypoxanthine', 'Chemical', 'MESH:D019271', (85, 97))	('GTP', 'Chemical', 'MESH:D006160', (44, 47))	('PDH', 'Gene', '54704', (16, 19))
545	35216362	It has been demonstrated that the IMPDH-dependent de novo synthesis of guanine nucleotides is critical for radiation resistance of glioblastoma cells.	('glioblastoma', 'Disease', (131, 143))	('PDH', 'Gene', (36, 39))	('de novo synthesis of guanine nucleotides', 'MPA', (50, 90))	('radiation resistance', 'CPA', (107, 127))	('PDH', 'Gene', '54704', (36, 39))	('glioblastoma', 'Disease', 'MESH:D005909', (131, 143))	('guanine nucleotides', 'Chemical', 'MESH:D006150', (71, 90))
546	35216362	Mycophenolic acid (MPA), preventing the formation of guanosine monophosphate, can deplete GTP concentrations and sensitize glioblastoma cells to radiation treatment in a dose-dependent fashion.	('glioblastoma', 'Disease', (123, 135))	('deplete GTP concentrations', 'MPA', (82, 108))	('preventing', 'NegReg', (25, 35))	('sensitize', 'PosReg', (113, 122))	('guanosine monophosphate', 'Chemical', 'MESH:D006157', (53, 76))	('GTP', 'Chemical', 'MESH:D006160', (90, 93))	('Mycophenolic acid', 'Chemical', 'MESH:D009173', (0, 17))	('glioblastoma', 'Disease', 'MESH:D005909', (123, 135))	('MPA', 'Chemical', 'MESH:D009173', (19, 22))
550	35216362	Cellular enzymes of the pyrimidine metabolic pathway partially convert the pyrimidine analogs, but these metabolites impair the functions of one or more downstream enzymes critical in DNA synthesis.	('convert', 'Reg', (63, 70))	('pyrimidine analogs', 'MPA', (75, 93))	('impair', 'NegReg', (117, 123))	('functions', 'MPA', (128, 137))	('pyrimidine', 'Chemical', 'MESH:C030986', (24, 34))	('pyrimidine', 'Chemical', 'MESH:C030986', (75, 85))
551	35216362	Recent findings indicated that thymidylate kinase (TMPK) is needed to elevate dNTPs pools in the vicinity of DNA damages, which can be determinant for the repair of DSBs.	('elevate', 'PosReg', (70, 77))	('TMPK', 'Gene', (51, 55))	('dNTPs pools in the vicinity', 'MPA', (78, 105))	('thymidylate kinase', 'Gene', (31, 49))	('thymidylate kinase', 'Gene', '1841', (31, 49))	('dNTPs', 'Chemical', '-', (78, 83))	('TMPK', 'Gene', '1841', (51, 55))	('DSBs', 'Chemical', 'MESH:C007563', (165, 169))
552	35216362	Thymidylate synthase (TS) activity is the de novo source of thymidylate for DNA synthesis as part of the folate cycle, which is a valuable target for antimetabolites drug development.	('Thymidylate synthase', 'Gene', (0, 20))	('activity', 'MPA', (26, 34))	('folate', 'Chemical', 'MESH:D005492', (105, 111))	('TS', 'Gene', '7298', (22, 24))	('Thymidylate synthase', 'Gene', '7298', (0, 20))
553	35216362	Fluorouracil (5-FU) which inhibits thymidylate synthase, is an analog of pyrimidine nucleoside.	('inhibits', 'NegReg', (26, 34))	('thymidylate synthase', 'Gene', (35, 55))	('Fluorouracil', 'Chemical', 'MESH:D005472', (0, 12))	('5-FU', 'Chemical', 'MESH:D005472', (14, 18))	('thymidylate synthase', 'Gene', '7298', (35, 55))	('pyrimidine nucleoside', 'Chemical', 'MESH:D011741', (73, 94))
554	35216362	5-FU has been widely used to treat multiple solid tumors, including breast, prostate, colon, and cholangiocarcinoma cancers.	('cholangiocarcinoma cancers', 'Disease', (97, 123))	('breast', 'Disease', (68, 74))	('colon', 'Disease', (86, 91))	('prostate', 'Disease', (76, 84))	('tumors', 'Disease', (50, 56))	('tumors', 'Disease', 'MESH:D009369', (50, 56))	('cholangiocarcinoma cancers', 'Disease', 'MESH:D009369', (97, 123))	('colon', 'Disease', 'MESH:D003110', (86, 91))	('5-FU', 'Chemical', 'MESH:D005472', (0, 4))
556	35216362	Antifolates act by disrupting one-carbon moieties supplied by the folate (vitamin B-9).	('one-carbon moieties', 'MPA', (30, 49))	('disrupting', 'NegReg', (19, 29))	('folate', 'Chemical', 'MESH:D005492', (4, 10))	('folate', 'Chemical', 'MESH:D005492', (66, 72))	('folates', 'Chemical', 'MESH:D005492', (4, 11))	('vitamin B-9', 'Chemical', 'MESH:D005492', (74, 85))	('carbon', 'Chemical', 'MESH:D002244', (34, 40))
558	35216362	The mammalian target of rapamycin (mTOR) regulates a number of cellular processes, including cell survival, proliferation, and metabolism, and activation of mTOR signaling pathways is associated with human cancer.	('mTOR', 'Gene', (157, 161))	('activation', 'PosReg', (143, 153))	('mTOR', 'Gene', (35, 39))	('associated', 'Reg', (184, 194))	('mammalian target of rapamycin', 'Gene', (4, 33))	('cancer', 'Disease', (206, 212))	('mTOR', 'Gene', '2475', (157, 161))	('cancer', 'Disease', 'MESH:D009369', (206, 212))	('human', 'Species', '9606', (200, 205))	('mTOR', 'Gene', '2475', (35, 39))	('mammalian target of rapamycin', 'Gene', '2475', (4, 33))
559	35216362	It has been found recently that mTORC1 protein kinase complex induces purine synthesis by upregulating transcription factor ATF4, further augmenting the level of the methylenetetrahydrofolate dehydrogenase 2.	('ATF4', 'Gene', (124, 128))	('upregulating', 'PosReg', (90, 102))	('purine synthesis', 'MPA', (70, 86))	('augmenting', 'PosReg', (138, 148))	('induces', 'PosReg', (62, 69))	('mTORC1', 'Gene', (32, 38))	('purine', 'Chemical', 'MESH:C030985', (70, 76))	('tetrahydrofolate', 'Chemical', 'MESH:C030371', (175, 191))	('ATF4', 'Gene', '468', (124, 128))	('mTORC1', 'Gene', '382056', (32, 38))
560	35216362	Serial events lead to rewiring the anabolic purine synthesis pathways in cancer cells and supply the required precursor metabolites for cancer cell the growth with availability of required precursor metabolites.	('cancer', 'Disease', (136, 142))	('anabolic purine synthesis pathways', 'Pathway', (35, 69))	('cancer', 'Disease', (73, 79))	('purine', 'Chemical', 'MESH:C030985', (44, 50))	('cancer', 'Disease', 'MESH:D009369', (73, 79))	('cancer', 'Disease', 'MESH:D009369', (136, 142))
561	35216362	Methotrexate (MTX), formerly known as amethopterin, inhibits de novo purine synthesis in human breast cancer cells by blocking dihydrofolate reductase reaction.	('de novo purine synthesis', 'MPA', (61, 85))	('breast cancer', 'Disease', (95, 108))	('inhibits', 'NegReg', (52, 60))	('blocking', 'NegReg', (118, 126))	('dihydrofolate reductase reaction', 'MPA', (127, 159))	('purine', 'Chemical', 'MESH:C030985', (69, 75))	('Methotrexate', 'Chemical', 'MESH:D008727', (0, 12))	('amethopterin', 'Chemical', 'MESH:D008727', (38, 50))	('breast cancer', 'Disease', 'MESH:D001943', (95, 108))	('human', 'Species', '9606', (89, 94))	('MTX', 'Chemical', 'MESH:D008727', (14, 17))	('folate', 'Chemical', 'MESH:D005492', (134, 140))
562	35216362	It has been known that dihydrofolate reductase (inhibited by methotrexate) and thymidylate synthase (inhibited by pemetrexed) are two key members of the folate cycle.	('dihydrofolate reductase', 'Enzyme', (23, 46))	('thymidylate synthase', 'Gene', (79, 99))	('inhibited', 'NegReg', (48, 57))	('pemetrexed', 'Chemical', 'MESH:D000068437', (114, 124))	('folate', 'Chemical', 'MESH:D005492', (153, 159))	('thymidylate synthase', 'Gene', '7298', (79, 99))	('methotrexate', 'Chemical', 'MESH:D008727', (61, 73))	('folate', 'Chemical', 'MESH:D005492', (30, 36))
564	35216362	Drawbacks remain, however, as it has been reported that patients treated with a combination of MTX and ionizing radiation can cause a diversity of clinical syndromes, including neurotoxicities, as seen in children with acute lymphoblastic leukemia.	('cause', 'Reg', (126, 131))	('acute lymphoblastic leukemia', 'Disease', (219, 247))	('neurotoxicities', 'Disease', (177, 192))	('neurotoxicities', 'Disease', 'MESH:D020258', (177, 192))	('MTX', 'Chemical', 'MESH:D008727', (95, 98))	('acute lymphoblastic leukemia', 'Disease', 'MESH:D054198', (219, 247))	('patients', 'Species', '9606', (56, 64))	('children', 'Species', '9606', (205, 213))
565	35216362	The development of resistance in tumor cells toward pyrimidine and purine antimetabolite therapy generally results from an evolutionary process found in heterogenous tumor cell populations as they undergo the stress of cytotoxic therapies.	('tumor', 'Disease', (33, 38))	('resistance', 'MPA', (19, 29))	('tumor', 'Disease', (166, 171))	('tumor', 'Disease', 'MESH:D009369', (166, 171))	('purine', 'Chemical', 'MESH:C030985', (67, 73))	('pyrimidine', 'Chemical', 'MESH:C030986', (52, 62))	('tumor', 'Disease', 'MESH:D009369', (33, 38))
566	35216362	In addition to the de novo purine and pyrimidine synthesis, the salvage pathway can also recycle free purines and pyrimidines for nucleoside and nucleotide biosynthesis.	('recycle free purines', 'MPA', (89, 109))	('salvage pathway', 'Pathway', (64, 79))	('pyrimidines', 'Chemical', 'MESH:D011743', (114, 125))	('purines', 'Chemical', 'MESH:D011687', (102, 109))	('purine', 'Chemical', 'MESH:C030985', (27, 33))	('nucleoside', 'Chemical', 'MESH:D009705', (130, 140))	('pyrimidine', 'Chemical', 'MESH:C030986', (114, 124))	('purine', 'Chemical', 'MESH:C030985', (102, 108))	('pyrimidine', 'Chemical', 'MESH:C030986', (38, 48))
567	35216362	Understanding the regulation of the nucleotide salvage pathways by cancer cells can be vital to unfold new strategies to target cancer cell proliferation.	('cancer', 'Disease', (128, 134))	('cancer', 'Disease', (67, 73))	('nucleotide salvage pathways', 'Pathway', (36, 63))	('regulation', 'MPA', (18, 28))	('cancer', 'Disease', 'MESH:D009369', (67, 73))	('cancer', 'Disease', 'MESH:D009369', (128, 134))
568	35216362	DNA damages demand cells to rewire their metabolic pathways to synthesize dNTP pool for better DNA repair abilities and a survival advantage.	('synthesize dNTP pool for', 'MPA', (63, 87))	('DNA repair abilities', 'CPA', (95, 115))	('survival advantage', 'CPA', (122, 140))	('dNTP', 'Chemical', '-', (74, 78))
569	35216362	Glioma is one of the solid tumors exhibiting pronounced intratumoral genomic heterogeneity, therefore, inhibition of purine and pyrimidine nucleotide metabolism is an effective approach independent of genotype.	('tumors', 'Disease', (27, 33))	('tumor', 'Disease', (61, 66))	('inhibition', 'NegReg', (103, 113))	('Glioma', 'Disease', (0, 6))	('tumor', 'Disease', (27, 32))	('tumor', 'Disease', 'MESH:D009369', (27, 32))	('purine', 'Chemical', 'MESH:C030985', (117, 123))	('tumors', 'Disease', 'MESH:D009369', (27, 33))	('tumor', 'Disease', 'MESH:D009369', (61, 66))	('Glioma', 'Disease', 'MESH:D005910', (0, 6))	('pyrimidine nucleotide', 'Chemical', 'MESH:D011742', (128, 149))
570	35216362	The upregulated enzyme of de novo GTP synthesis is associated with lower survival rate in GBM patients.	('lower', 'NegReg', (67, 72))	('enzyme', 'MPA', (16, 22))	('de novo GTP synthesis', 'MPA', (26, 47))	('upregulated', 'PosReg', (4, 15))	('survival rate', 'CPA', (73, 86))	('GTP', 'Chemical', 'MESH:D006160', (34, 37))	('patients', 'Species', '9606', (94, 102))
571	35216362	Therefore, pharmacological inhibition of GTP synthesis can substantially sensitize radiation-resistant glioma cells.	('sensitize radiation-resistant', 'CPA', (73, 102))	('GTP', 'Protein', (41, 44))	('inhibition', 'NegReg', (27, 37))	('glioma', 'Disease', (103, 109))	('GTP', 'Chemical', 'MESH:D006160', (41, 44))	('glioma', 'Disease', 'MESH:D005910', (103, 109))
572	35216362	It was further demonstrated that MYC takes over the control of purine synthesis by reprogramming metabolisms of brain tumor initiating cells.	('reprogramming metabolisms', 'CPA', (83, 108))	('purine synthesis', 'MPA', (63, 79))	('MYC', 'Gene', (33, 36))	('brain tumor', 'Disease', (112, 123))	('brain tumor', 'Disease', 'MESH:D001932', (112, 123))	('purine', 'Chemical', 'MESH:C030985', (63, 69))	('MYC', 'Gene', '4609', (33, 36))
575	35216362	One particular feature of cancer cells is that they are able to reprogram their metabolic pathways to supply their increasing demand for energy as well as building blocks.	('cancer', 'Disease', (26, 32))	('reprogram', 'CPA', (64, 73))	('increasing demand for energy', 'MPA', (115, 143))	('metabolic pathways', 'Pathway', (80, 98))	('cancer', 'Disease', 'MESH:D009369', (26, 32))
576	35216362	The rewired cellular metabolism not only promotes tumor growth, but also contributes to the tumor-associated biological and clinical features such as invasion, migration, and resistance to treatments.	('resistance', 'CPA', (175, 185))	('tumor', 'Disease', (92, 97))	('cellular metabolism', 'MPA', (12, 31))	('promotes', 'PosReg', (41, 49))	('invasion', 'CPA', (150, 158))	('tumor', 'Disease', (50, 55))	('migration', 'CPA', (160, 169))	('contributes', 'Reg', (73, 84))	('tumor', 'Disease', 'MESH:D009369', (50, 55))	('tumor', 'Disease', 'MESH:D009369', (92, 97))
578	35216362	Given fatty acids (FAs) are indispensable components in maintaining cellular energy storage and cell membrane integrity, targeting the lipid biosynthesis or lipogenesis of cancer cells has become a new antineoplastic therapeutic strategy.	('cancer', 'Disease', (172, 178))	('lipid biosynthesis', 'MPA', (135, 153))	('targeting', 'Reg', (121, 130))	('lipogenesis', 'MPA', (157, 168))	('lipid', 'Chemical', 'MESH:D008055', (135, 140))	('fatty acids', 'Chemical', 'MESH:D005227', (6, 17))	('FAs', 'Chemical', 'MESH:D005227', (19, 22))	('cancer', 'Disease', 'MESH:D009369', (172, 178))
582	35216362	It has been shown that ACC is essential for the growth and survival of non-small-cell lung cancer (NSCLC) cells.	('lung cancer', 'Disease', (86, 97))	('growth', 'CPA', (48, 54))	('NSCLC', 'Disease', (99, 104))	('ACC', 'Protein', (23, 26))	('survival', 'CPA', (59, 67))	('lung cancer', 'Disease', 'MESH:D008175', (86, 97))	('NSCLC', 'Disease', 'MESH:D002289', (99, 104))
583	35216362	ND-646, an allosteric inhibitor of the ACC enzymes, can impair tumor growth in the xenograft and genetically engineered mouse models.	('ACC enzymes', 'Enzyme', (39, 50))	('xenograft', 'CPA', (83, 92))	('ND-646', 'Var', (0, 6))	('impair', 'NegReg', (56, 62))	('tumor', 'Disease', (63, 68))	('tumor', 'Disease', 'MESH:D009369', (63, 68))	('ND-646', 'Chemical', 'MESH:C000621677', (0, 6))	('mouse', 'Species', '10090', (120, 125))
584	35216362	Furthermore, despite initially being used as a drug to treat obesity and diabetes, Soraphen A can be repurposed as an inhibitor of acetyl CoA carboxylase activity interfering with de novo lipogenesis and beta-oxidation.	('inhibitor', 'NegReg', (118, 127))	('interfering', 'NegReg', (163, 174))	('activity', 'MPA', (154, 162))	('acetyl CoA carboxylase', 'Enzyme', (131, 153))	('de novo lipogenesis', 'MPA', (180, 199))	('obesity', 'Disease', (61, 68))	('diabetes', 'Disease', (73, 81))	('beta-oxidation', 'MPA', (204, 218))	('Soraphen A', 'Chemical', 'MESH:C086151', (83, 93))	('diabetes', 'Disease', 'MESH:D003920', (73, 81))	('obesity', 'Disease', 'MESH:D009765', (61, 68))
585	35216362	Pharmacological blockade of acetyl-CoA carboxylase using soraphen A can reduce the mammosphere formation in a dose-dependent manner, diminish the expansion of stem cell population, and potentially overcome chemotherapy and radiation resistance of CSCs.	('overcome', 'NegReg', (197, 205))	('reduce', 'NegReg', (72, 78))	('diminish', 'NegReg', (133, 141))	('CSCs', 'Disease', (247, 251))	('mammosphere formation', 'CPA', (83, 104))	('acetyl-CoA carboxylase', 'Enzyme', (28, 50))	('expansion of stem cell population', 'CPA', (146, 179))	('blockade', 'NegReg', (16, 24))	('soraphen A', 'Chemical', 'MESH:C086151', (57, 67))	('acetyl-CoA', 'Chemical', 'MESH:D000105', (28, 38))
586	35216362	Although it is unclear if inhibition of ACC could magnify the radiation sensitivity, it has been suggested that obese tissues can facilitate tumor hypoxic TME, which potentially leads to resistance to radiation therapy.	('tumor hypoxic TME', 'Disease', (141, 158))	('radiation sensitivity', 'MPA', (62, 83))	('leads to', 'Reg', (178, 186))	('magnify', 'PosReg', (50, 57))	('ACC', 'Gene', (40, 43))	('facilitate', 'PosReg', (130, 140))	('inhibition', 'Var', (26, 36))	('resistance to', 'MPA', (187, 200))	('obese', 'Disease', (112, 117))	('obese', 'Disease', 'MESH:D009765', (112, 117))	('tumor hypoxic TME', 'Disease', 'MESH:D009369', (141, 158))
587	35216362	Fatty acid synthase (FASN) is the rate-limiting enzyme for endogenous de novo production of FAs, and a druggable lipogenic oncogene.	('Fatty acid synthase', 'Gene', (0, 19))	('FASN', 'Gene', (21, 25))	('Fatty acid synthase', 'Gene', '2194', (0, 19))	('FASN', 'Gene', '2194', (21, 25))	('FAs', 'Chemical', 'MESH:D005227', (92, 95))
588	35216362	Normal cells usually have low levels of FASN mRNA and protein expression.	('low', 'NegReg', (26, 29))	('FASN', 'Gene', (40, 44))	('FASN', 'Gene', '2194', (40, 44))
589	35216362	However, upregulation of FASN represents a common phenotypic alteration in many cancers, which indicates that lipogenic oncogenes have indispensable roles in tumor growth and tumor survival.	('cancers', 'Disease', (80, 87))	('upregulation', 'PosReg', (9, 21))	('tumor', 'Disease', (175, 180))	('tumor', 'Disease', (158, 163))	('FASN', 'Gene', (25, 29))	('tumor', 'Disease', 'MESH:D009369', (158, 163))	('FASN', 'Gene', '2194', (25, 29))	('cancers', 'Disease', 'MESH:D009369', (80, 87))	('tumor', 'Disease', 'MESH:D009369', (175, 180))
590	35216362	FASN expression has been significantly associated with progression and outcome of several types of cancer such as colon, prostate, and soft tissue sarcomas.	('sarcomas', 'Disease', (147, 155))	('prostate', 'Disease', (121, 129))	('expression', 'MPA', (5, 15))	('associated', 'Reg', (39, 49))	('cancer', 'Disease', (99, 105))	('colon', 'Disease', (114, 119))	('FASN', 'Gene', (0, 4))	('cancer', 'Disease', 'MESH:D009369', (99, 105))	('FASN', 'Gene', '2194', (0, 4))	('sarcomas', 'Disease', 'MESH:D012509', (147, 155))	('colon', 'Disease', 'MESH:D003110', (114, 119))
591	35216362	Studies have demonstrated that Food and Drug Administration (FDA)-approved proton pump inhibitors can effectively inhibit FASN and sensitize breast cancer cells to the doxorubicin and ionizing radiation therapy in a large breast cancer patient cohort.	('breast cancer', 'Disease', (222, 235))	('breast cancer', 'Disease', (141, 154))	('sensitize', 'PosReg', (131, 140))	('inhibit', 'NegReg', (114, 121))	('proton pump', 'Gene', (75, 86))	('FASN', 'Gene', (122, 126))	('FASN', 'Gene', '2194', (122, 126))	('breast cancer', 'Disease', 'MESH:D001943', (222, 235))	('proton pump', 'Gene', '495', (75, 86))	('patient', 'Species', '9606', (236, 243))	('doxorubicin', 'Chemical', 'MESH:D004317', (168, 179))	('breast cancer', 'Disease', 'MESH:D001943', (141, 154))
592	35216362	Carnitine palmitoyltransferase 1A CPT1 (Carnitine palmitoyl transferase I) and CPT2 (Carnitine palmitoyl transferase II) are a pair of rate-limiting enzymes that mediate oxidation of long-chain fatty acids (FAO) in mitochondrial.	('oxidation', 'MPA', (170, 179))	('CPT2', 'Gene', (79, 83))	('Carnitine palmitoyltransferase 1A CPT1', 'Gene', (0, 38))	('CPT2', 'Gene', '1376', (79, 83))	('FAO', 'Chemical', '-', (207, 210))	('Carnitine palmitoyltransferase 1A CPT1', 'Gene', '1374', (0, 38))	('long-chain fatty acids', 'Chemical', '-', (183, 205))
593	35216362	Mutations in the CPT1A gene restrain the normal cells from converting long-chain fatty acids into energy.	('restrain', 'NegReg', (28, 36))	('Mutations', 'Var', (0, 9))	('CPT1A', 'Gene', (17, 22))	('long-chain fatty acids', 'Chemical', '-', (70, 92))	('CPT1A', 'Gene', '1374', (17, 22))
594	35216362	The in vitro experiments demonstrate that the PPAR coactivator-1alpha (PGC1alpha) binds to CCAAT/enhancer binding protein beta (CEBPB) and increases FAO regulated by CPT1A in nasopharyngeal carcinoma (NPC) cells.	('FAO regulated', 'MPA', (149, 162))	('CEBPB', 'Gene', (128, 133))	('PPAR', 'Gene', (46, 50))	('increases', 'PosReg', (139, 148))	('PGC1alpha', 'Gene', (71, 80))	('CPT1A', 'Gene', (166, 171))	('CCAAT/enhancer binding protein beta', 'Gene', (91, 126))	('carcinoma', 'Disease', (190, 199))	('binds', 'Interaction', (82, 87))	('FAO', 'Chemical', '-', (149, 152))	('PPAR', 'Gene', '5465', (46, 50))	('CCAAT/enhancer binding protein beta', 'Gene', '1051', (91, 126))	('PGC1alpha', 'Gene', '10891', (71, 80))	('CEBPB', 'Gene', '1051', (128, 133))	('carcinoma', 'Disease', 'MESH:D009369', (190, 199))	('CPT1A', 'Gene', '1374', (166, 171))
595	35216362	The upregulation of the PGC1alpha/CEBPB/CPT1A/FAO signaling pathway confers the radiation resistance and is linked with poor outcome of patients with NPC.	('radiation resistance', 'MPA', (80, 100))	('NPC', 'Disease', (150, 153))	('linked', 'Reg', (108, 114))	('confers', 'MPA', (68, 75))	('CEBPB', 'Gene', (34, 39))	('PGC1alpha', 'Gene', (24, 33))	('upregulation', 'PosReg', (4, 16))	('CPT1A', 'Gene', (40, 45))	('PGC1alpha', 'Gene', '10891', (24, 33))	('patients', 'Species', '9606', (136, 144))	('CPT1A', 'Gene', '1374', (40, 45))	('FAO', 'Chemical', '-', (46, 49))	('CEBPB', 'Gene', '1051', (34, 39))
596	35216362	Healthy cells and cancer cells can utilize lipids from the bloodstream through the de novo lipogenesis, but it was discovered that almost esterified FAs in tumor cells were obtained through de novo synthesis.	('tumor', 'Disease', (156, 161))	('esterified', 'MPA', (138, 148))	('cancer', 'Disease', (18, 24))	('lipids', 'Chemical', 'MESH:D008055', (43, 49))	('FAs', 'Chemical', 'MESH:D005227', (149, 152))	('tumor', 'Disease', 'MESH:D009369', (156, 161))	('cancer', 'Disease', 'MESH:D009369', (18, 24))
597	35216362	The studies indicate that when cancer cells have limited access to dietary cholesterol and fatty acids, de novo lipogenesis is activated in cancer cells.	('cancer', 'Disease', (140, 146))	('cancer', 'Disease', (31, 37))	('activated', 'PosReg', (127, 136))	('de novo lipogenesis', 'MPA', (104, 123))	('cholesterol', 'Chemical', 'MESH:D002784', (75, 86))	('cancer', 'Disease', 'MESH:D009369', (31, 37))	('fatty acids', 'Chemical', 'MESH:D005227', (91, 102))	('cancer', 'Disease', 'MESH:D009369', (140, 146))
598	35216362	The anti-proliferation effect of lipogenesis inhibitors can be augmented by limiting exogenous fatty acid supplementation.	('exogenous fatty acid supplementation', 'MPA', (85, 121))	('lipogenesis', 'Protein', (33, 44))	('limiting', 'NegReg', (76, 84))	('anti-proliferation', 'CPA', (4, 22))	('augmented', 'PosReg', (63, 72))	('fatty acid', 'Chemical', 'MESH:D005227', (95, 105))
599	35216362	Efforts have been made to understand the relationship between de novo lipid synthesis and exogenous lipids and determine their particular roles in chemo and radiation therapy resistance.	('de novo lipid synthesis', 'MPA', (62, 85))	('roles', 'Reg', (138, 143))	('exogenous lipids', 'MPA', (90, 106))	('chemo', 'CPA', (147, 152))	('lipids', 'Chemical', 'MESH:D008055', (100, 106))	('lipid', 'Chemical', 'MESH:D008055', (70, 75))	('lipid', 'Chemical', 'MESH:D008055', (100, 105))
600	35216362	The ketogenic diet is a high-fat, low-carbohydrate diet that increases ketone bodies in the blood.	('increases', 'PosReg', (61, 70))	('ketone bodies in the blood', 'MPA', (71, 97))	('ketone', 'Chemical', 'MESH:D007659', (71, 77))	('carbohydrate', 'Chemical', 'MESH:D002241', (38, 50))
601	35216362	An intracranial mouse model of malignant glioma suggests that animals receiving a ketogenic diet displayed elevated levels of beta-hydroxybutyrate and enhanced the anti-tumor effect of radiation.	('malignant glioma', 'Disease', (31, 47))	('radiation', 'CPA', (185, 194))	('enhanced', 'PosReg', (151, 159))	('levels of beta-hydroxybutyrate', 'MPA', (116, 146))	('elevated', 'PosReg', (107, 115))	('tumor', 'Disease', (169, 174))	('malignant glioma', 'Disease', 'MESH:D005910', (31, 47))	('beta-hydroxybutyrate', 'Chemical', 'MESH:D020155', (126, 146))	('tumor', 'Disease', 'MESH:D009369', (169, 174))	('mouse', 'Species', '10090', (16, 21))
602	35216362	This study indicates that cellular lipid metabolic alterations induced through the ketogenic diet may be useful to treat human malignant gliomas.	('cellular lipid metabolic alterations', 'MPA', (26, 62))	('malignant gliomas', 'Disease', (127, 144))	('malignant gliomas', 'Disease', 'MESH:D005910', (127, 144))	('human', 'Species', '9606', (121, 126))	('lipid', 'Chemical', 'MESH:D008055', (35, 40))
604	35216362	However, the ketogenic diet failed to increase the efficacy of reirradiation in patients with recurrent malignant gliomas.	('malignant gliomas', 'Disease', (104, 121))	('efficacy', 'MPA', (51, 59))	('increase', 'PosReg', (38, 46))	('reirradiation', 'CPA', (63, 76))	('patients', 'Species', '9606', (80, 88))	('malignant gliomas', 'Disease', 'MESH:D005910', (104, 121))
605	35216362	It has been suggested that radiation-induced FASN expression is essential for glioma cell survival.	('expression', 'MPA', (50, 60))	('FASN', 'Gene', (45, 49))	('glioma', 'Disease', (78, 84))	('FASN', 'Gene', '2194', (45, 49))	('glioma', 'Disease', 'MESH:D005910', (78, 84))
606	35216362	Accordingly, it has been hypothesized that the uptake of exogenous lipids can bypass the suppressed lipid biosynthesis caused by FASN inhibition.	('suppressed lipid biosynthesis', 'MPA', (89, 118))	('FASN', 'Gene', (129, 133))	('uptake', 'MPA', (47, 53))	('FASN', 'Gene', '2194', (129, 133))	('lipids', 'Chemical', 'MESH:D008055', (67, 73))	('lipid', 'Chemical', 'MESH:D008055', (67, 72))	('lipid', 'Chemical', 'MESH:D008055', (100, 105))
607	35216362	A recent study reported that both exogenous and endogenous cholesterol could promote the radioresistance of cancer cells in in vitro and in vivo models.	('cancer', 'Disease', (108, 114))	('promote', 'PosReg', (77, 84))	('cholesterol', 'Chemical', 'MESH:D002784', (59, 70))	('cancer', 'Disease', 'MESH:D009369', (108, 114))
608	35216362	In contrast, blocking sterol response element-binding protein 1 (SREBP1) and FASN signaling can enhance radiation-induced CRC cell death.	('SREBP1', 'Gene', (65, 71))	('blocking', 'NegReg', (13, 21))	('CRC cell death', 'Disease', (122, 136))	('FASN', 'Gene', (77, 81))	('enhance', 'PosReg', (96, 103))	('SREBP1', 'Gene', '6720', (65, 71))	('FASN', 'Gene', '2194', (77, 81))	('sterol', 'Chemical', 'MESH:D013261', (22, 28))	('CRC cell death', 'Disease', 'MESH:D015179', (122, 136))
609	35216362	Cerulenin synthetic analog C75, an inhibitor of fatty acid synthase, combined with X-ray irradiation can enhance radiation-induced apoptosis and delay the spheroid growth of prostate carcinoma in vitro.	('enhance', 'PosReg', (105, 112))	('radiation-induced apoptosis', 'CPA', (113, 140))	('delay the spheroid growth of prostate carcinoma', 'Disease', (145, 192))	('C75', 'Var', (27, 30))	('fatty acid synthase', 'Gene', (48, 67))	('C75', 'Chemical', '-', (27, 30))	('delay the spheroid growth of prostate carcinoma', 'Disease', 'MESH:D011471', (145, 192))	('Cerulenin', 'Chemical', 'MESH:D002569', (0, 9))	('fatty acid synthase', 'Gene', '2194', (48, 67))
610	35216362	Furthermore, recent studies suggested that lung cancer cell sublines previously exposed to the fractionated radiation in vitro confer notable radioresistance compared to their parental cells.	('radioresistance', 'CPA', (142, 157))	('lung cancer', 'Disease', (43, 54))	('lung cancer', 'Disease', 'MESH:D008175', (43, 54))
611	35216362	Chemical inhibition of carnitine palmitoyltransferase 1A (CPT1A) by Etomoxir can significantly enhance radiosensitivity by downregulating the DNA repair pathways promoting the survival of lung cancer cells exposed to the ionized radiation.	('DNA repair pathways', 'Pathway', (142, 161))	('lung cancer', 'Disease', (188, 199))	('survival', 'CPA', (176, 184))	('carnitine palmitoyltransferase 1A', 'Gene', (23, 56))	('inhibition', 'NegReg', (9, 19))	('CPT1A', 'Gene', (58, 63))	('promoting', 'PosReg', (162, 171))	('enhance', 'PosReg', (95, 102))	('radiosensitivity', 'CPA', (103, 119))	('downregulating', 'NegReg', (123, 137))	('carnitine palmitoyltransferase 1A', 'Gene', '1374', (23, 56))	('lung cancer', 'Disease', 'MESH:D008175', (188, 199))	('Etomoxir', 'Chemical', 'MESH:C054207', (68, 76))	('CPT1A', 'Gene', '1374', (58, 63))
612	35216362	It is worth noting that an ideal radiation sensitizer only enhances the cell killing in the irradiated tumors but does not display single agent toxicity on tumor and normal cells.	('tumor', 'Disease', (156, 161))	('tumors', 'Disease', (103, 109))	('enhances', 'PosReg', (59, 67))	('toxicity', 'Disease', (144, 152))	('tumor', 'Disease', (103, 108))	('cell killing', 'CPA', (72, 84))	('tumor', 'Disease', 'MESH:D009369', (103, 108))	('tumor', 'Disease', 'MESH:D009369', (156, 161))	('tumors', 'Disease', 'MESH:D009369', (103, 109))	('toxicity', 'Disease', 'MESH:D064420', (144, 152))
613	35216362	Further work in this area led to the discovery of hypoxia-inducible factor 1 alpha (Hif1alpha) and vascular endothelial growth factor (VEGF) whose expressions in concert drive angiogenesis, energy metabolism, and tumor cell invasion.	('energy metabolism', 'MPA', (190, 207))	('angiogenesis', 'CPA', (176, 188))	('vascular endothelial growth factor', 'Gene', (99, 133))	('Hif1alpha', 'Gene', (84, 93))	('tumor', 'Disease', (213, 218))	('VEGF', 'Gene', (135, 139))	('drive', 'Reg', (170, 175))	('expressions', 'MPA', (147, 158))	('hypoxia-inducible factor 1 alpha', 'Gene', (50, 82))	('hypoxia-inducible factor 1 alpha', 'Gene', '3091', (50, 82))	('Hif1alpha', 'Gene', '3091', (84, 93))	('vascular endothelial growth factor', 'Gene', '7422', (99, 133))	('VEGF', 'Gene', '7422', (135, 139))	('tumor', 'Disease', 'MESH:D009369', (213, 218))
614	35216362	Hypoxia-inducible factor-1a (HIF-1a), overexpressed in advanced cancers, in part, due to aberrant vascularization, often directly or indirectly reprograms the cancer-associated fibroblasts, macrophages, and extracellular matrix.	('cancer', 'Disease', (159, 165))	('Hypoxia-inducible factor-1a', 'Gene', (0, 27))	('reprograms', 'CPA', (144, 154))	('cancer', 'Disease', (64, 70))	('cancers', 'Disease', (64, 71))	('HIF-1a', 'Gene', (29, 35))	('cancer', 'Disease', 'MESH:D009369', (159, 165))	('cancers', 'Disease', 'MESH:D009369', (64, 71))	('Hypoxia-inducible factor-1a', 'Gene', '3091', (0, 27))	('HIF-1a', 'Gene', '3091', (29, 35))	('cancer', 'Disease', 'MESH:D009369', (64, 70))
615	35216362	These non-tumorous cells in the TME are remodeled by hypoxia and HIFs, leading to their functions to promote cancer growth.	('tumor', 'Disease', (10, 15))	('leading', 'Reg', (71, 78))	('HIFs', 'Disease', (65, 69))	('promote', 'PosReg', (101, 108))	('cancer', 'Disease', (109, 115))	('functions', 'MPA', (88, 97))	('hypoxia', 'Disease', (53, 60))	('HIFs', 'Disease', 'None', (65, 69))	('cancer', 'Disease', 'MESH:D009369', (109, 115))	('tumor', 'Disease', 'MESH:D009369', (10, 15))	('hypoxia', 'Disease', 'MESH:D000860', (53, 60))
616	35216362	VEGFs and their receptors (VEGFRs) are important pro-angiogenic factors that regulate the formation of new blood vessels.	('VEGF', 'Gene', (27, 31))	('VEGF', 'Gene', (0, 4))	('formation of new blood vessels', 'CPA', (90, 120))	('VEGF', 'Gene', '7422', (0, 4))	('VEGF', 'Gene', '7422', (27, 31))
617	35216362	The tumor VEGF mediates the angiogenic response of irradiated tumors and ameliorates the radiation resistance in different cancer types.	('angiogenic response', 'CPA', (28, 47))	('radiation resistance', 'CPA', (89, 109))	('ameliorates', 'NegReg', (73, 84))	('tumors', 'Disease', (62, 68))	('tumor', 'Disease', (4, 9))	('cancer', 'Disease', (123, 129))	('tumor', 'Disease', (62, 67))	('VEGF', 'Gene', (10, 14))	('tumor', 'Disease', 'MESH:D009369', (62, 67))	('tumors', 'Disease', 'MESH:D009369', (62, 68))	('cancer', 'Disease', 'MESH:D009369', (123, 129))	('VEGF', 'Gene', '7422', (10, 14))	('tumor', 'Disease', 'MESH:D009369', (4, 9))
618	35216362	Several classes of inhibitors have been designed to target the VEGF activity or the surface receptor function to reduce tumor-initiated angiogenesis.	('activity', 'MPA', (68, 76))	('surface', 'Protein', (84, 91))	('tumor', 'Disease', (120, 125))	('VEGF', 'Gene', (63, 67))	('reduce', 'NegReg', (113, 119))	('tumor', 'Disease', 'MESH:D009369', (120, 125))	('VEGF', 'Gene', '7422', (63, 67))
619	35216362	Anti-VEGF monoclonal antibody bevacizumab, targeting all isoforms of VEGF-A, is the most widely tested anti-angiogenesis therapy.	('VEGF', 'Gene', (5, 9))	('anti-angiogenesis', 'CPA', (103, 120))	('VEGF', 'Gene', (69, 73))	('VEGF-A', 'Gene', (69, 75))	('VEGF', 'Gene', '7422', (5, 9))	('bevacizumab', 'Chemical', 'MESH:D000068258', (30, 41))	('VEGF-A', 'Gene', '7422', (69, 75))	('VEGF', 'Gene', '7422', (69, 73))
620	35216362	Clinical studies have demonstrated that bevacizumab benefits patients with advanced colorectal cancer, cervical cancer, and renal cell carcinoma.	('cancer', 'Disease', (112, 118))	('renal cell carcinoma', 'Disease', (124, 144))	('cancer', 'Disease', (95, 101))	('colorectal cancer', 'Disease', (84, 101))	('colorectal cancer', 'Disease', 'MESH:D015179', (84, 101))	('cancer', 'Disease', 'MESH:D009369', (95, 101))	('renal cell carcinoma', 'Disease', 'MESH:C538614', (124, 144))	('patients', 'Species', '9606', (61, 69))	('bevacizumab', 'Chemical', 'MESH:D000068258', (40, 51))	('cancer', 'Disease', 'MESH:D009369', (112, 118))
621	35216362	Not all cancer cells are created equal, and they are instead organized hierarchically in heterogeneous tumor populations.	('cancer', 'Disease', (8, 14))	('tumor', 'Disease', (103, 108))	('tumor', 'Disease', 'MESH:D009369', (103, 108))	('cancer', 'Disease', 'MESH:D009369', (8, 14))
622	35216362	Cancer stem cells (CSC) are a subtle subpopulation within a tumor, which possess self-renewal and DNA repair capacities.	('tumor', 'Disease', (60, 65))	('Cancer', 'Disease', (0, 6))	('DNA repair capacities', 'CPA', (98, 119))	('self-renewal', 'CPA', (81, 93))	('Cancer', 'Disease', 'MESH:D009369', (0, 6))	('tumor', 'Disease', 'MESH:D009369', (60, 65))
623	35216362	How to eradicate all remaining CSC after surgical resection of a neoplasm become the root of tumor recurrence and metastases.	('tumor', 'Disease', (93, 98))	('metastases', 'Disease', (114, 124))	('neoplasm', 'Disease', (65, 73))	('metastases', 'Disease', 'MESH:D009362', (114, 124))	('tumor', 'Disease', 'MESH:D009369', (93, 98))	('neoplasm', 'Disease', 'MESH:D009369', (65, 73))
624	35216362	Immune cells within the TME display altered tumor metabolism in response to radiation and immunotherapies likely contributing to treatment resistance and ultimately recurrent disease.	('tumor metabolism', 'Disease', (44, 60))	('recurrent', 'CPA', (165, 174))	('altered', 'Reg', (36, 43))	('tumor metabolism', 'Disease', 'MESH:D008659', (44, 60))
625	35216362	In response to these cellular stresses, T cells, macrophages, and other components of the adaptive and innate immune system produce altered levels of oxidative species (ROS), fatty acid metabolism, and mTOR expression.	('fatty acid metabolism', 'MPA', (175, 196))	('altered', 'Reg', (132, 139))	('levels of oxidative species', 'MPA', (140, 167))	('mTOR', 'Gene', (202, 206))	('fatty acid', 'Chemical', 'MESH:D005227', (175, 185))	('mTOR', 'Gene', '2475', (202, 206))	('ROS', 'Chemical', 'MESH:D017382', (169, 172))
627	35216362	Using functional molecular imaging targeting the metabolite 2-[(18)F]fluoro-2-deoxy-d-glucose researchers have demonstrated that GSCs display altered oxygen consumption, intracellular ATP-levels, lactate production, glucose metabolism, and pyruvate kinase expression (PKM1/PKM2) when compared to their progenitors.	('PKM2', 'Gene', (273, 277))	('lactate production', 'CPA', (196, 214))	('pyruvate', 'Enzyme', (240, 248))	('intracellular ATP-levels', 'MPA', (170, 194))	('altered', 'Reg', (142, 149))	('glucose metabolism', 'Disease', (216, 234))	('oxygen consumption', 'MPA', (150, 168))	('lactate', 'Chemical', 'MESH:D019344', (196, 203))	('glucose', 'Chemical', 'MESH:D005947', (86, 93))	('pyruvate', 'Chemical', 'MESH:D019289', (240, 248))	('glucose metabolism', 'Disease', 'MESH:D044882', (216, 234))	('oxygen', 'Chemical', 'MESH:D010100', (150, 156))	('ATP-', 'Chemical', 'MESH:D000255', (184, 188))	('PKM2', 'Gene', '5315', (273, 277))	('glucose', 'Chemical', 'MESH:D005947', (216, 223))
629	35216362	A post-hoc genomic analysis of RTOG 9802 supports the observations that patients with IDH-mutant glioma can benefit from chemoradiation therapy.	('glioma', 'Disease', (97, 103))	('IDH', 'Gene', (86, 89))	('RTOG', 'Var', (31, 35))	('benefit', 'Reg', (108, 115))	('chemoradiation therapy', 'CPA', (121, 143))	('IDH', 'Gene', '3417', (86, 89))	('glioma', 'Disease', 'MESH:D005910', (97, 103))	('patients', 'Species', '9606', (72, 80))
630	35216362	Several novel medicines targeting IDH mutant activity, such as ivosidenib (AG-120), IDH305, FT-2102, AG-221, and AG-881 are currently being tested in clinical trials.	('IDH', 'Gene', (84, 87))	('IDH', 'Gene', (34, 37))	('AG-221', 'Chemical', 'MESH:C000605269', (101, 107))	('FT-2102', 'Chemical', '-', (92, 99))	('IDH', 'Gene', '3417', (84, 87))	('AG-881', 'Chemical', '-', (113, 119))	('AG-120', 'Chemical', 'MESH:C000627630', (75, 81))	('IDH', 'Gene', '3417', (34, 37))	('IDH305', 'Chemical', '-', (84, 90))	('ivosidenib', 'Chemical', 'MESH:C000627630', (63, 73))
631	35216362	Preliminary phase I clinical data suggest that most of these IDH1 or 2 inhibitors are well tolerated, are associated with lower cellular 2-HG levels, and have potential antitumor activity, especially in IDH1-mutated gliomas.	('IDH1', 'Gene', (61, 65))	('lower', 'NegReg', (122, 127))	('tumor', 'Disease', (173, 178))	('cellular 2-HG levels', 'MPA', (128, 148))	('gliomas', 'Disease', (216, 223))	('2-HG', 'Chemical', 'MESH:C019417', (137, 141))	('gliomas', 'Disease', 'MESH:D005910', (216, 223))	('tumor', 'Disease', 'MESH:D009369', (173, 178))	('IDH1', 'CellLine', '9606', (203, 207))	('IDH1', 'CellLine', '9606', (61, 65))
632	35216362	Phase I study NCT02073994 demonstrated that AG-120 with maximum tolerated dose is associated with favorable safety profile and prolonged tumor control in patients with advanced glioma.	('glioma', 'Disease', (177, 183))	('AG-120', 'Var', (44, 50))	('tumor', 'Disease', (137, 142))	('glioma', 'Disease', 'MESH:D005910', (177, 183))	('patients', 'Species', '9606', (154, 162))	('AG-120', 'Chemical', 'MESH:C000627630', (44, 50))	('tumor', 'Disease', 'MESH:D009369', (137, 142))
633	35216362	Phase II study of IDH1 Inhibitor AG-120 in combination with nivolumab is being investigated in patients with IDH1 mutant gliomas.	('gliomas', 'Disease', (121, 128))	('mutant', 'Var', (114, 120))	('IDH1', 'Gene', (109, 113))	('IDH1', 'Gene', (18, 22))	('nivolumab', 'Chemical', 'MESH:D000077594', (60, 69))	('AG-120', 'Chemical', 'MESH:C000627630', (33, 39))	('gliomas', 'Disease', 'MESH:D005910', (121, 128))	('IDH1', 'CellLine', '9606', (18, 22))	('IDH1', 'CellLine', '9606', (109, 113))	('patients', 'Species', '9606', (95, 103))
634	35216362	Studies to further evaluate the tumor control rate of IDH inhibitors with radiation in combination are ongoing.	('tumor', 'Disease', (32, 37))	('IDH', 'Gene', (54, 57))	('IDH', 'Gene', '3417', (54, 57))	('tumor', 'Disease', 'MESH:D009369', (32, 37))
635	35216362	Phase I/II trial NCT02273739 aims to determine the safety and maximum tolerable dose of AG-221 in the treatment of several types of IDH2 mutated solid tumors.	('IDH', 'Gene', (132, 135))	('tumors', 'Disease', (151, 157))	('AG-221', 'Var', (88, 94))	('IDH', 'Gene', '3417', (132, 135))	('AG-221', 'Chemical', 'MESH:C000605269', (88, 94))	('tumors', 'Disease', 'MESH:D009369', (151, 157))
636	35216362	The administration of 2-DG to cancer patients has proved its efficacy in lowering blood glucose levels and reducing the glycolysis rate in the cancer patients; however, side effects exhibited include diaphoresis, flushing, drowsiness, and hypothermia, especially, are associated with 2-DG uptake.	('hypothermia', 'Disease', (239, 250))	('drowsiness', 'Disease', (223, 233))	('flushing', 'Disease', (213, 221))	('glycolysis rate', 'MPA', (120, 135))	('lowering', 'NegReg', (73, 81))	('diaphoresis', 'Disease', (200, 211))	('cancer', 'Disease', (30, 36))	('cancer', 'Disease', (143, 149))	('blood glucose levels', 'MPA', (82, 102))	('reducing', 'NegReg', (107, 115))	('flushing', 'Disease', 'MESH:D005483', (213, 221))	('patients', 'Species', '9606', (150, 158))	('cancer', 'Disease', 'MESH:D009369', (143, 149))	('cancer', 'Disease', 'MESH:D009369', (30, 36))	('patients', 'Species', '9606', (37, 45))	('hypothermia', 'Disease', 'MESH:D007035', (239, 250))	('2-DG', 'Chemical', 'MESH:D003847', (22, 26))	('2-DG', 'Chemical', 'MESH:D003847', (284, 288))	('glucose', 'Chemical', 'MESH:D005947', (88, 95))
637	35216362	The limited success of this inhibitor is like due to 2-DG-mediated alteration of energy production and radiation responses vary substantially in different cancer cell types.	('energy production', 'MPA', (81, 98))	('cancer', 'Disease', (155, 161))	('2-DG-mediated', 'Protein', (53, 66))	('radiation', 'MPA', (103, 112))	('alteration', 'Reg', (67, 77))	('2-DG', 'Chemical', 'MESH:D003847', (53, 57))	('cancer', 'Disease', 'MESH:D009369', (155, 161))
638	35216362	Small molecule allosteric activator TEPP-46 stabilizes the tetrameric form of PKM2 and blocks PKM2 nuclear translocation, inhibiting tumor growth in a preclinical setting.	('tetrameric', 'MPA', (59, 69))	('stabilizes', 'MPA', (44, 54))	('PKM2', 'Gene', (78, 82))	('tumor', 'Disease', (133, 138))	('inhibiting', 'NegReg', (122, 132))	('PKM2', 'Gene', (94, 98))	('nuclear translocation', 'MPA', (99, 120))	('blocks', 'NegReg', (87, 93))	('TEPP-46', 'Gene', (36, 43))	('PKM2', 'Gene', '5315', (94, 98))	('PKM2', 'Gene', '5315', (78, 82))	('tumor', 'Disease', 'MESH:D009369', (133, 138))	('TEPP-46', 'Chemical', '-', (36, 43))
640	35216362	Hexokinase II (HK2) protein expression has been shown to be elevated in GBM, which could serve as a useful therapeutic target.	('elevated', 'PosReg', (60, 68))	('protein expression', 'MPA', (20, 38))	('Hexokinase', 'Gene', (0, 10))	('HK2', 'Gene', (15, 18))	('Hexokinase', 'Gene', '3098', (0, 10))	('HK2', 'Gene', '3099', (15, 18))
641	35216362	The azole class of antifungal inhibitors that includes ketoconazole and posaconazole also displayed the antitumor effect on GBM in vitro in a small screening test.	('tumor', 'Disease', (108, 113))	('GBM', 'CPA', (124, 127))	('azole', 'Chemical', 'MESH:D001393', (79, 84))	('azole', 'Chemical', 'MESH:D001393', (4, 9))	('tumor', 'Disease', 'MESH:D009369', (108, 113))	('ketoconazole', 'Chemical', 'MESH:D007654', (55, 67))	('posaconazole', 'Chemical', 'MESH:C101425', (72, 84))	('azole', 'Chemical', 'MESH:D001393', (62, 67))
642	35216362	Two early phase I trials (NCT04869449 and NCT04825275) have been posted in early 2021 to establish the neuro-pharmacokinetic profiles of these HK2 inhibitors.	('NCT04869449', 'Var', (26, 37))	('neuro-pharmacokinetic profiles', 'MPA', (103, 133))	('NCT04825275', 'Var', (42, 53))	('HK2', 'Gene', (143, 146))	('HK2', 'Gene', '3099', (143, 146))
643	35216362	The mitochondrial enzyme glutaminases (GLS1 and GLS2) convert glutamine to glutamate; then glutamate is further converted to TCA cycle the substrate, alpha-ketoglutarate, via glutamate dehydrogenase (GLUD).	('GLS2', 'Gene', (48, 52))	('glutamate', 'MPA', (91, 100))	('TCA cycle', 'MPA', (125, 134))	('GLS1', 'Gene', (39, 43))	('glutaminase', 'Gene', (25, 36))	('alpha-ketoglutarate', 'Chemical', 'MESH:D007656', (150, 169))	('GLS1', 'Gene', '2744', (39, 43))	('glutamate', 'Chemical', 'MESH:D018698', (91, 100))	('glutaminase', 'Gene', '2744', (25, 36))	('glutamate', 'Chemical', 'MESH:D018698', (75, 84))	('GLS2', 'Gene', '27165', (48, 52))	('TCA', 'Chemical', 'MESH:D014233', (125, 128))	('glutamine to glutamate', 'Mutation', 'None', (62, 84))	('glutamate', 'Chemical', 'MESH:D018698', (175, 184))
644	35216362	To translate these findings to the clinic, a GLS-specific inhibitor CB-839 was developed to determine if cancer cells can gain response to chemotherapy or radiation treatment by suppressing glutaminolysis.	('glutaminolysis', 'MPA', (190, 204))	('gain', 'PosReg', (122, 126))	('cancer', 'Disease', (105, 111))	('response', 'MPA', (127, 135))	('suppressing', 'NegReg', (178, 189))	('CB-839', 'Var', (68, 74))	('cancer', 'Disease', 'MESH:D009369', (105, 111))	('CB-839', 'Chemical', 'MESH:C000593334', (68, 74))
645	35216362	CB-839 demonstrated antiproliferative activity in a triple-negative breast cancer (TNBC) cells and human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells as a single agent or combined with paclitaxel.	('CB-839', 'Var', (0, 6))	('breast cancer', 'Disease', (68, 81))	('epidermal growth factor receptor 2', 'Gene', (105, 139))	('HER2', 'Gene', (141, 145))	('antiproliferative', 'MPA', (20, 37))	('breast cancer', 'Disease', (156, 169))	('TNBC', 'Disease', (83, 87))	('TNBC', 'Disease', 'None', (83, 87))	('CB-839', 'Chemical', 'MESH:C000593334', (0, 6))	('epidermal growth factor receptor 2', 'Gene', '2064', (105, 139))	('breast cancer', 'Disease', 'MESH:D001943', (68, 81))	('HER2', 'Gene', '2064', (141, 145))	('human', 'Species', '9606', (99, 104))	('paclitaxel', 'Chemical', 'MESH:D017239', (211, 221))	('breast cancer', 'Disease', 'MESH:D001943', (156, 169))
646	35216362	The c-Myc-regulated amino acid transporter ASCT2 (SLC1A5) regulates the glutamine uptake in cancer cells.	('ASCT2', 'Gene', (43, 48))	('regulates', 'Reg', (58, 67))	('cancer', 'Disease', (92, 98))	('c-Myc', 'Gene', (4, 9))	('SLC1A5', 'Gene', (50, 56))	('glutamine uptake', 'MPA', (72, 88))	('SLC1A5', 'Gene', '6510', (50, 56))	('glutamine', 'Chemical', 'MESH:D005973', (72, 81))	('cancer', 'Disease', 'MESH:D009369', (92, 98))	('c-Myc', 'Gene', '4609', (4, 9))	('ASCT2', 'Gene', '6510', (43, 48))
647	35216362	In combination with an ASCT2 inhibitor V-9302, the glutamine dependent cells can be sensitized to CB-839 treatment in several cancer types.	('sensitized', 'PosReg', (84, 94))	('CB-839', 'Var', (98, 104))	('cancer', 'Disease', (126, 132))	('glutamine dependent', 'MPA', (51, 70))	('ASCT2', 'Gene', (23, 28))	('glutamine', 'Chemical', 'MESH:D005973', (51, 60))	('cancer', 'Disease', 'MESH:D009369', (126, 132))	('ASCT2', 'Gene', '6510', (23, 28))	('CB-839', 'Chemical', 'MESH:C000593334', (98, 104))	('V-9302', 'Chemical', '-', (39, 45))
648	35216362	The ongoing phase Ib trial (NCT03528642) is investigating the glutaminase inhibitor CB-839 in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma.	('IDH', 'Gene', (172, 175))	('glutaminase', 'Gene', (62, 73))	('anaplastic astrocytoma', 'Disease', (195, 217))	('CB-839', 'Var', (84, 90))	('patients', 'Species', '9606', (158, 166))	('temozolomide', 'Chemical', 'MESH:D000077204', (133, 145))	('IDH', 'Gene', '3417', (172, 175))	('anaplastic astrocytoma', 'Disease', 'MESH:D001254', (195, 217))	('glutaminase', 'Gene', '2744', (62, 73))	('CB-839', 'Chemical', 'MESH:C000593334', (84, 90))
649	35216362	Arginine, one of the common amino acids, has been linked to improving the immune system in people with brain tumors.	('brain tumors', 'Disease', (103, 115))	('immune system', 'CPA', (74, 87))	('Arginine', 'Chemical', 'MESH:D001120', (0, 8))	('brain tumors', 'Disease', 'MESH:D001932', (103, 115))	('people', 'Species', '9606', (91, 97))
650	35216362	A clinical trial has been completed to assess if the oral administration of arginine in powder form changes the immune function of GBM patients (NCT02017249).	('immune function', 'CPA', (112, 127))	('changes', 'Reg', (100, 107))	('arginine', 'Chemical', 'MESH:D001120', (76, 84))	('patients', 'Species', '9606', (135, 143))
651	35216362	A pegylated form of prokaryotic arginine deiminase (ADI-PEG 20) has been investigated in phase I and II clinical trials and has been shown to catalyze the irreversible hydrolysis of arginine to citrulline and ammonia thus creating low cellular arginine levels.	('catalyze', 'MPA', (142, 150))	('ADI-PEG 20', 'Var', (52, 62))	('irreversible hydrolysis of arginine', 'MPA', (155, 190))	('cellular arginine levels', 'MPA', (235, 259))	('low', 'NegReg', (231, 234))	('arginine', 'Chemical', 'MESH:D001120', (182, 190))	('citrulline', 'Chemical', 'MESH:D002956', (194, 204))	('ADI-PEG 20', 'Chemical', 'MESH:C512527', (52, 62))	('arginine', 'Chemical', 'MESH:D001120', (244, 252))	('arginine', 'Chemical', 'MESH:D001120', (32, 40))	('ammonia', 'Chemical', 'MESH:D000641', (209, 216))
652	35216362	A phase I study evaluating the safety and tolerability of ADI-PEG 20 in combination with radiotherapy and temozolomide in newly diagnosed GBM started recently (NCT04587830).	('GBM started', 'Disease', (138, 149))	('ADI-PEG', 'Var', (58, 65))	('ADI-PEG 20', 'Chemical', 'MESH:C512527', (58, 68))	('temozolomide', 'Chemical', 'MESH:D000077204', (106, 118))
653	35216362	PRT811 is a protein arginine N-methyltransferase 5 (PRMT5) inhibitor that exhibits the blood-brain barrier penetration.	('PRMT5', 'Gene', (52, 57))	('blood-brain barrier penetration', 'CPA', (87, 118))	('protein arginine N-methyltransferase 5', 'Gene', (12, 50))	('PRMT5', 'Gene', '10419', (52, 57))	('protein arginine N-methyltransferase 5', 'Gene', '10419', (12, 50))
654	35216362	Although PRMT5 does not directly alter the arginine metabolism, it has been pursued as an alternative treatment choice because patients with high-grade gliomas have limited treatment options (NCT04089449).	('PRMT5', 'Gene', (9, 14))	('gliomas', 'Disease', (152, 159))	('gliomas', 'Disease', 'MESH:D005910', (152, 159))	('PRMT5', 'Gene', '10419', (9, 14))	('arginine', 'Chemical', 'MESH:D001120', (43, 51))	('patients', 'Species', '9606', (127, 135))
656	35216362	Although no increase in hematologic toxicity was observed, the addition of 6 MP did not demonstrate a significant survival benefit.	('survival benefit', 'CPA', (114, 130))	('hematologic toxicity', 'Disease', (24, 44))	('hematologic toxicity', 'Disease', 'MESH:D006402', (24, 44))
657	35216362	A phase II study evaluates the efficacy and safety of craniospinal radiation combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating pediatric astrocytoma and adult anaplastic ependymoma; the combination of TPDCV chemotherapy and radiation therapy does not differ substantially from radiation alone in with progression-free survival and overall survival.	('astrocytoma', 'Disease', (208, 219))	('adult anaplastic ependymoma', 'Disease', (224, 251))	('6-thioguanine', 'Chemical', 'MESH:D013866', (91, 104))	('TPDCV', 'Chemical', '-', (272, 277))	('vincristine', 'Chemical', 'MESH:D014750', (152, 163))	('dibromodulcitol', 'Chemical', 'MESH:D008936', (120, 135))	('procarbazine', 'Chemical', 'MESH:D011344', (106, 118))	('astrocytoma', 'Disease', 'MESH:D001254', (208, 219))	('TPDCV', 'Chemical', '-', (165, 170))	('adult anaplastic ependymoma', 'Disease', 'MESH:D004806', (224, 251))	('lomustine', 'Chemical', 'MESH:D008130', (137, 146))
659	35216362	Although gemcitabine has a modest ability to pass BBB, the concentration of gemcitabine in glioma cells is high enough for radiation sensitization.	('concentration', 'MPA', (59, 72))	('glioma', 'Disease', (91, 97))	('radiation sensitization', 'MPA', (123, 146))	('gemcitabine', 'Chemical', 'MESH:C056507', (9, 20))	('glioma', 'Disease', 'MESH:D005910', (91, 97))	('gemcitabine', 'Chemical', 'MESH:C056507', (76, 87))
660	35216362	Pre-irradiation gemcitabine chemotherapy demonstrated the safety profile but not effective in tumor control in phase II studies with newly diagnosed and recurrent GBM patients.	('GBM', 'Disease', (163, 166))	('tumor', 'Disease', (94, 99))	('tumor', 'Disease', 'MESH:D009369', (94, 99))	('gemcitabine', 'Chemical', 'MESH:C056507', (16, 27))	('patients', 'Species', '9606', (167, 175))
662	35216362	BXQ-350 is a novel antitumor agent that suppresses glioma growth through interacting with the cancer cell membrane.	('interacting', 'Interaction', (73, 84))	('glioma', 'Disease', (51, 57))	('BXQ-350', 'Var', (0, 7))	('suppresses', 'NegReg', (40, 50))	('cancer', 'Disease', (94, 100))	('tumor', 'Disease', (23, 28))	('tumor', 'Disease', 'MESH:D009369', (23, 28))	('glioma', 'Disease', 'MESH:D005910', (51, 57))	('BXQ-350', 'Chemical', '-', (0, 7))	('cancer', 'Disease', 'MESH:D009369', (94, 100))
664	35216362	The safety profiles and pharmacodynamics of BXQ-350 are being determined in several pediatric and adult brain tumors at the phase I stage (NCT04771897, NCT02859857, and NCT04404569).	('adult brain tumors', 'Disease', (98, 116))	('NCT04404569', 'Var', (169, 180))	('BXQ-350', 'Var', (44, 51))	('NCT02859857', 'Var', (152, 163))	('pediatric', 'Disease', (84, 93))	('NCT04771897', 'Var', (139, 150))	('adult brain tumors', 'Disease', 'MESH:D001932', (98, 116))	('BXQ-350', 'Chemical', '-', (44, 51))
665	35216362	A recent study indicated that abundant cholesterol supply is essential to sustain the progression of glioma cells.	('glioma', 'Disease', (101, 107))	('cholesterol supply', 'MPA', (39, 57))	('progression', 'CPA', (86, 97))	('cholesterol', 'Chemical', 'MESH:D002784', (39, 50))	('glioma', 'Disease', 'MESH:D005910', (101, 107))
667	35216362	To re-purpose this antibody inhibitor to cancer patients, NCT04937413 is a phase 0 study to determine the pharmacokinetics and pharmacodynamics of evolocumab in patients with high-grade glioma.	('pharmacodynamics', 'MPA', (127, 143))	('cancer', 'Disease', (41, 47))	('glioma', 'Disease', (186, 192))	('pharmacokinetics', 'MPA', (106, 122))	('NCT04937413', 'Var', (58, 69))	('cancer', 'Disease', 'MESH:D009369', (41, 47))	('patients', 'Species', '9606', (48, 56))	('patients', 'Species', '9606', (161, 169))	('glioma', 'Disease', 'MESH:D005910', (186, 192))	('evolocumab', 'Chemical', 'MESH:C577155', (147, 157))
668	35216362	Hif-1alpha supports cancer cell survival under hypoxic conditions through its activation of nuclear factor kappa B (NF-kappaB) as well as promotion of expression of ligands for program death receptor 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).	('cancer', 'Disease', (20, 26))	('hypoxic', 'Disease', (47, 54))	('activation', 'PosReg', (78, 88))	('NF-kappaB', 'Gene', (116, 125))	('Hif-1alpha', 'Gene', (0, 10))	('cytotoxic T-lymphocyte-associated protein 4', 'Gene', (213, 256))	('promotion', 'PosReg', (138, 147))	('expression', 'MPA', (151, 161))	('death', 'Disease', (185, 190))	('CTLA-4', 'Gene', (258, 264))	('nuclear factor kappa B', 'Gene', (92, 114))	('cytotoxic T-lymphocyte-associated protein 4', 'Gene', '1493', (213, 256))	('CTLA-4', 'Gene', '1493', (258, 264))	('NF-kappaB', 'Gene', '4790', (116, 125))	('Hif-1alpha', 'Gene', '3091', (0, 10))	('PD-1', 'CellLine', '9823', (203, 207))	('cancer', 'Disease', 'MESH:D009369', (20, 26))	('nuclear factor kappa B', 'Gene', '4790', (92, 114))	('hypoxic', 'Disease', 'MESH:D000860', (47, 54))	('death', 'Disease', 'MESH:D003643', (185, 190))
669	35216362	To date, 31 trials have investigated inhibitors of the PD-1/PDL-1/CTLA-4 axis in high-grade gliomas.	('CTLA-4', 'Gene', (66, 72))	('PDL-1', 'Gene', (60, 65))	('inhibitors', 'MPA', (37, 47))	('gliomas', 'Disease', (92, 99))	('gliomas', 'Disease', 'MESH:D005910', (92, 99))	('PD-1', 'CellLine', '9823', (55, 59))	('PDL-1', 'Gene', '29126', (60, 65))	('CTLA-4', 'Gene', '1493', (66, 72))
670	35216362	Checkmate-143 (NCT 02017717), a randomized phase III trial, found a small improvement in progression free survival, median overall survival, and overall response rate with the addition of ipilimumab to nivolumab versus nivolumab alone in GBM.	('median overall', 'MPA', (116, 130))	('improvement', 'PosReg', (74, 85))	('overall response rate', 'CPA', (145, 166))	('progression free survival', 'CPA', (89, 114))	('nivolumab', 'Chemical', 'MESH:D000077594', (219, 228))	('nivolumab', 'Chemical', 'MESH:D000077594', (202, 211))	('ipilimumab', 'Chemical', 'MESH:D000074324', (188, 198))
673	35216362	Avelumab is a fully humanized monoclonal antibody blocking the interaction between PD-L1 and PD-1 and restoring the cytotoxic T cell response.	('PD-1', 'Protein', (93, 97))	('cytotoxic T cell response', 'CPA', (116, 141))	('blocking', 'NegReg', (50, 58))	('interaction between', 'Interaction', (63, 82))	('restoring', 'PosReg', (102, 111))	('PD-L1', 'Gene', (83, 88))	('human', 'Species', '9606', (20, 25))	('PD-1', 'CellLine', '9823', (93, 97))	('PD-L1', 'Gene', '29126', (83, 88))
674	35216362	Although PD-1/PDL-1 inhibitors haven't had the same success as in NSCLC/SCLC, they remain a viable therapeutic option in this patient population which hasn't seen significant progress since temozolomide was adopted as first line therapy in 2005.	('SCLC', 'Disease', (72, 76))	('SCLC', 'Disease', (67, 71))	('NSCLC', 'Disease', (66, 71))	('PDL-1', 'Gene', (14, 19))	('SCLC', 'Disease', 'MESH:D018288', (72, 76))	('temozolomide', 'Chemical', 'MESH:D000077204', (190, 202))	('SCLC', 'Disease', 'MESH:D018288', (67, 71))	('NSCLC', 'Disease', 'MESH:D002289', (66, 71))	('PDL-1', 'Gene', '29126', (14, 19))	('PD-1', 'CellLine', '9823', (9, 13))	('patient', 'Species', '9606', (126, 133))
676	35216362	Unfortunately, F18-FDG PET demonstrates diffuse activity in the brain given its high metabolic demand, making the tumor to background ratio not ideal for differentiating tumor from normal brain.	('tumor', 'Disease', (170, 175))	('not', 'NegReg', (140, 143))	('diffuse', 'MPA', (40, 47))	('tumor', 'Disease', (114, 119))	('F18', 'Gene', (15, 18))	('activity', 'MPA', (48, 56))	('tumor', 'Disease', 'MESH:D009369', (114, 119))	('tumor', 'Disease', 'MESH:D009369', (170, 175))	('F18', 'Gene', '10046', (15, 18))	('FDG', 'Chemical', 'MESH:D019788', (19, 22))
677	35216362	This is especially true when differentiating tumor recurrence from post-treatment changes, such as pseudoprogression and radiation necrosis.	('radiation necrosis', 'Disease', (121, 139))	('tumor', 'Disease', (45, 50))	('pseudoprogression', 'Disease', (99, 116))	('radiation necrosis', 'Disease', 'MESH:D009336', (121, 139))	('tumor', 'Disease', 'MESH:D009369', (45, 50))
678	35216362	Radiolabeled amino acids were introduced in the 1980s as positron emission tomography (PET) tracers for brain tumors, due to an increased amino acid utilization within glial tumors.	('glial tumors', 'Disease', (168, 180))	('brain tumors', 'Disease', (104, 116))	('amino acid utilization', 'MPA', (138, 160))	('increased', 'PosReg', (128, 137))	('glial tumors', 'Disease', 'MESH:D005910', (168, 180))	('brain tumors', 'Disease', 'MESH:D001932', (104, 116))
679	35216362	Active amino acid transport in tumor cells is supposed to be one of the rate-limiting factors of amino acid imaging and is upregulated in tumor cell membranes.	('Active amino acid transport', 'MPA', (0, 27))	('tumor', 'Disease', (31, 36))	('upregulated', 'PosReg', (123, 134))	('tumor', 'Disease', (138, 143))	('tumor', 'Disease', 'MESH:D009369', (31, 36))	('tumor', 'Disease', 'MESH:D009369', (138, 143))
681	35216362	Amino acid PET has demonstrated higher diagnostic accuracy when compared to MRI for glioma grading, differentiation of glioma from non-neoplastic lesions, and differentiation of glioma recurrence from treatment induced changes.	('Amino', 'Var', (0, 5))	('glioma', 'Disease', (84, 90))	('diagnostic', 'MPA', (39, 49))	('glioma', 'Disease', (178, 184))	('glioma', 'Disease', (119, 125))	('higher', 'PosReg', (32, 38))	('glioma', 'Disease', 'MESH:D005910', (178, 184))	('glioma', 'Disease', 'MESH:D005910', (119, 125))	('glioma', 'Disease', 'MESH:D005910', (84, 90))
682	35216362	Amino acid PET is superior to MRI for assessment of treatment response as well as delineation of glioma extent for enhancing and non-enhancing tumors.	('glioma', 'Disease', (97, 103))	('tumors', 'Disease', (143, 149))	('glioma', 'Disease', 'MESH:D005910', (97, 103))	('tumors', 'Disease', 'MESH:D009369', (143, 149))
683	35216362	In glioma, patients' treatment-related effects, otherwise known as pseudoprogression or radiation necrosis, limits the reliability of conventional MRI to assess treatment response.	('limits', 'NegReg', (108, 114))	('glioma', 'Disease', (3, 9))	('radiation necrosis', 'Disease', (88, 106))	('pseudoprogression', 'Disease', (67, 84))	('glioma', 'Disease', 'MESH:D005910', (3, 9))	('radiation necrosis', 'Disease', 'MESH:D009336', (88, 106))	('patients', 'Species', '9606', (11, 19))
684	35216362	Several studies reported only a limited value of early post-radiotherapy quantitative FDG PET changes for the assessment of response to radiotherapy, either alone or with concomitant temozolomide.	('FDG PET changes', 'MPA', (86, 101))	('response', 'MPA', (124, 132))	('FDG', 'Chemical', 'MESH:D019788', (86, 89))	('temozolomide', 'Chemical', 'MESH:D000077204', (183, 195))
685	35216362	Early changes of tumor-to-brain FET uptake ratios following chemoradiation with temozolomide in newly diagnosed GBM patients have been shown to be a strong predictor for progression-free and overall survival.	('tumor', 'Disease', (17, 22))	('progression-free', 'CPA', (170, 186))	('temozolomide', 'Chemical', 'MESH:D000077204', (80, 92))	('patients', 'Species', '9606', (116, 124))	('tumor', 'Disease', 'MESH:D009369', (17, 22))
686	35216362	Development of [18 F] DASA-23 for imaging tumor glycolysis has been tested in the Phase 1 study (NCT03539731) to evaluate the pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors or recurrent GBM as well as healthy volunteers by positron emission tomography (PET) scan technique.	('PKM2', 'Gene', (146, 150))	('GBM', 'Disease', (213, 216))	('tumor glycolysis', 'Disease', (42, 58))	('expression', 'MPA', (152, 162))	('intracranial tumors', 'Disease', (180, 199))	('patients', 'Species', '9606', (166, 174))	('pyruvate', 'Chemical', 'MESH:D019289', (126, 134))	('tumor glycolysis', 'Disease', 'MESH:C564972', (42, 58))	('PKM2', 'Gene', '5315', (146, 150))	('DASA-23', 'Chemical', '-', (22, 29))	('intracranial tumors', 'Disease', 'MESH:D001932', (180, 199))
687	35216362	The primary goal of this study is to determine whether the [18F]DASA 23 PET scan can predict tumor's responsiveness to antitumor therapy.	('predict', 'Reg', (85, 92))	('[18F]DASA 23', 'Protein', (59, 71))	('tumor', 'Disease', (93, 98))	('tumor', 'Disease', (123, 128))	('DASA', 'Chemical', 'MESH:C000469', (64, 68))	('tumor', 'Disease', 'MESH:D009369', (93, 98))	('tumor', 'Disease', 'MESH:D009369', (123, 128))
691	35216362	The imbalanced BCAAs in serum is a physiological evidence of chronic liver diseases.	('liver diseases', 'Disease', (69, 83))	('imbalanced BCAAs', 'MPA', (4, 20))	('liver diseases', 'Disease', 'MESH:D008107', (69, 83))	('BCAAs', 'Chemical', 'MESH:D000597', (15, 20))
693	35216362	The goal of this study is to determine if tryptophan metabolism is a useful approach to distinguish between different types of brain tumors.	('brain tumors', 'Disease', (127, 139))	('tryptophan metabolism', 'MPA', (42, 63))	('brain tumors', 'Disease', 'MESH:D001932', (127, 139))	('tryptophan', 'Chemical', 'MESH:D014364', (42, 52))
695	35216362	Resistance to chemo- and radiotherapy is the decisive implication of cancer treatment failure.	('Resistance', 'CPA', (0, 10))	('cancer', 'Disease', (69, 75))	('cancer', 'Disease', 'MESH:D009369', (69, 75))
697	35216362	This systematic and molecular knowledge of glioma cells allows us to revisit many signaling pathways and complex interactions, including cancer metabolism and DNA repair activities.	('interactions', 'Interaction', (113, 125))	('glioma', 'Disease', (43, 49))	('DNA', 'CPA', (159, 162))	('cancer', 'Disease', (137, 143))	('cancer', 'Disease', 'MESH:D009369', (137, 143))	('glioma', 'Disease', 'MESH:D005910', (43, 49))
698	35216362	In glioma cells, intracellular glucose, lipid, amino acid, and nucleotide levels are dramatically upregulated through extracellular uptake, de novo synthesis, and other molecular mechanisms; in so doing, the metabolic reprogramming supports aggressive proliferation, progression, and chemoradiation resistance in gliomas.	('metabolic', 'MPA', (208, 217))	('glioma', 'Disease', (3, 9))	('aggressive proliferation', 'CPA', (241, 265))	('chemoradiation', 'Disease', (284, 298))	('gliomas', 'Disease', (313, 320))	('intracellular glucose', 'MPA', (17, 38))	('glioma', 'Disease', (313, 319))	('upregulated', 'PosReg', (98, 109))	('progression', 'CPA', (267, 278))	('glioma', 'Disease', 'MESH:D005910', (313, 319))	('glucose', 'Chemical', 'MESH:D005947', (31, 38))	('glioma', 'Disease', 'MESH:D005910', (3, 9))	('gliomas', 'Disease', 'MESH:D005910', (313, 320))	('lipid', 'Chemical', 'MESH:D008055', (40, 45))
699	35216362	One of the resistance mechanisms is that aberrant glioma metabolism boosts the rapid repair of DNA lesions introduced by radiotherapies.	('boosts', 'PosReg', (68, 74))	('aberrant glioma metabolism', 'Disease', (41, 67))	('rapid repair', 'MPA', (79, 91))	('aberrant glioma metabolism', 'Disease', 'MESH:D005910', (41, 67))
700	35216362	Through decades of study, it has been proven that the strategy of genetic and pharmacological inhibition of glioma metabolism combined with radiotherapy has achieved limited success to different solid tumors, including glioma.	('inhibition', 'NegReg', (94, 104))	('glioma metabolism', 'Disease', (108, 125))	('glioma', 'Disease', (219, 225))	('glioma', 'Disease', (108, 114))	('limited', 'NegReg', (166, 173))	('tumors', 'Disease', (201, 207))	('glioma metabolism', 'Disease', 'MESH:D005910', (108, 125))	('glioma', 'Disease', 'MESH:D005910', (219, 225))	('tumors', 'Disease', 'MESH:D009369', (201, 207))	('glioma', 'Disease', 'MESH:D005910', (108, 114))
701	35216362	However, it is necessary to consider the inter-and intra-tumoral heterogeneity and the immune TME because glioma cells can dodge the therapeutic stress (e.g., radiotherapy) through fostering tumor cell evolution and interacting with different TME cell populations.	('therapeutic', 'MPA', (133, 144))	('evolution', 'CPA', (202, 211))	('glioma', 'Disease', (106, 112))	('dodge', 'MPA', (123, 128))	('interacting', 'Interaction', (216, 227))	('tumor', 'Disease', (57, 62))	('intra-tumoral', 'Disease', (51, 64))	('tumor', 'Disease', (191, 196))	('fostering', 'PosReg', (181, 190))	('tumor', 'Disease', 'MESH:D009369', (191, 196))	('intra-tumoral', 'Disease', 'MESH:D009369', (51, 64))	('tumor', 'Disease', 'MESH:D009369', (57, 62))	('glioma', 'Disease', 'MESH:D005910', (106, 112))
702	35216362	(2) Many solid malignancies, including glioma, are treated with radiation therapy and/or chemotherapy that trigger the same or similar molecular pathways leading to the very similar outcome and, therefore, extend this review to other malignancies.	('trigger', 'Reg', (107, 114))	('glioma', 'Disease', (39, 45))	('malignancies', 'Disease', (15, 27))	('malignancies', 'Disease', (234, 246))	('malignancies', 'Disease', 'MESH:D009369', (234, 246))	('malignancies', 'Disease', 'MESH:D009369', (15, 27))	('glioma', 'Disease', 'MESH:D005910', (39, 45))
703	35216362	The authors acknowledge the support of U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), and U24CA196067 (NRG Specimen Bank), and from the National Cancer Institute (NCI) and Merck.	('U10CA180868', 'Var', (39, 50))	('U24CA196067', 'Var', (115, 126))	('Cancer', 'Disease', (170, 176))	('Bank', 'Gene', (141, 145))	('U10CA180822', 'Var', (78, 89))	('Cancer', 'Disease', 'MESH:D009369', (170, 176))	('Bank', 'Gene', '55024', (141, 145))
704	35216362	Additionally, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01 (NCI), Brain Tumor Funders Collaborative Grant, and the Ohio State University CCC (all to A.C.).	('R01CA169368', 'Var', (27, 38))	('RC2CA148190', 'Var', (40, 51))	('Brain Tumor', 'Disease', (75, 86))	('U10CA180850-01', 'Var', (53, 67))	('R01CA108633', 'Var', (14, 25))	('Brain Tumor', 'Disease', 'MESH:D001932', (75, 86))
